EXHIBIT & INNOVATION GUIDE

EXHIBIT HALL HOURS
Sunday-Tuesday
10:30 a.m.-3:30 p.m.

Visit the ATS 2019 Online Exhibitor Directory for more info.
conference.thoracic.org/attendees/exhibit-hall
SEEKING TALENTED CLINICAL DEVELOPMENT PROFESSIONALS

Are you a talented, creative, passionate and dedicated clinical development professional with hands-on experience in early and/or late-stage clinical studies? Are you looking to join a seasoned and scientifically focused team that is fearless in its quest to discover, develop and commercialize breakthrough therapies for fibrotic diseases?

If you would like to be considered for a Medical Director position at Pliant Therapeutics, or view our other open positions, please submit your resume and cover letter to careers@pliantrx.com.

“Historically, fibrosis has been studied in silos. At Pliant, we have developed a comprehensive approach that has enabled us to better define pathological processes, identify the key molecular targets, and treat fibrosis. With this approach, we aim to transform the lives of patients with these debilitating diseases.”

– Bernard Coulie, M.D., Ph.D., president and CEO

Pliant Therapeutics is a clinical stage biotechnology company unravelling and targeting the key biological pathways driving fibrosis. By leveraging our powerful product discovery engine, Pliant is developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately, preserving organ function.

Fearless in our quest to uncover the biological drivers of fibrosis
Our success depends on the excellence of our people.
Contents

Welcome to dallas tx

4

4 Easy Ways to Navigate the Exhibit Hall

6

What’s Happening in the Exhibit Hall

12

Together, We Are Improving Lung Health

16

Exhibitor Feature: Morgan Scientific Inc.

17

EDUCATIONAL OPPORTUNITIES
In-Booth Demonstrations and Activities .................................................................18
Practical Workshops Schedule .................................................................................20
Guru Bar Schedule ......................................................................................................21
Industry Theaters Schedule .......................................................................................25
Non-CME Symposia Schedule ..................................................................................30
Non-CME Symposia Hotel Map ................................................................................31

FLOOR PLANS
Exhibit Hall Floor Plan ............................................................................................36
Clinical Trials Awareness Floor Plan ........................................................................36

EXHIBITOR INDEXES
Exhibitors Alphabetically ..........................................................................................38
Exhibitors by Booth Number ....................................................................................39
Exhibitors by Product Category ...............................................................................41
Exhibitors by Disease State .......................................................................................46

EXHIBITORS
Clinical Trials Awareness Exhibitors ........................................................................53
Global Community Exhibitors ................................................................................54
About the Exhibitors .................................................................................................55
Advertiser Index .......................................................................................................72

STAY CONNECTED
#ATS2019
@atscommunity
facebook.com/americanthoracic
linkedin.com/company/american-thoracic-society_2
The ATS Would Like to Acknowledge our 2019 Corporate Members

BENEFACTOR

Astellion
AstraZeneca
Boehringer Ingelheim
Genentech
GlaxoSmithKline
Novartis
Sanofi Genzyme
Regeneron
Sunovion
Teva
Theravance Biopharma
United Therapeutics

PATRON

Bayer
Insmed
Mallinckrodt Pharmaceuticals
Mylan
Vertex

SUPPORTER

Bellerophon Therapeutics
Boston Scientific
Fisher & Paykel Healthcare
Galápagos

SHIONOGI INC.
Verona Pharma

FRIEND

Bristol-Myers Squibb
PulmonX
Santhera
Veracyte
Vitalograph
Vivus

Thank you for your support.

CORPORATE MEMBERSHIP PROGRAM | www.thoracic.org
WELCOME to Big D!

Big D could stand for big data, big discoveries, or big demos, because you’ll find all of these and more during the ATS 2019 International Conference in Dallas—the original Big D. Now marking its 115th year, the conference offers the latest groundbreaking research in pulmonary, critical care, and sleep medicine. Inside the Exhibit Hall, myriad opportunities provide attendees with access to vendors, networking, special events, in-hall learning opportunities, and other valuable information to make your educational exposure at ATS 2019 bigger than ever. Plan ahead to make these key features a part of your agenda:

• Visit more than 200 exhibitors showcasing products and services designed to improve patient care. Learn how to participate in clinical trials and explore international societies.

• Engage with staff at the ATS Center, which has been reimagined for 2019 to help you discover your community, your excellence, your voice—your ATS.

• Enjoy the benefits of Restoring Joy in Health Care. This popular returning feature, located in Booth 4733, helps physicians crowd source ways to improve the professional environment. While in the booth, be sure to view the National Academy of Medicine’s Expressions of Clinician Well-Being art installation. Additionally, everyone’s favorite—therapy dogs—will be on hand Monday and Tuesday.

• Celebrate the progress of ATS during a Toast to Innovation on Tuesday. This networking event offers an evening to connect with colleagues in our shared success.

• Catch up with colleagues over coffee and healthy snacks starting at 11 a.m. each day. Coffee & Connections are located in Booths 705, 3121, 4136, and 4710.

Enjoy!

Polly Parsons, MD, ATSF
President, 2018-2019
American Thoracic Society
HYDRATION/HEADSHOTS/HEALTH CARE (WELLNESS BOOTH)

STAY HYDRATED and stay alert by filling up your ATS water bottle throughout the day from one of the many water fountains located around the Kay Bailey Hutchison Convention Center Dallas. Look for the water drop when you get thirsty.
Hydration Stations sponsored by Regeneron/Sanofi

RESTORING JOY IN HEALTH CARE (WELLNESS BOOTH)  Booth 4733

What does burnout look like and how can we change things personally and professionally for the better? Explore the Restoring Joy in Health Care booth to view the NAM Expressions of Wellbeing art installation, crowd source ways to improve the professional environment, or visit with a therapy dog to bring you back to center.

GET YOUR PROFESSIONAL PHOTO TAKEN  Booth 1112

1. People connect with those they know, like, and trust. Having a professional headshot helps people feel like they know you before you’ve even met.
2. It’s a good marketing tool for the hospital, medical group, or university websites, brochures and other communication channels.
3. You never know when someone is going to ask you for your headshot so it’s good to have it on hand. Maybe you won an award, got a promotion, became a chairperson of an assembly, or were recognized for volunteer work... all reasons to need a professional headshot.

Complimentary for Everyone. Available during Exhibit Hall hours only. Headshots are emailed the same day.
4 EASY WAYS to Navigate the Exhibit Hall

Exhibit Hall Hours
Exhibit Halls C-E
10:30 a.m.-3:30 p.m. Sunday-Tuesday

YOU ARE HERE SIGNAGE
Never get lost in the Exhibit Hall with our You Are Here signage. A popular feature, these large signs assist you in navigating Exhibit Halls C-E. The signs are located at each entrance and several other locations throughout the Hall.

ONLINE EXHIBITOR DIRECTORY
ats19.mapyourshow.com

ATS INTERNATIONAL CONFERENCE MOBILE APP
Available in App Store or Google Play

Let your smartphone be your guide. Navigate the Online Exhibitor Directory to find your way to more than 200 exhibitor booths. Tap the Get Started Now link at the bottom of the screen and log in. You can bookmark exhibitors, sessions, abstracts, and industry programs, and create a personal agenda. This is an efficient way to organize your time in the Exhibit Hall.

The ATS International Conference Mobile App allows you to search exhibitors and the Exhibit Hall floor plan, create a personalized schedule, and complete post-session evaluations. Find complete app details on page 15.
Make your way around the Exhibit Hall with ease. Let these navigational tools guide you along the way, from events to exhibitors and everything in between.

EXHIBIT HALL FLOOR PLAN
This tried-and-true method of navigating the Exhibit Hall can be found on pages 36-37 of this Guide. Prominent ATS venues are highlighted in teal on the floor plan to help guide you along the way. Additionally, ATS Corporate Members are highlighted in red on the floor plan.

Look for exhibitors:
Alphabetically, starting on page 38
By Booth Number, starting on page 39
By Product Category, starting on page 41
By Disease State, starting on page 46

Find complete exhibitor information starting on page 53.

DISCOVERY QUEST
Want a chance to win an Apple Watch? Play Discovery Quest on the ATS International Conference Mobile App, and you may be one of the four winners selected each day. Increase your chances of winning by visiting participating exhibitors, scanning QR codes, and answering questions.

Find participating exhibitors by looking for this icon in the Exhibitor section (beginning on page 53) of this Guide. Look for booths highlighted in green on the Exhibit Hall Floor Plan (see pages 36-37).

Find a QR code reader in the ATS International Conference Mobile App, and use it to take part in the Discovery Quest game.

DISCOVERY QUEST EXHIBITORS (as of April 5, 2019)

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Booth Number</th>
<th>Booth Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleron Pharma</td>
<td>808</td>
<td>nSpire Health</td>
</tr>
<tr>
<td>BD</td>
<td>1712</td>
<td>NTM Info &amp; Research, Inc.</td>
</tr>
<tr>
<td>Hermansky-Pudlak Syndrome Network, Inc.</td>
<td>2915</td>
<td>PracticeLink</td>
</tr>
<tr>
<td>iDbyDNA, Inc.</td>
<td>4419</td>
<td>Pulmonary Fibrosis Foundation</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>1108</td>
<td>Pulmonary Wellness Online</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
<td>Reata Pharmaceuticals (located in Clinical</td>
</tr>
<tr>
<td>Monaghan Medical Corporation</td>
<td>4938</td>
<td>Trial Area, Lobby A/B, Level 2)</td>
</tr>
<tr>
<td>Mount Sinai Health System</td>
<td>812</td>
<td></td>
</tr>
</tbody>
</table>

conference.thoracic.org • 7
INDICATION
LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

IMPORTANT SAFETY INFORMATION
LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

INDICATION
LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

IMPORTANT SAFETY INFORMATION
LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

In this virtual reality experience, you can tour a simulated home to observe the lives of hypothetical LONHALA MAGNAIR patients.

AND test your COPD Knowledge!
Take the COPD Expert Challenge and compete to earn a HIGH SCORE!

COPD = chronic obstructive pulmonary disease

Visit Sunovion Pharmaceuticals Inc. at Booth #3901 to learn more about COPD through 2 engaging experiences!

Through an immersive, educational Virtual Reality Experience explore LONHALA MAGNAIR (glycopyrrolate) Inhalation Solution.
According to GOLD, the choice of device should be individualized based on patient ability and preference.¹

**INDICATION**
LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

**IMPORTANT SAFETY INFORMATION**
LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see the Brief Summary of Prescribing Information on the following page. Please see full Prescribing Information and Patient Information for LONHALA MAGNAIR available at www.sunovionprofile.com/lonhala-magnair.

**References:**

LONHALA and MAGNAIR are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license. SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. © 2019 Sunovion Pharmaceuticals Inc. All rights reserved. 3/19 RESP-US-00016-19

---

**Visit Sunovion Pharmaceuticals Inc. at booth #3901 to learn more.**

**Jet Nebulizers**

LONHALA® MAGNAIR® (glycopyrrolate) Inhalation Solution for the treatment of COPD including chronic bronchitis and/or emphysema

**Inhalers**

According to GOLD, randomized trials have not identified superiority of one device/formulation.² GOLD does not endorse any specific treatments.

Administers medication via natural breathing²
Portable and compact design allows it to fit in a discreet carrying bag²
Administered in 2-3 minutes with proper assembly and cleaning²,³
Virtually silent administration⁴

Visit Sunovion Pharmaceuticals Inc. at booth #3901 to learn more.

Do you have patients who want something in-between?

---

¹ According to GOLD, the choice of device should be individualized based on patient ability and preference.

² HANDSET is 2.4 x 4.7 inches. Controller is 1.6 x 4.6 inches. MAGNAIR weighs 10.2 ounces (including batteries).

³ Improper cleaning and maintenance may increase administration time.

⁴ COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease
**LONHALA® MAGNAIR®**

(glycopyrrolate) inhalation solution, for oral inhalation use

**BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION**

Please see package insert for full Prescribing Information, including Patient Information.

**INDICATIONS AND USAGE:** LONHALA® MAGNAIR® is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

**CONTRAINDICATIONS:** LONHALA® MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or any of the ingredients.

**WARNINGS AND PRECAUTIONS:** Deterioration of Disease and Acute Episodes: LONHALA MAGNAIR should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD. LONHALA MAGNAIR has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta,-agonist. COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If LONHALA MAGNAIR no longer controls symptoms of bronchocstriction the patient’s inhaled, short-acting beta,-agonist becomes less effective; or the patient needs more inhalations of a short-acting beta,-agonist than usual, these may be markers of deterioration of disease. In setting up to evaluate the patient and the COPD treatment regimen n=-/should be undertaken at once. Increasing the daily dose of LONHALA MAGNAIR beyond the recommended dose is not appropriate in this situation.

**Paradoxical Bronchospasm:** As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately, and alternative therapy instituted.

**Immediate Hypersensitivity Reactions:** Immediate hypersensitivity reactions may occur after administration of LONHALA MAGNAIR. If signs suggesting allergic reactions occur, in particular, angioedema (including difficulty swallowing, swelling of the tongue, lips, and face), urticaria, or skin rash, LONHALA MAGNAIR should be discontinued immediately, and alternative therapy instituted.

**Worsening of Narrow-Angle Glaucoma: LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop. Worsening of Urinary Retention: LONHALA MAGNAIR should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

**ADVERSE REACTIONS:**

**Clinical Trials Experience:** Because clinical trials are conducted under specific conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The LONHALA MAGNAIR safety database included 2379 subjects with COPD in two 12-week efficacy trials and one 48-week long-term safety trial. Approximately 12% of the subjects were treated with LONHALA MAGNAIR 25 mcg twice-daily (BID). The safety data described below are based on the two 12-week trials and the one 48-week trial. 12-Week Trials: LONHALA MAGNAIR was studied in two 12-week placebo-controlled trials in 431 subjects with COPD, treated with LONHALA MAGNAIR at the recommended dose of 25 mcg, twice daily. The population had a mean age of 63 years (ranging from 40 to 87 years), with 56% males, 90% Caucasian, and a mean post-bronchodilator forced expiratory volume in one second (FEV₁) percent predicted of 52% of predicted normal value (20%-80%) at study entry. The study population also included subjects with pre-existing cardiovascular disease as well as subjects with a history of use of stable long-acting bronchodilator (LABA) or inhaled corticosteroid (ICS) and irapratropium bromide background therapy. Subjects with unstable cardiac disease, narrow-angle glaucoma, or symptomatic prostatic hypertrophy or bladder outlet obstruction were excluded from these studies. The proportion of subjects who discontinued treatment due to adverse reactions was 5%, for the LONHALA MAGNAIR-treated subjects and 9% for placebo-treated subjects.

**OVERDOSAGE:** An overdose of glycopyrrolate may lead to anticholinergic signs and symptoms such as nausea, vomiting, dizziness, lightheadedness, blurred vision, increased intracranial pressure (causing pain, vision disturbances, or reddening of the eye), obtipation or difficulties in voiding. In COPD patients, orally inhaled administration of LONHALA MAGNAIR at a total daily dose of 200 mcg for 28 consecutive days (maximum of 1 mg) was well tolerated.

**PATIENT COUNSELING INFORMATION:** Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

LONHALA® MAGNAIR is a registered trademark and is a trademark of Sunovion Pharmaceuticals Inc. MAGNAR® is a registered trademark of PARI GmbH, used under license. SUNOVION® and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. PARI® and are registered trademarks of PARI GmbH. eFlow is a registered trademark of PARI GmbH. Made under license of the Technology Partnership plc.

©2018 Sunovion Pharmaceuticals Inc. All rights reserved.
Third Annual ATS Walking Challenge

Step up to the Third Annual ATS Walking Challenge.

Every step helps raise money for the ATS Foundation. The top 3 overall steppers win a prize and 3 randomly selected participants reaching the 30,000 step goal win a prize. Watch it all unfold on leaderboards in the Mylan, Inc. booth #4333 or at the ATS Walking Challenge booth.

The first 2,000 registrants receive a free ATS wireless activity tracker to use with the App (distributed on a ‘first-come, first-served’ basis). The App also supports attendees that prefer to use their own FitBit, Jawbone or iPhone/Android smart phone step counters.

The three individuals who log the most steps win an iPad Air.

Three randomly selected individuals reaching the 30,000 step goal win Bose QuietControl 30 Wireless headphones!

Learn more and pre-register online at: hekahealth.com/ats2019 or stop by the Walking Challenge Booth in Lobby D, level 2 at the Kay Bailey Hutchison Convention Center.

Supported by:

Visit the Mylan, Inc. booth #4333 each day for a step booster.

The more you visit, the more you receive:

Day 1 - 500 steps; Day 2 - 750 steps; and Day 3 - 1,000 steps.

Walk for a good cause! For every participant who walks 30,000 steps, Mylan, Inc. will make a donation of $100 to the ATS Foundation, for a total maximum donation of $50,000. Learn more at Foundation.Thoracic.org.

May 17 - May 22, 2019 | conference.thoracic.org
WHAT’S HAPPENING in the Exhibit Hall?

The Exhibit Hall features hundreds of the latest products and services, but there’s more. Explore the many activities, too, that make the Exhibit Hall a favorite destination during ATS 2019 Dallas.
RETURNING FAVORITES

RESTORING JOY IN HEALTH CARE
Booth 4733
Physician burnout remains prevalent. To address the professional and personal effects of burnout, Restoring Joy in Health Care returns to the Exhibit Hall. Stop by the booth to crowdsource ways to improve the professional environment or enjoy time with a therapy dog. Therapy dogs are in the booth on Monday and Tuesday.

While in the booth, view the National Academy of Medicine’s (NAM) Expressions of Clinician Well-Being art exhibition. NAM asked a variety of artists to express the ideas of clinician burnout, well-being, and resilience in art form. Four of the pieces from this curated traveling gallery are on display.

ATS WALKING CHALLENGE
Take steps to contribute to ATS research by participating in the ATS Walking Challenge, supported by Mylan. Here’s what you do:
• Sign up in the ATS Walking Challenge Booth located in Lobby D (Level 2).
• Track your steps from Saturday through Tuesday.
• Walk a total of 30,000 steps.
• Get a daily step booster by visiting Mylan, Inc., Booth 4333. On Day 1, get 500 additional steps; on Day 2, get 750 extra steps; and on Day 3, get 1,000 extra steps.
• The top three steppers will win an Apple iPad Air, and three randomly selected participants reaching the 30,000 step goal will receive Bose QuietControl 30 wireless headphones.

Each time a participant completes the challenge, Mylan Inc. donates $100 to the ATS Foundation Research Program, or up to $50,000 in total. Be one of the first 2,000 participants to sign up for the challenge and get a step tracker from ATS.

POISED TO LEARN

IN-BOOTH DEMONSTRATIONS AND ACTIVITIES
Various booths
Hands-on demonstrations at exhibitor booths give you the opportunity to learn on the spot. Experience innovative products up close and speak with experts to explore innovation and technological advancements. See pages 18-19 for complete details on all exhibitors hosting in-booth demonstrations.

PRACTICAL WORKSHOPS
Booth 1917
Take part in 90-minute learning opportunities to gain hands-on education and skill-building. The workshops are hosted by medical device companies and manufacturers 12:30 to 2 p.m., Sunday through Tuesday. See page 20 for more information.

GURU BARS
Booths 1700, 1703, 1900, and 1903
These short, lightning-learning sessions provide you the opportunity to collaborate with leaders on an array of subjects. Each session features a 10-minute outline of a problem statement, mitigating factors, and the host’s perspective/solution. The sessions end with a challenge or question posed to participants who discuss it for the remaining 10 minutes. Each Guru Bar provides space for 25 seated participants, with standing room around the perimeter. This combines to create an atmosphere for dynamic and interactive discussion. Guru Bars are organized by categories of interest:
• Guru Bars 1 and 2: Education/Awareness/Prevention or Diagnosis
• Guru Bars 3 and 4: Treatment or Adherence/Compliance
See pages 21-24 for more information.

INDUSTRY THEATERS
Booths 101, 116, 3249, and 4549
Learn and lunch at this year’s Industry Theaters. Stop by to get a deeper understanding of disease areas and explore the latest products from pulmonary, critical care, and sleep medicine. Complimentary boxed lunches are provided by the ATS while supplies last. See pages 25-29 for more information.

EXPAND YOUR NETWORK

TOAST TO INNOVATION
TIME: 1:15-2:15 p.m.
DAY: Tuesday
LOCATION: Exhibit Halls C-E
Here’s your opportunity to connect with colleagues at a networking event designed to recognize the latest in scientific advancements. Take a moment to salute the progress our specialty has achieved.

COFFEE & CONNECTIONS
TIME: Snacks and coffee served at 11 a.m.
DAYS: Sunday-Tuesday
LOCATION: Booths 705, 3121, 4136, and 4710
Grab a chair, a coffee, and a healthy snack while catching up with a colleague. This comfortable space provides the opportunity to regroup and relax between sessions.
LEARN MORE ABOUT …

your community
• Renew your membership or join today.
• Visit the ATS Store to purchase memorabilia.
• Learn about how Assemblies can help build your career, including mentorship.

where today’s science meets tomorrow’s care
• Learn about grant opportunities for early career investigators.
• Rediscover our three specialty-leading peer-reviewed journals.
• Plan ahead for the ATS 2020 International Conference in Philadelphia.

your excellence
• Download clinical guidelines and patient fact sheets.
• See how the ATS can help advance your career.
• Play the ATS Trivia Challenge, and win a prize.

your voice
• See how the ATS is fighting for the profession and patient care, and learn how you can help.
• Meet your peers and find a mentor.
• Learn about local education and networking opportunities.
• Join the conversation via ATS social media.
THE ATS INTERNATIONAL CONFERENCE MOBILE APP

App supported by Gilead Sciences, Inc.

Carry the entire conference in your pocket.

➤ CREATE a personalized schedule.
➤ SEARCH scientific sessions and abstracts.
➤ NETWORK with other attendees.
➤ FIND info on exhibitors and industry programs.
➤ VIEW the Exhibit Hall floor plan.
➤ STAY up to date on conference activities.
➤ SUBMIT in-session audience response and post-session evaluations.

THANK YOU for your support.
The ATS would like to thank the following companies and organizations for providing support through industry-sponsored programs, the use of equipment for our non-CME hands-on learning activities, or general support for the ATS 2019 International Conference.

Acceleron Pharma
Allergan
Ambu
AstraZeneca
Auris Health
BD
BioFire Diagnostics, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Boston Scientific
BTG Vascular
Clement Clarke
Cook Medical
CSL Behring
EKOS, a BTG International group company
ERBE USA, Inc.
Fisher & Paykel Healthcare Inc.
Fisher Paykel
Galapagos NV
Genentech, A Member of the Roche Group
Genentech/Novartis
Getinge
Gilead Sciences, Inc.
GlaxoSmithKline
Guerbet, LLC
Hermansky-Pudlak Syndrome Network
Hill-Rom
IDbyDNA, Inc.
Insmed Incorporated
International Biophysics
Jazz Pharmaceuticals
Konica Minolta Medical Imaging USA, Inc.
Mallinckrodt Pharmaceuticals
MCG Diagnostics
Med Learning Group
MedQIA
Medtronic
Merck
Merit Medical Endotek
MIR - Medical International Research
Managhan Medical Corporation
Mount Sinai Health System
Mylan, Inc.
National Jewish Health
ndd Medical Technologies, Inc.
NEJM Group
Northwestern Medicine
Novartis Pharmaceuticals Corporation
nSpire Health, Inc.
NTM Info and Research, Inc.
Olympus America Inc
Penn State Health Milton S. Hershey Medical Center
Philips Respironics
Plant Therapeutics, Inc.
PracticeLink
Pulmonary Fibrosis Foundation
Pulmonary Wellness & Rehabilitation Center
Pulmonox Corporation
PVI, Peerview Institute for Medical Education
Reata Pharmaceutical
ResMed
RespirTech, a Philips company
RMEI Medical Education
Sanofi Genzyme and Regeneron
Stanford Children’s Health. Lucile Packard Children’s Hospital Stanford
Sunovion Pharmaceuticals, Inc.
Teva Respiratory
The France Foundation
United Therapeutics Corporation
University of Pittsburgh Medical Center
VeraEye, Inc.
Vindico Medical Education
Vyaire Medical

As of April 11, 2019
Join the ATS initiative to improve lung health in patients around the globe. Take part in one or more of these valuable activities.

**ATS PAR PATH**

*Location: Exhibit Hall, Booths 2815-2823, 2915-2923, and 3126*

Members of the ATS Public Advisory Roundtable (PAR) share the important work of patient advocacy in the lung and airways disorder space. Join the PAR Path, beginning at Booths 2815 and 2915, to visit booths from each PAR member. They’ll provide patient interest organizations with the opportunity to engage with physicians, scientists, and other conference attendees. Simply follow the footsteps along the path to discover important resources. Stop by ATS PAR Booth 2922 for more information.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy and Asthma Network</td>
<td>2916</td>
</tr>
<tr>
<td>ARDS Foundation</td>
<td>2823</td>
</tr>
<tr>
<td>Children’s Interstitial &amp; Diffuse Lung Disease</td>
<td>2815</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
<td>2915</td>
</tr>
<tr>
<td>Hermansky-Pudlak Syndrome</td>
<td>2816</td>
</tr>
<tr>
<td>Network, Inc.</td>
<td>2817</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2917</td>
</tr>
<tr>
<td>LUNGevity Foundation</td>
<td>2920</td>
</tr>
<tr>
<td>NTM Info &amp; Research, Inc.</td>
<td>2815</td>
</tr>
<tr>
<td>PCD Foundation</td>
<td>2920</td>
</tr>
<tr>
<td>Pulmonary Fibrosis Foundation</td>
<td>3126</td>
</tr>
<tr>
<td>Scleroderma Foundation</td>
<td>2916</td>
</tr>
<tr>
<td>The LAM Foundation/ Lymphangioleiomyomatosis</td>
<td>2820</td>
</tr>
<tr>
<td>Tuberous Sclerosis Alliance</td>
<td>2920</td>
</tr>
</tbody>
</table>

**CLINICAL TRIALS AWARENESS**

*Location: Lobby A/B (Level 2)*

Looking for a clinical connection? Clinical Trials Awareness is the on-site stop to pursue opportunities to be an investigator for clinical trials or ongoing trials for your patients. The area is identified by large signs that list the current clinical trials in progress from participating exhibitors and ATS Corporate Members. Get more information about the trials by scanning the QR code located on the main signage in the area. See page 53 for exhibitor information.

If you need a QR code reader on your mobile device, search QR Code Reader in the App Store or Google Play.

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altavant Sciences</td>
<td>4</td>
</tr>
<tr>
<td>ALung Technologies</td>
<td>5</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>FibroGen, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Galapagos NV</td>
<td>1</td>
</tr>
<tr>
<td>Reata Pharmaceuticals</td>
<td>8</td>
</tr>
<tr>
<td>Santhera Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>ThermoFisher</td>
<td>11</td>
</tr>
</tbody>
</table>

**GLOBAL COMMUNITY**

*Location: Exhibit Hall, Booths 3433-3445 and 3536-3541*

Visit the Global Community to learn what other thoracic and respiratory societies from around the globe have achieved. This space allows you to exchange information and ideas about the programming while you network with international representatives from pulmonary, critical care, and sleep medicine societies to advance science and improve patient care. Global collaboration can make a dramatic difference in the lung health of patients worldwide.

<table>
<thead>
<tr>
<th>Society</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian Pacific Society of Respirology</td>
<td>3540</td>
</tr>
<tr>
<td>Asociacion Argentina de Medicina Respiratoria</td>
<td>3536</td>
</tr>
<tr>
<td>Asociacion Latinoamericana de Torax - ALAT</td>
<td>3438</td>
</tr>
<tr>
<td>Brazilian Thoracic Society</td>
<td>3434</td>
</tr>
<tr>
<td>Canadian Thoracic Society</td>
<td>3433</td>
</tr>
<tr>
<td>Egyptian Pediatric Pulmonology Society</td>
<td>3541</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>International Society for Aerosols in Medicine</td>
<td>3437</td>
</tr>
<tr>
<td>International Union Against Tuberculosis and Lung Disease</td>
<td>3441</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Japanese Respiratory Society</td>
<td>3538</td>
</tr>
<tr>
<td>Pan African Thoracic Society (PATS)</td>
<td>3435</td>
</tr>
<tr>
<td>Public Health Foundation of India</td>
<td>3440</td>
</tr>
<tr>
<td>Taiwan Society of Pulmonary and Critical Care Medicine</td>
<td>3537</td>
</tr>
<tr>
<td>Thoracic Society of Australia and New Zealand</td>
<td>3443</td>
</tr>
<tr>
<td>Turkish Thoracic Society</td>
<td>3436</td>
</tr>
</tbody>
</table>

**Improve Lung Health TOGETHER, WE ARE**
Harnessing cutting-edge technology has been key to Morgan Scientific’s success in providing effective tools for pulmonary function testing.

In 1980, the Haverhill, Massachusetts, company pioneered valuable software that has changed the face of the pulmonary function market. Along the way, it earned the respect and cooperation of Boston’s renown teaching hospitals. It was there that, in 1985, Morgan Scientific completed an early milestone: An EMR interface between a pulmonary software product and one of the first electronic medical record systems.

It all began when an innovative group of engineers at Morgan Scientific began writing clinical data acquisition and runtime graphical interfaces. They steadily developed powerful, stable software, which became the foundation of the business. Morgan Scientific’s software has integrated with a range of instrumentation, including some of the most innovative and respected designs produced. From the original single breath diffusion apparatus (the Morgan Transfer Test) to the body plethysmographs of today, Morgan Scientific has been at the forefront of pulmonary function testing and design.

The company has been a veteran exhibitor at ATS since 1980. “The ATS International Conference provides us a unique opportunity to meet our customers, to show them advances in our product development, and to gather feedback while sharing ideas,” says Morgan Scientific CEO and Founder Patrick Morgan. “The ATS International Conference tends to attract physicians from academic backgrounds and those often on the leading edge of research. This audience is particularly interested in our work because, over the years, we have engaged in many collaborations of software development and information sharing initiatives.”

Both the company’s products and reputation have benefited from a culture that invites customer input and actively seeks out new ideas, according to Morgan. In fact, many of its customers today are still operating equipment they were supplied more than 15 years ago while using the latest software, he says.

The demanding background of clinical excellence and years of pulmonary function expertise culminated in Morgan Scientific’s latest design of ComPAS2 software. ComPAS2 combines an exquisitely redesigned user interface with state-of-the-art processing that excels at handling the demands of today’s data integration needs. This is coupled with the flexibility to navigate the most complex of IT environments. Written with a passion for clinical data integrity, ease of operation, and the latest in regulatory and cybersecurity standards, ComPAS2 is in a class of its own.

2019 promises to be a break-out year for Morgan Scientific. The launch of ComPAS2 will set an entirely new standard for comprehensive pulmonary function software. For the first time in the company’s history, Morgan Scientific products will be available outside the U.S. to a global audience. Look for ComPAS2 and Morgan Scientific’s renowned fire-breathing dragon in Booth 1508.

Morgan Scientific could be called ‘the listening PFT company.’ Nowhere else can customers get such a warm invitation to influence product development in a way that gets results. So many customer ideas will be on display as we launch ComPAS2 this year, but the process is always evolving, and collaborative ideas are welcome.”

Patrick Morgan, CEO and Founder, Morgan Scientific Inc.
In-Booth Demos and Activities

Several exhibitors are offering a look at their products and services with In-Booth Demos and Activities. Visit these exhibitors to see the latest technology and generate new ideas. Experts are on hand to lead these demonstrations and activities.

ALLIANCE TECH MEDICAL, INC. 3524
Product/Activity: MDI & pMDI Techniques
Get hands-on experience with the new G-16 In-Check Dial.

ARDS FOUNDATION 2823
Product/Activity: Partner With a Patient Organization
ARDS Foundation is a patient/family organization connected with the ARDS community and medical professionals involved with ARDS research.

BOSTON MEDICAL PRODUCTS / NOVATECH 3533
Product/Activity: Stent Placement
Hands-on DUMON stent placement with rigid bronchoscopy.

DYNARIS 3424
Product/Activity: Monitor Your Own Nasal Resistance
You can interact with Dynaris’ oxygen delivery technology while compensating efficiently for changes in unilateral nasal resistance. Visit anytime.

EMMS 3624
Product/Activity: Respiratory Measurement Techniques in Preclinical Applications
Walk through the most common respiratory measurement techniques in preclinical applications: WBP, RC, Double Chamber PFT, and Forced Oscillation Technique.

FOUNDATION FOR SARCOIDOSIS RESEARCH 2921
Product/Activity: Sarcoidosis Education and Grant-Making Opportunities
Monday, Tuesday
Takeaways and one-on-one discussion on FSR’s research support and education to advance the sarcoidosis space.

GENENTECH, A MEMBER OF THE ROCHE GROUP 2106
Product/Activity: A Case-Based Approach to Patient Management
Sunday, 11:30 a.m.
An expert-led case-based discussion of a patient on Esbriet® (pirfenidone), including diagnosis, treatment, and management throughout the journey.

Product/Activity: Utilizing Radiologic Findings for the Differential Diagnoses of ILDs
Sunday, 1:30 p.m., Monday, 11:30 a.m.
A radiologist-led discussion on identifying unique radiologic patterns and proper CT technique for the differential diagnoses of various ILDs.

JAMA NETWORK 4633
Product/Activity: JN Listen
Sunday, 12 p.m.
JN Listen lets you listen to podcasts from JAMA and earn CME credit on your time. Hosted by physician editors who cover clinical medicine topics.

MARSHFIELD CLINIC HEALTH SYSTEM 4226
Product/Activity: Seeking Pulm/CC Physicians for Midwest Opportunities
Monday, 12 p.m.
Marshfield Clinic is seeking BC/BE pulmonary/critical care physicians to join well-balanced departments with a welcoming environment from colleagues.

NSPIRE HEALTH 2608
Product/Activity: How Do You Know Your PFT Devices Are Performing to Spec?
Sunday, 1:15 p.m., Monday, 1:15 p.m.
Learn why current QC practices are insufficient and how to empower your PFT lab to consistently deliver valid results for all of your PFT devices.
### OLYMPUS AMERICA INC. 3500
**Product/Activity:** Ask the Expert
**Sunday, 10:30 a.m., Monday, 10:30 a.m.**
Physicians speaking to attendees about their area of expertise, including EBUS, Peripheral Bronchoscopy, and the Spiration Valve System.

### PUBLIC HEALTH FOUNDATION OF INDIA 3440
**Product/Activity:** Certificate Course in Management of COPD and Asthma
CCCA is a joint certificate program designed, implemented, and delivered by PHFI, CRF, Pune, and Narayana Health, Bengaluru.

### PULMONE USA INC. 4130
**Product/Activity:** Live Demos: Desktop Pulmonary Function Testing
Learn how you can perform desktop plethysmography with the MiniBox+. Live demos daily. Fully reimbursable, used by physicians in more than 30 states.

---

### Reasons You Should Visit the Exhibit Hall

1. The Exhibit Hall is an extension of the learning process.
2. Take part in interactive hands-on demonstrations.
3. Find the latest innovations and newest advances in pulmonary, critical care, and sleep medicine.
4. Compare all relevant products and services in one place.
5. Researchers can find solutions to pressing needs.
6. Obtain patient information from the Public Advisory Roundtable (PAR) exhibitors.
7. Learn from top industry experts at the Industry Theater, Practical Workshop, or Guru Bar presentations.
8. Connect with peers and colleagues, or just take a break.
10. Get a professional head shot taken.
Medical device companies and manufacturers host a series of 90-minute practical workshops. These informative sessions offer learning and skill-building opportunities that you can take back to your practice.

**SUNDAY**

**12:30-2 p.m.**

**Zephyr Endobronchial Valves for Severe Emphysema**

The Zephyr® Endobronchial Valve is a bronchoscopic lung volume reduction (BLVR) procedure that has been proven to significantly improve lung function, exercise capacity, and quality of life for patients with severe emphysema. This practical workshop will feature an overview of clinical evidence and instructions on proper patient selection, hands-on interactive case studies, lobe selection, and assessment of collateral ventilation using the StratX and Chartis Systems, and Zephyr Valve placement and removal.

**Speakers:** Richard Sue, MD, Banner University Medical Center; Dirk-Jan Slebos, MD, University Medical Center of Groningen, Netherlands; Douglas Kyle Hogarth, MD, University of Chicago Hospital; Michela Bezzi, MD, Asst Spedali Civili Brescia; Karin Klooster, PhD, University Medical Center of Groningen, Netherlands

**Company:** Pulmonx Corporation

**MONDAY**

**12:30-2 p.m.**

**Mobile HFCWO Airway Clearance Therapy—Practical Application and Quality of Life: A Hand-On Workshop**

Join International Biophysics, manufacturer of the AffloVest mobile HFCWO airway clearance therapy, for a practical hands-on workshop on the application of mobile HFCWO as a treatment option for certain respiratory diseases such as bronchiectasis, cystic fibrosis, and other neurological disorders. The workshop will be a hands-on exploration of design features that have been engineered to render the therapy as patient-friendly as possible in order to encourage maximum adherence to therapy and maintain quality of life. Integration of the AffloVest with other therapies will be discussed including use in conjunction with nebulizer treatments, exercise, and postural drainage techniques.

**Speaker:** Bobby Lankford, director of sales

**Company:** International Biophysics
Guru Bar Schedule

Tackle a challenge and discuss a solution in these burst sessions. In just 10 minutes, you’re provided with a problem statement, mitigating factors, and the host’s perspective/solution. The session closes with a challenge question and five to 10 minutes to discuss solutions among a small group of session attendees.

SUNDAY

GURU BAR 1
Education/Awareness/Prevention or Diagnosis

11:30-11:50 a.m.
Best Practices in PFT Data Quality and Interpretation
Incongruences between pulmonary function test results, other respiratory diagnostic exams, and/or symptoms adversely affect clinical decisions in millions of cases where pulmonary functions testing is indicated each year. Learn how new best practices can eliminate these incongruences and provide diagnostic confidence in the PFT data you receive from your labs.
Speaker: Tad Scheiblich, BS, MBA, director, clinical applications, nSpire Health
Company: nSpire Health

12:30-12:50 p.m.
Bronchoscopic Lung Volume Reduction With the Spiration Valve System
Join us as we discuss the Spiration Valve System, an innovative endobronchial therapy that offers patients with severe emphysema a customized, minimally invasive treatment option for lung volume reduction with a favorable risk-benefit profile. Patients treated with the Spiration Valve System in clinical trials experienced improvements in breathlessness, lung function, and quality of life. For complete benefit and risk information, please visit svs.olympusamerica.com.
Speaker: Gerard J. Criner, MD, founding chair and professor of thoracic medicine and surgery of Temple University Health System
Company: Olympus America Inc.

1:30-1:50 p.m.
Fluoroscopic Navigation Technology: Solving for CT to Body Divergence
As pioneers of ENB procedures, we take our responsibility of transforming lung cancer from a deadly disease to a managed condition seriously. That’s why we continue to create technologies that help enable a better outcome for patients—including our latest innovation: Fluoroscopic Navigation Technology. Our new software algorithms use multiple fluoroscopic images which provide enhanced visualization of soft tissue objects like lung lesions, accurate modeling of 3-D distances on 2-D images, local registration to help compensate for local CT-to-Body divergence, updated catheter position relative to nodule, and the ability to visualize smaller nodules. Join us and Dr. Krish Bhadra in the discussion.
Speaker: Krishnendu Bhadra, MD, interventional pulmonologist, CHI Memorial Medical Group
Company: Medtronic

GURU BAR 2
Education/Awareness/Prevention or Diagnosis

12-12:20 p.m.
A New Therapeutic Option for Oral Corticosteroid Dependent Asthma
Our speaker will lead an interactive discussion of a hypothetical case with moderate to severe oral corticosteroid dependent asthma. The speaker will describe the data supporting an add-on maintenance treatment option that may reduce and possibly even eliminate the needs for the corticosteroids.
Speaker: Cedric “Jamie” Rutland, MD, assistant clinical professor of internal medicine, University of California Riverside
Company: Sanofi Genzyme and Regeneron
Guru Bar Schedule: Sunday

1-1:20 p.m.
Olympus Peripheral Solution—The Power to Bring the Periphery Closer
Join us for a discussion about the Olympus Peripheral Bronchoscopy Solution which incorporates state-of-the-art bronchoscopes and devices that expand your possibility to reach more distal peripheral lesions better than before. The revolutionary BF-MP190F ultra-slim bronchoscope combined with the radial EBUS probe and the PeriView FLEX TBNA needle, enhance access and improve sampling capabilities bringing the periphery closer.

Speakers: Alexander Chen, MD, assistant professor of medicine and surgery, director of interventional pulmonology, Washington University School of Medicine; Ali Sadoughi, MD, director of interventional pulmonology and bronchoscopy, assistant professor of medicine, Montefiore Medical Center

Company: Olympus America Inc.

GURU BAR 3
Treatment or Adherence/Compliance

11:30-11:50 a.m.
Minimizing Patient Escalation With Effective Nasal High Flow
Confirm mechanisms of action and physiological effects. Outline role of nasal high flow with minimizing patient escalation. Practical application of nasal high flow.

Speaker: Chris Hutchinson, senior product manager

Company: Fisher & Paykel Healthcare

12:30-12:50 p.m.
Optimizing Post-Extubation With Effective Nasal High Flow
Confirm mechanisms of action and physiological effects. Outline role of nasal high flow with optimizing post-extubation. Practical application of nasal high flow.

Speaker: Chris Hutchinson, senior product manager

Company: Fisher & Paykel Healthcare

1:30-1:50 p.m.
COPD Exacerbations: Beyond Inhaler Treatment
Learn more about an available treatment option for patients with uncontrolled COPD continuing to exacerbate on current bronchodilator therapy. Enhance your knowledge and discuss an alternative to help prevent COPD exacerbations.

Speaker: Sanjay Sethi, MD, VA WNY Healthcare System

Company: AstraZeneca

12-12:20 p.m.
Corecath: A Novel Way of Debulking Airways
As pioneers of ENB procedures, we take our responsibility of transforming lung cancer from a deadly disease to a managed condition seriously. That’s why we continue to create technologies that help enable a better outcome for patients—including our latest innovation: the CoreCath™ 2.7S device. This electrosurgical device lets you remove soft tissue obstructions in the upper airways and tracheobronchial tree by debulking, coagulating, and evacuating surgical smoke with integrated suction. This multiple-application tool provides electrosurgical hemostasis and may be delivered through the working channel of a flexible bronchoscope, and is designed to reduce the number of tools in a procedure. Join us and Dr. Mahajan in the discussion.

Speaker: Amit “Bobby” Mahajan, MD, FCCP, DAABIP, medical director of interventional pulmonology, Inova Heart and Vascular Center

Company: Medtronic

1-1:20 p.m.
Robotics and the Future of Lung Cancer Diagnosis: A Community Hospital’s Experience With the Monarch Platform
Stephen Kovacs, DO, FCCP, will host a presentation about his current use of the Monarch Platform in U.S. cases. Visit Booth 613 to learn more about the Monarch Platform.

Speaker: Stephen Kovacs, DO, FCCP, co-director, UPMC Hamot Comprehensive Lung Center, UPMC

Company: Auris Health
GURU BAR 1
Education/Awareness/Prevention or Diagnosis

11:30-11:50 a.m.
Novel Approaches to Lung Nodule Management: Percepta Bronchial Genomic Classifier
A clinically proven complement to lung cancer diagnostic bronchoscopies, the Percepta classifier down-classes patients to low risk to avoid invasive procedures. A special clinician speaker will discuss the Percepta test and review patient cases.
Company: Veracyte, Inc.

12:30-12:50 p.m.
Innovative Trial Design: How to Bring the Real World of IPF Management Into Phase 3 Programs
Galapagos is committed to being a valued scientific partner in the race to combat idiopathic pulmonary fibrosis (IPF). The current poor clinical prognosis for patients and a median survival at diagnosis of two to five years underscores the need for novel treatments and approaches to address the high unmet need in IPF. Please join us during this session as a member of our clinical team will present the ISABELA phase 3 program, and discuss with the audience the value and challenges of novel trials designed to assess investigational drugs in a real-world management setting.
Speaker: Paul Ford, MD, PhD, VP & TA, head of respiratory medicine, Galapagos
Company: Galapagos NV

1:30-1:50 p.m.
Envisia Genomic Classifier—Improving Confidence in ILD Diagnosis
Learn how the Envisia classifier identifies a genomic UIP pattern utilizing transbronchial biopsy tissue for a more confident ILD diagnosis. Hear from a clinician on how the Envisia test is being used in practice.
Company: Veracyte, Inc.

GURU BAR 2
Education/Awareness/Prevention or Diagnosis

12-12:20 p.m.
A Closer Lens on the Relationship Between COPD Exacerbations and Outcomes
Exacerbations are not only a common cause of hospital admissions in COPD patients, but they are also associated with significant impact in morbidity, mortality, and overall changes in quality of life. Explore the evidence regarding exacerbations and their life-changing impact on patients’ lives.
Speaker: Antonio Anzueto, MD, University of Texas Health Science Center at San Antonio
Company: AstraZeneca

GURU BAR 3
Treatment or Adherence/Compliance

12:30-12:50 p.m.
Implementing Humidified High Flow on the General Care Floor
Confirm mechanisms of action and physiological effects. Outline role of humidified high flow on the general care floor in patients who have recently suffered an AECOPD. Practical application of humidified high flow on general care floor.
Speaker: James Gibbons, product manager
Company: Fisher & Paykel Healthcare

1:30-1:50 p.m.
Diagnosis of Bronchiectasis and Subsequent Treatment Options
Alan Barker, MD, professor of medicine, pulmonary and critical care, Oregon Health & Science University (OHSU), will present on the diagnosis and treatment of bronchiectasis. Dr. Barker will briefly cover the pathogenesis of bronchiectasis and the chest imaging characteristics. The importance of confirming diagnosis of bronchiectasis using the gold standard of HRCT will be emphasized and best practices of working with your radiologist will be discussed. Subsequent treatment options for bronchiectasis will be covered, including the role of airway clearance therapy techniques such as HFCWO vest therapy.
Speaker: Alan Barker, MD, professor of medicine, pulmonary and critical care, Oregon Health & Science University
Company: International Biophysics


**GURU BAR 4**
Treatment or Adherence/Compliance

**1:10 p.m.**
**Robotic-Assisted Bronchoscopy With the Monarch™ Platform: Technical, Pre-Clinical, and Clinical Consideration**

Auris will host a presentation by a physician currently using the Monarch Platform in U.S. cases. Visit Booth 613 to learn more about the Monarch Platform.

**Speaker:** Alexander Chen, MD, interventional pulmonologist, Washington University School of Medicine in St. Louis

**Company:** Auris Health

---

**TUESDAY**

**GURU BAR 1**
Education/Awareness/Prevention or Diagnosis

**11:30-11:50 a.m.**
**Insights in ILD.com: A Comprehensive Educational Resource for Health Care Professionals**

This Guru Bar will feature a presentation delivered by an expert pulmonologist on the various diseases associated with interstitial lung disease (ILD). The presentation will highlight the value of recognizing commonalities and differences of the fibrotic ILD patterns that are seen across the diseases, underscoring the importance of clinical consideration of the ILD component shared among many diseases. This program will also highlight the recently launched InsightsinILD.com website, an in-depth resource for learning about ILDs.

**Speaker:** Marilyn Glassberg, MD, professor of medicine, surgery; director, Rare and Interstitial Lung Disease Program, University of Miami Miller School of Medicine

**Company:** Boehringer Ingelheim Pharmaceuticals, Inc.

---

**12:30-12:50 p.m.**
**Implementing Humidified High Flow on the General Care Floor**

Confirm mechanisms of action and physiological effects. Outline role of humidified high flow in patients with respiratory failure on the general care floor. Practical application of humidified high flow on general care floor.

**Speaker:** Clemmis Futrell, US AIRVO manager

**Company:** Fisher & Paykel Healthcare

---

**GURU BAR 3**
Treatment or Adherence/Compliance

**12:30-12:50 p.m.**
**Innovative Trial Design: How to Bring the Real World of IPF Management Into Phase 3 Programs**

Galapagos is committed to being a valued scientific partner in the race to combat idiopathic pulmonary fibrosis (IPF). The current poor clinical prognosis for patients and a median survival at diagnosis of two to five years underscores the need for novel treatments and approaches to address the high unmet need in IPF. Please join us during this session as a member of our clinical team will present the ISABELA phase 3 program and discuss with the audience the value and challenges of novel trials designed to assess investigational drugs in a real-world management setting.

**Speaker:** Niyati Prasad, Dr., senior clinical director, Galapagos

**Company:** Galapagos
Industry Theaters Schedule

Lunch and learn during Industry Theaters, Medium Theaters, and Mini Industry Theaters in the Exhibit Hall. Here, select companies provide you with the latest clinical updates related to pulmonary, critical care, and sleep medicine. Attendees receive a complimentary boxed lunch while supplies last.

SUNDAY

THEATER 1

11:30 a.m.-12:15 p.m.
Eosinophilic Asthma: Patient Identification and a Targeted Treatment Approach
Eosinophilic asthma is a common type of severe asthma in adult patients. Eosinophils can contribute to exacerbations and lung function decline in patients with allergic or non-allergic severe asthma. This complimentary symposium will highlight the growing body of literature on eosinophils and severe asthma. The presenter will use a case-based approach to help clinicians identify eosinophilic asthma in clinical practice and will discuss a targeted approach to the management of severe eosinophilic asthma. Attendees should leave being able to translate the growing science of eosinophils into real-world applications for severe asthma patients in the clinic.

Speaker: Reynold Panettieri Jr., MD, professor and vice chancellor clinical and translational science, Rutgers University
Company: AstraZeneca

1:15-2 p.m.
Company: Sanofi Genzyme and Regeneron

THEATER 2

11:30 a.m.-12:15 p.m.
Rethinking the “O” in COPD
This symposium will explore how the physiologic finding of “airflow obstruction” became central to the definition, classification, and treatment of COPD, even though this occurs late in the disease process. Rethinking how we approach disease modification in the future will require that we rethink what comprises early disease, before obstruction is present, and focus on important phenotypes, endotypes, and treatable traits that will guide interventions.

Speakers: Bart Celli, MD, professor of medicine, Harvard Medical School; David Mannino, MD, U.S. medical expert, GlaxoSmithKline; Brad Drummond, MD, associate professor of medicine, director, Obstructive Lung Diseases Clinical and Translational Research Center, University of North Carolina; MeiLan K. Han, MD, professor, division pulmonary and critical care, University of Michigan
Company: GlaxoSmithKline

1:15-2 p.m.
The First LAMA for Inhalation Using Natural Breathing

Speaker: Donald A. Mahler, MD, emeritus professor of medicine, Geisel School of Medicine at Dartmouth
Company: Sunovion Pharmaceuticals Inc.
Industry Theaters Schedule: Sunday

**MEDIUM THEATER**

12:20-1:05 p.m.  
*An Oral Treatment for Pulmonary Arterial Hypertension (PAH, WHO Group I): Targeting the Prostacyclin Pathway*

The management of pulmonary arterial hypertension (PAH) continues to evolve with targeting multiple pathways through sequential combination therapy now at the forefront of our treatment strategies. This interactive case-based theater will feature a PAH thought leader who will discuss an oral treatment for PAH targeting the prostacyclin pathway. Lunch will be provided. (Lunch will not be provided to physicians and other HCPs licensed in Vermont or other states where gifts and meals are prohibited.) This presentation is sponsored by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, and is open to all ATS 2019 International Conference attendees. This promotional educational activity is not accredited.

**Speakers:** Rajeev Saggar, MD, executive director, Lung Institute, director of pulmonary hypertension and fibrosis programs, University of Arizona, COM-Phoenix Banner University Medical Center-Phoenix, Phoenix, Arizona

**Company:** Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

1:30-2 p.m.  
*Interstitial Lung Disease in Systemic Sclerosis: A Case-Based Discussion*

This presentation will enlist an expert pulmonologist and rheumatologist who will present patient case studies providing insight into the interactions required to recognize and diagnose systemic sclerosis-associated interstitial lung disease (SSc-ILD). The presentation of these case studies will underscore the importance of the interactions that occur between these specialties to diagnose SSc-ILD and monitor disease progression. An overview of the current knowledge regarding SSc examining the pulmonary manifestations of the disease will also be reviewed.

**Speakers:** S. Samuel Weigt, MD, MS, director, UCLA Interstitial Lung Disease Center, associate professor of medicine, David Geffen School of Medicine at UCLA; Elizabeth Volkmann, MD, MS, founder, co-director, UCLA Connective Tissue Disease-Related Interstitial Lung Disease Program, assistant professor of medicine, David Geffen School of Medicine at UCLA

**Company:** Boehringer Ingelheim Pharmaceuticals, Inc.

**MINI THEATER**

11:30 a.m.-12 p.m.  
*Going Beyond the Prescription – Consider First the Medication Delivery System*

Device delirium. So many choices of inhalers and aerosol delivery systems lead to patient confusion. What needs to be taken into consideration when prescribing medication devices?

**Speaker:** James B. Fink, PhD, RRT, FAARC, FCCP, chief scientific officer, Aerogen Pharma Corp.

**Company:** Philips

12:30-1 p.m.  
*What You Didn’t Know About Budesonide*

A retrospective review of the budesonide molecule and its history. Challenge your assumptions, revisit data, and learn new information as this session takes you into a deep dive of budesonide’s mechanism, unique characteristics, and other considerations.

**Speaker:** Donald Tashkin, MD, professor emeritus of medicine, David Geffen School of Medicine at UCLA

**Company:** AstraZeneca

**MONDAY**

**THEATER 1**

11:30 a.m.-12:15 p.m.  
*Advancing the Treatment of Eosinophilic Disease*

Join us for an engaging program exploring the role of eosinophils in disease management. We will examine key efficacy and safety data for a treatment that reduces eosinophils, including long-term data in patients with severe asthma. We will also discuss clinical approaches for identifying appropriate patient types that may benefit from a targeted treatment to reduce eosinophils. In addition, hear from a patient about a journey with eosinophilic disease and treatment.

**Speaker:** Mario Castro, MD, MPH, professor of medicine, Washington University School of Medicine

**Company:** GSK
1:15-2 p.m.  
**Mepolizumab: Choosing the Right Patient for Lasting Efficacy**  
Several biologics targeting the IL-5 pathway are now available to treat severe eosinophilic asthma. This Industry Theater will help HCPs navigate these options to make informed clinical decisions. The first presentation will discuss “Blood Eosinophils: A Simple Biomarker to Identify a Responder Patient,” and review the patient profile most likely to benefit from treatment with mepolizumab. In the second presentation, titled “Mepolizumab: The Evidence of Lasting Efficacy to Support Clinician’s Choice,” we will focus on the latest long-term data available for mepolizumab, which has up to 4.5 years of consistent efficacy and safety data in severe asthma patients.  
**Speakers:** Emilio Pizzichini, MD, PhD, professor, GSK and Universidade Federal de Santa Catarina; Neil Barnes, FRCP, professor, GSK; Ian D. Pavord, FMedSci, professor, University of Oxford  
**Company:** GSK

**THEATER 2**  
11:30 a.m.-12:15 p.m.  
**A Treatment Option for Adult Patients With Refractory MAC Lung Disease**  
Although patients with Mycobacterium Avium Complex (MAC) lung disease often achieve culture conversion on guideline-recommended therapy, many patients are refractory to treatment. Appropriate management of refractory MAC lung disease can be challenging for both physicians and patients, given the limited treatment options for refractory MAC patients. This is an interactive program for U.S. health care professionals that will provide insight into the treatment of adult patients with refractory MAC lung disease.  
**Speaker:** David E. Griffith, MD, professor of medicine, pulmonary infectious disease section chief, University of Texas Health Science Center  
**Company:** Insmed

1:15-2 p.m.  
**Exploring Trends in COPD Treatment With Dual Bronchodilator and Triple Therapy Approaches**  
Join COPD experts as they provide an in-depth examination of some of today’s important topics surrounding the management and treatment of patients with COPD using dual bronchodilator and triple therapy options. The panel will address commonly asked questions, review evolving approaches, and discuss clinical data.  
**Company:** GSK

**MEDIUM THEATER**  
12:20-1:05 p.m.  
**More Than an Airway Problem? Understanding Excessive Daytime Sleepiness in Obstructive Sleep Apnea (OSA)**  
Emerging science suggests that chronic intermittent hypoxia and sleep fragmentation caused by OSA may produce alterations to wake-promoting regions of the brain. One consequence of these changes may be excessive daytime sleepiness. This presentation will discuss the science related to potential brain changes and the diagnosis of excessive daytime sleepiness in OSA.  
**Speakers:** Richard K. Bogan, MD, FCCP, FAASM, medical director, SleepMed of South Carolina; Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, associate professor of medicine, Medical University of South Carolina  
**Company:** Jazz Pharmaceuticals

**MINI THEATER**  
11:30 a.m.-12 p.m.  
**EVOLVE EBUS**  
As the oncologists demands EVOLVE by requesting additional tissue samples for full molecular testing, sarcoid, and lymphoma, we will discuss BSC’s CoreDx™ Pulmonary Mini-Forceps (pending 510(k) clearance, not available for sale in the United States) as an internodal mini forceps biopsy. The CoreDx device may provide you with different experiences than today’s EBUS-TBNA procedure which may potentially satisfy the demands of your oncologist and pathologist.  
**Speakers:** Momen Wahidi, MD, interventional pulmonologist, Duke University; Amit (Bobby) Mahajan, MD, interventional pulmonologist, Inova Fairfax; Chakravarthy Reddy, MD, interventional pulmonologist, University of Utah  
**Company:** Boston Scientific
EDUCATIONAL OPPORTUNITIES

Industry Theaters Schedule: Monday

12:30-1 p.m.
Comparison of Various Forms of Positive Airway Pressure Therapies for Sleep-Disordered Breathing in Heart Failure
Treatment of sleep disorders with servo ventilation has been questioned following past studies. Learn about recent clinical evidence that demonstrates the result of those studies may have been due to a device-effect and not a class-effect.

Speaker: Salma Patel, MD, MPH, assistant professor of medicine, UA Health Sciences
Company: Philips

1:30-2 p.m.
Breakthroughs in Diagnosing Respiratory Infections: Identifying Previously Missed Pathogens Using Explify® Respiratory, a Novel Next-Generation Sequencing (NGS) Based Test
Due to limitations in testing methods, pathogens are never identified in up to 60 percent of pneumonia cases. Explify® Respiratory is a metagenomics-based test that utilizes DNA/RNA sequencing and data analytics to identify pathogens conventional tests miss. Explify Respiratory can quickly and accurately identify more than 50,000 bacteria, fungi, viruses, and parasites—including more than 3,000 pathogens—to provide clinicians with more actionable information. This program will cover current limitations in diagnosing respiratory infections and the consequences, and how testing patients with Explify Respiratory can address these issues. Case studies will be presented demonstrating how Explify Respiratory has improved outcomes in clinical settings.

Speaker: Robert Schlaberg, MD, PhD, chief medical officer, IDbyDNA
Company: IDbyDNA

TUESDAY

THEATER 1

11:30 a.m.-12:15 p.m.
Driving Improved Patient Outcomes in COPD
This GSK-sponsored Industry Theater will help HCPs achieve COPD treatment goals of reducing symptoms and future risk of exacerbations by answering two key questions. Professor Claus Vogelmeier will examine the current evidence supporting the use of dual bronchodilators in patients with high symptom burden, including data showing the benefit of early optimization of maintenance therapy with LAMA/LABA, to answer the question, “Why wouldn’t we optimize bronchodilation in symptomatic COPD patients?” Professor Alberto Papi will then consider the evidence for the use of triple therapy in patients with at least one exacerbation in the past 12 months and discuss “Why wouldn’t we intervene earlier in patients at risk of exacerbation?”

Speakers: Paul Jones, MD, PhD, professor, GSK, UK; Claus F. Vogelmeier, MD, professor, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany; Alberto Papi, MD, professor, University of Ferrara, Italy
Company: GSK

1:15-2 p.m.
Evolving Understanding of Inflammatory Mediators in Asthma
Company: Novartis Pharmaceuticals

THEATER 2

11:30 a.m.-12:15 p.m.
Type 2 Inflammation and Developments in the Management of Asthma
This presentation will provide an overview of the contributory role of Type 2 inflammation in asthma and treatment strategy development. The speaker will describe the data supporting an add-on maintenance treatment option for certain patients with uncontrolled moderate to severe asthma.

Speaker: Reynold A. Panettieri Jr., MD, professor of medicine, Robert Wood Johnson Medical School
Company: Sanofi Genzyme and Regeneron
EDUCATIONAL OPPORTUNITIES

Industry Theaters Schedule: Tuesday

1:15-2 p.m.
**Biomarkers in Severe Asthma: What They Tell Us and What They Don’t**
This biomarkers symposium will provide an in-depth discussion around the data on IgE levels, exhaled nitric oxide, and circulating eosinophil counts in severe asthma. The role of these measurements as biomarkers for predicting exacerbations, evaluating disease control, and determining response to biologic therapies will be reviewed.

**Speakers:** Eugene Bleecker, MD, professor of medicine, co-chief, Division of Genetics, Genomics and Precision Medicine, UA Department of Medicine co-director, Division of Pharmacogenomics, UA Center for Applied Genetics and Genomic Medicine, The University of Arizona Health Sciences; Geoffrey Chupp, MD, professor of medicine, director, Yale Center for Asthma and Airways Disease, director, Pulmonary Function Laboratory, Yale-New Haven Hospital

**Company:** GlaxoSmithKline

---

12:30-1 p.m.
**Intervening in Pulmonary Embolism With EKOS Therapy**
EKOS Therapy, an exciting option for treating PE. Join us to learn how EKOS’ therapy with a tpa dose as low as 8 mg and a treatment time as short as 2 hours can transform your interventional options for PE. This interactive symposia will feature clinical data, case presentations, and evidence of a shorter length of stay.

**Speaker:** Kennedy Omonuwa, MD, attending, Pulmonary/Critical Care Medicine, Lincoln Medical Center, Bronx, NY

**Company:** BTG Vascular

---

1:30-2 p.m.
**Insights in ILD Podcast Live: Commonalities Among the Interstitial Lung Diseases**
During this live podcast conversation, two expert pulmonologists will provide a broad overview of recognizing, diagnosing, and managing interstitial lung diseases (ILDs), highlighting the common signs and symptoms. Faculty will then discuss key tests performed to diagnose patients with an ILD and strategies used for symptom management.

**Speakers:** Erica Herzog, MD, PhD, associate professor of medicine (pulmonary), director, Translational Lung Research Program, co-director, Yale Fibrosis Program, assistant director, medical student research, Department of Medicine, director, Interstitial Lung Disease Center of Excellence, Yale Pulmonary & Critical Care Medicine; Steven D. Nathan, MD, medical director, Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital

**Company:** Boehringer Ingelheim Pharmaceuticals, Inc.

---

12:20-1:05 p.m.
**MEDIUM THEATER**

**Company:** Sanofi Genzyme and Regeneron

---

11:30 a.m.-12 p.m.
**MINI THEATER**

**Company:** BioFire Diagnostics

---

11:30 a.m.-12 p.m.
**Molecular Diagnostics for Pneumonia: An Initial Evaluation of the BioFire Pneumonia Panel**
For pneumonia patients, bacterial culture from lower respiratory tract specimens is the primary method of pathogen identification. Culture results take days, and frequently do not identify a causative agent of infection. Recently, molecular diagnostics for lower respiratory tract infections have been FDA cleared and are commercially available. These technologies offer increased sensitivity and reduced turnaround time, but questions remain about their practical implementation. In this Industry Mini Theater, Richard Wunderink, MD, will discuss the current state of molecular diagnostics for pneumonia and present results from an initial clinical evaluation of the BioFire Pneumonia Panel.

**Company:** BioFire Diagnostics
Non-CME Symposia Schedule

Be sure to attend Non-CME Symposia during the ATS 2019 International Conference. These highly encouraged sessions are integral to the conference experience and learning. See the facing page for a map of hotels hosting symposia.

SUNDAY

6:30-9:30 p.m.
A Disease-State Presentation: Exploring Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Hyatt Regency Dallas, Landmark Ballroom C
Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare vasculitis that often involves the respiratory tract, affects small-to-medium vessels, and is associated with asthma and eosinophilia. EGPA is difficult to diagnose and manage due to its rarity and complexity. Early recognition is critical to avoid organ damage. This educational session will review the pathogenesis, clinical manifestations, classification criteria, diagnosis, and prognosis of EGPA.

Speaker: Michael Wechsler, MD, MMSc, professor of medicine, director of the asthma program at National Jewish Health, director of the Cohen Family NJH Asthma Institute, division of pulmonary, critical care and sleep medicine in the department of medicine at National Jewish Health and University of Colorado School of Medicine
Company: GlaxoSmithKline

6:30-9:30 p.m.
A Multidisciplinary Case Study Approach: From Recognition to Progression of Fibrosing ILDs
Sheraton Dallas Hotel, Lone Star Ballroom A2-A4
This symposium will enlist an expert multidisciplinary panel detailing various clinical presentations of progressive fibrosing interstitial lung diseases. Case studies will be used and will focus on initial clinical presentations of various fibrotic ILDs, disease progression over time, and how identifying the progressive phenotype of ILD-associated diseases will help guide patient care decisions. This interactive panel discussion will demonstrate the importance of multidisciplinary discussions in resolving diagnostic challenges.

Speakers: Gregory P. Cosgrove, MD, FCCP, assistant director of the interstitial lung disease program, endowed chair in interstitial lung disease at National Jewish Health; Flavia V. Castelino, MD, director of the scleroderma program, assistant professor of medicine at Massachusetts General Hospital, Harvard Medical School; Lida Hariri, MD, PhD, assistant pathologist, assistant professor of pathology at Massachusetts General Hospital, Harvard Medical School; Geoffrey D. Rubin, MD, MBA, FACR, George G. Gellar Distinguished Professor of Radiology at Duke University School of Medicine
Company: Boehringer Ingelheim Pharmaceuticals, Inc.

6:30-9:30 p.m.
An Add-On Maintenance Treatment Option for Patients With Moderate-to-Severe Uncontrolled Asthma Driven by Type 2 Inflammation
Fairmont Dallas, International Ballroom
The session will begin with a presentation of an add-on maintenance treatment option for certain patients with moderate-to-severe asthma. The presentation will cover the approved indication, mechanism of action, and supporting clinical data. Following the session, our moderators will lead an interactive discussion of several hypothetical patient cases for whom this treatment option may be appropriate. Our discussion will focus on rationales for considering this treatment option for heterogeneous patients with distinct clinical characteristics suggesting that Type 2 inflammation contributes to their uncontrolled asthma.

Speakers: Geoffrey Chupp, MD, director at the Yale Center for Asthma and Airway Disease; Laren Tan, MD, assistant professor of internal medicine at Loma Linda University Medical Center
Company: Sanofi Genzyme and Regeneron
6:30-9:30 p.m. 
**Bronchiectasis: Emerging Trends and Unmet Needs**

**Fairmont Dallas, Regency Ballroom**
Emerging evidence shows that non-cystic fibrosis bronchiectasis (NCFB) is more common than previously thought and is viewed as a severe comorbidity of COPD. Appropriate diagnosis and treatment are key to improving outcomes and quality of life, and to helping reduce health care costs. In this non-CME educational symposium, global NCFB experts describe why awareness of the condition is growing, how to accurately identify patients with NCFB, and how to address symptoms within the framework of “treatable traits.” They will present the latest research, clinical guidelines, and actionable information related to this under-recognized but critically important pulmonary condition.

**Speakers:** Michael Polkey, MD, Royal Brompton Hospital in London, U.K.; Timothy Aksamit, MD, Mayo Clinic in Rochester, Minnesota; James Chalmers, MBChB, PhD, University of Dundee and Ninewells Hospital and Medical School in Dundee, U.K.; Tara Barto, MD, Baylor College of Medicine in Houston

**Company:** RespirTech, a Philips Company

---

6:30-9:30 p.m. 
**In Pursuit of the Leaking Lymph: Nonmalignant Thoracic Lymphatic Disorders**

**Sheraton Dallas Hotel, Lone Star Ballroom B**
Experts will discuss classification of pulmonary lymphatic disorders and evaluate new imaging and therapeutic approaches for the differentiation and management of lymphatic disorders. Attendees will hear from global experts in this field.

---

6:30-9:30 p.m. 
**Exploring Idiopathic Pulmonary Fibrosis With the Experts: A Multidisciplinary Program on the Diagnosis, Treatment, and Management of IPF**

**Sheraton Dallas Hotel, Austin Ballroom**
Join us for an innovative symposium led by a multidisciplinary team of idiopathic pulmonary fibrosis (IPF) experts. In this interactive and case-based program, attendees will explore such topics as the importance of prompt diagnosis, the potential benefits and risks of treating patients with an FDA-approved IPF-specific therapy, and the steps for initiating and maintaining a comprehensive management plan.

**Speakers:** Anne Whitney Brown, MD, director of clinical operations, Inova Advanced Lung Disease & Transplant Program, assistant professor of medicine, Virginia Commonwealth University School of Medicine; Inova Fairfax Campus Falls Church, Virginia; Cedric Jamie Rutland, MD, Pacific Pulmonary Medical Group, assistant clinical professor of internal medicine, University of California, Riverside School of Medicine, Riverside, California; Jubal Watts Jr., MD, Radiology of Huntsville, Huntsville, Alabama

**Company:** Genentech, A Member of the Roche Group

---

(continued on page 32)
**Non-CME Symposia Schedule: Sunday**

**6:30-9:30 p.m.**

**Systemic Sclerosis-Associated Interstitial Lung Disease: Expert Insights on Early Diagnosis and Optimal Management**

**Hyatt Regency Dallas, Marsalis Exhibit Hall A**

Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Interstitial lung disease (ILD) occurs in the majority of patients with SSc and is now the No. 1 cause of death in these patients. Treatment for SSc-associated ILD has historically been limited; however, novel therapies have shown promise in clinical trials. Through a live, non-CME MasterClass held during the American Thoracic Society International Conference on May 19, 2019, in Dallas, Texas, a panel of expert faculty will offer insight to help clinicians achieve a greater understanding into the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence with respect to emerging therapies.

**Speakers:** Marilyn K. Glassberg, MD, director, interstitial lung disease program director, pulmonary diseases at interdisciplinary stem cell institute, professor of medicine, surgery, and pediatrics vice chair of medicine for diversity and innovation at the University of Miami School of Medicine; Aryeh Fischer, MD, associate professor of medicine division of rheumatology, division of pulmonary sciences and critical care medicine at the University of Colorado School of Medicine; Kristin B. Highland, MD, MSCR, associate program director for research and scholarly activity, pulmonary fellowship at the Cleveland Clinic

**Company:** PVI, PeerView Institute for Medical Education, supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, A Member of the Roche Group

**Register:** PeerView.com/ILD19Dallas

---

**6:30-9:30 p.m.**

**Nasal High Flow in the Critical Care Setting**

**Hyatt Regency Dallas, Landmark Ballroom A**

This session highlights advances in improved care of respiratory failure and the clinical outcomes in critical care and emergency medicine using nasal high flow therapy. Nasal high flow is optimal humidified respiratory support at up to 60L/min with the AIRVO2 to provide reduction of dead space, delivery of a dynamic positive airway pressure, airway hydration, patient comfort, and supplemental oxygen. These mechanisms contribute to physiological effects such as reduced respiratory rate, improved oxygenation, reduced carbon dioxide levels, and improved mucus clearance. Clinical studies demonstrate that nasal high flow therapy may reduce escalation of care, reduce mortality rates, and improve symptomatic relief.

**Speakers:** Nicholas Hill, MD, professor at Tufts University; Gregory Schmidt, MD, professor at the University of Iowa; Tomaso Mauri, MD, PhD, associate professor at the University of Milan

**Company:** Fisher & Paykel Healthcare

---

**Treatment of these disorders. They will also assess pulmonary involvement in patients with lymphatic malformations. Interactive clinical case presentations will provide scientific pearls for integrating diagnostic and therapeutic algorithms into your practice.**

**Speakers:** Maxim Itkin, MD, FSIR, professor of radiology and pediatrics at the Center for Lymphatic Disorders at Perelman School of Medicine, University of Pennsylvania; Bruce K. Rubin, MD, MEng, MBA, FRCPC, Jessie Ball duPont Distinguished Professor and chair in the department of pediatrics, professor of biomedical engineering, and physician in chief at Virginia Commonwealth University School of Medicine and Children’s Hospital of Richmond at VCU; Christopher Towe, MD, assistant professor of pediatrics, pediatric pulmonary and pediatric lung transplant and director of rare lung diseases at Cincinnati Children’s Hospital Medical Center

**Company:** Vindico Medical Education, supported by an educational grant from Guerbet, LLC
6:30-9:30 p.m.  
Uncontrolled Obstructive Airway Diseases: Treatment and Stepwise Management Approaches to Severe Asthma and Exacerbations in Chronic Obstructive Pulmonary Disease (COPD)  
Hyatt Regency Dallas, Landmark Ballroom B  
Learn treatment and early management approaches to severe asthma and exacerbations in COPD. A national panel of experts will discuss the burden and impact of severe asthma as well as the challenges associated with overreliance on oral corticosteroids (OCS). Also, the importance of COPD exacerbations and their impact on patients in real-world clinical practice will be discussed as well as the need to help prevent future exacerbations.  
**Speakers:** Nicola Hanania, MD; Gene Bleecker, MD; Gary Ferguson, MD  
**Company:** AstraZeneca

---

6:30-9:30 p.m.  
Are We There Yet? Tips to Better IPF Management  
Hyatt Regency Dallas, Marsalis Exhibit Hall A  
Our faculty will engage learners in interactive “What would YOU do?” case-based questions and demonstrate the positive impact of shared decision-making. It will include a short patient testimonial as to the impact and burden that IPF has had on them and how shared decision-making made a positive difference in their care plan, treatment adherence, and quality of life.  
**Speakers:** Marilyn K. Glassberg, MD, professor of medicine and surgery at the Miller School of Medicine at the University of Miami, Florida; Lisa H. Lancaster, MD, program medical director of the interstitial lung disease program at the Vanderbilt University Medical Center in Nashville, Tennessee; Fernando J. Martinez, MD, MS, chief of the division of pulmonary and critical care medicine at New York Presbyterian Hospital/Weill Cornell Medical Center in New York  
**Company:** The France Foundation, supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, A Member of the Roche Group  
**Register:** pilotforpulmonary.org/ipf19

---

6:30-9:30 p.m.  
Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease: A Care Team Forum™  
Hyatt Regency Dallas, Landmark Ballroom A  
Learn what you’re missing about Alpha-1 antitrypsin deficiency (AATD) lung disease. Interact with world-renowned experts including Drs. Sandhaus, Stocks, Campos, and a live AATD patient during this dynamic evidence-based symposium. We’ll discuss several AATD patient types, such as high-risk genotype and low FEV1 as well as diagnostic considerations and therapeutic interventions, including augmentation therapy. In addition, you can submit your challenging AATD clinical cases and get expert opinions for management.  
**Speakers:** Robert A. Sandhaus, MD, PhD, FCCP, professor of medicine, division of pulmonary, critical care and sleep medicine director, Alpha-1 program at the National Jewish Medical and Research Center; Michael A. Campos, MD, associate professor of medicine, division of pulmonary, allergy, critical care at the University of Miami School of Medicine; James M. Stocks, MD, professor of medicine at the University of Texas Health Science Center at Tyler  
**Company:** RMEI Medical Education, supported by educational grants from Shire–part of Takeda, Grifols, and CSL Behring.

---

6:30-9:30 p.m.  
Paving the Way in Fibrotic Lung Disease: Expanding Applications for Existing Therapies  
Sheraton Dallas Hotel, Lone Star Ballroom A2-A4  
Expert faculty will discuss progressive fibrosing interstitial lung disease, providing guidance on its timely and accurate identification; they will also evaluate the expanding applications for current idiopathic pulmonary fibrosis therapies in other fibrotic lung diseases. Case presentations will provide scientific pearls for the integration of diagnostic and therapeutic algorithms into clinical practice.  
**Speakers:** Amy L. Olson, MD, MSPH, associate professor in the department of medicine and medical director of the pulmonary physiology unit at National Jewish Health; Kevin R. Flaherty, MD, MS, professor of medicine in the division of pulmonary/critical care medicine and medical director at the Michigan Medicine ILD Clinic, University of Michigan; Steven D. Nathan, MD, medical director of the advanced lung disease and transplant program and professor of medicine at Inova Fairfax Hospital and Virginia Commonwealth University, Inova Fairfax Campus  
**Company:** Vindico Medical Education, supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
**Non-CME Symposia Schedule: Tuesday**

**6:30-9:30 p.m.**
The Changing Landscape of Nontuberculous Mycobacterial Lung Disease (NTM-LD): A 3D View of Pathogenesis, Diagnosis, and Management

*Hyatt Regency Dallas, Landmark Ballroom C*
This engaging 3D satellite symposium offers a unique learning opportunity investigating NTM-LD. Worldwide prevalence has been increasing, with pervasive impacts exhibited among chronic and structural lung disease, aging, and immunocompromised populations. Through evidence-based didactics, case-based learning, and 3D animation, complexities of diagnosis and management will be explored for *M. avium* complex (MAC) and *M. abscessus* with the aim to: review microbiology, pathogenesis, and environmental aspects of NTM; summarize recent data on NTM epidemiology and risk factors; describe treatment goal personalization methodologies; assess drug-related adverse event prevention strategies; evaluate established and emerging therapy clinical data.

**Speakers:** Charles L. Daley, MD, chief of the division of mycobacterial and respiratory infections, professor of medicine at the National Jewish Health; Kevin Winthrop, MD, MPH, professor of public health, infectious disease, and ophthalmology at Oregon Health & Science University

**Company:** Insmed Incorporated

---

**6:30-9:30 p.m.**
The Current State of Idiopathic Pulmonary Fibrosis

*Fairmont Dallas, Regency Ballroom*
This symposium will enlist two expert pulmonologists presenting information on idiopathic pulmonary fibrosis (IPF). Current knowledge regarding IPF, including the updated 2018 ATS/ERS/JRS/ALAT diagnostic guidelines, as well as recommendations for use of multidisciplinary discussions in patient diagnosis, will be reviewed.

**Speakers:** Justin Oldham, MD, MS, director of the interstitial lung disease program, assistant professor at the University of California, Davis; Robert Sussman, MD, attending in the department of medicine at Morristown Medical Center, Overlook Medical Center

**Company:** Boehringer Ingelheim Pharmaceuticals, Inc.

---

**6:30-9:30 p.m.**
The Severe Asthma Challenge

*Hyatt Regency Dallas, Reunion Ballroom GH*
Test your knowledge of allergic asthma! Doctors William J. Calhoun and Reynold A. Panettieri Jr. will host a live game-show—The Severe Asthma Challenge—where dinner attendees will have the opportunity to compete against their peers. The highest-scoring contestants from the first round will move on to compete on the main stage in the final round. Questions will focus on the following topics: asthma phenotypes and endotypes, the role of biomarkers in asthma, and the role of immunoglobulin E (IgE) in allergic asthma.

**Speakers:** William J. Calhoun, MD, professor of medicine, vice chair for research, department of internal medicine, University of Texas Medical Branch, Galveston, Texas; Reynold A. Panettieri Jr., MD, professor of medicine, Robert Wood Johnson Medical School, Rutgers Institute for Translational Medicine, New Brunswick, New Jersey

**Company:** Genentech, A Member of the Roche Group, and Novartis Pharmaceuticals Corporation

---

**6:30-9:30 p.m.**
U.S. Presidents With Severe Asthma: Endotypes and Precision Medicine

*Fairmont Dallas, International Ballroom*
This activity will delve into the lives of U.S. presidents with asthma, to draw a contrast between treatment approaches of the past and current and emerging therapies that target specific disease mechanisms. We’ll summarize mechanisms of action as well as key efficacy and safety data for cytokine antagonists being used or investigated for severe asthma treatment. The information learned will then be applied, using case scenarios, in selecting personalized treatments based on asthma phenotypes and endotypes.

**Speakers:** Tara Carr, MD, associate professor of medicine, associate professor of otolaryngology, director of the Adult Allergy Program, director of the Allergy & Immunobiology Fellowship Program, The University of Arizona Health Sciences; Nicola Hanania, MD, associate professor of medicine—pulmonary, director of the Airways Clinical Research Center, director of the asthma and COPD clinic at Baylor College of Medicine; Linda Rogers, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai

**Company:** The France Foundation, supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

**Register:** pilotforpulmonary.org/asthma19
Zero in on pneumonia bugs faster than ever.

1 Test. 33 Targets. ~1 Hour.

Pneumonia cases can be complex, and the infectious agents are masters of disguise. The BioFire® FilmArray® Pneumonia Panel lets you quickly zero in on an extensive watch list of pathogens and antimicrobial resistance genes. For bacteria that can be normal flora, semi quantitative results give you the intelligence you need to make informed treatment decisions.

Molecular diagnostics for pneumonia:
An initial evaluation of the BioFire Pneumonia Panel

Mini Theater | May 21, 2019 | 11:30 am–12 pm

Richard G. Wunderink, MD
Professor of Medicine (Pulmonary and Critical Care), Feinberg School of Medicine, Northwestern University

A discussion of the current state of molecular diagnostics for pneumonia, including results from an initial clinical evaluation of the BioFire Pneumonia Panel.

biofiredx.com | booth #4524
ATS Corporate Members
These exhibitors are noted in red on the floor plan.

Actelion Pharmaceuticals 3908
AstraZeneca 4308
Bayer 3315
Bellerophon Therapeutics* 2
BMS/Pfizer 3411
Boehringer Ingelheim Pharmaceuticals, Inc., 2800, 2811, 4438
Boston Scientific Corporation 2412
Fisher & Paykel Healthcare Inc. 2112
Galapagos NV* 1
Genentech, A Member of the Roche Group 2106
GlaxoSmithKline 3715
Insmed Incorporated 3722
Mallinckrodt Pharmaceuticals 4122
Mylan Inc. 3733, 4333
Novartis Pharmaceuticals 1500
Pulmonx Corp. 1505
Regeneron Pharmaceuticals/Sanofi Genzyme 3111, 4515
Santhera Pharmaceuticals* 9
Sunovion Pharmaceuticals Inc. 3901
TEVA Pharmaceuticals 1412
United Therapeutics 3511
Veracyte, Inc. 4838
Vertex Pharmaceuticals, Inc. 3729
Vitalograph, Inc. 1708

Discovery Quest
These exhibitors are noted in green on the floor plan.

Acceleron Pharma 808
BD 1712
Hermansky-Pudlak Syndrome Network, Inc. 2915
IDbyDNA, Inc. 4419
Jazz Pharmaceuticals, Inc. 1108
MedQIA 4233
Monaghan Medical Corporation 4938
Mount Sinai Health System 812
nSpire Health 2608
NTM Info & Research, Inc. 2815
PracticeLink 4125
Pulmonary Fibrosis Foundation 3126
Pulmonary Wellness Online 712
Reata Pharmaceuticals* 8

Don't let pneumonia bugs evade detection.

Learn more at BioFire booth #4524.
EXHIBIT HALL HOURS
10:30 a.m.-3:30 p.m.
Sunday-Tuesday
### Exhibitors Alphabetically

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC National Center for Environmental Health</td>
<td>902</td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention</td>
<td>4326</td>
</tr>
<tr>
<td>Children’s Intestinal &amp; Diffuse Lung Disease Foundation (chILD)</td>
<td>2816</td>
</tr>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital</td>
<td>1406</td>
</tr>
<tr>
<td>Circassia Pharmaceuticals, Inc.</td>
<td>1912</td>
</tr>
<tr>
<td>Contec Medical Systems Co., Ltd.</td>
<td>3323</td>
</tr>
<tr>
<td>COOK MEDICAL</td>
<td>3504</td>
</tr>
<tr>
<td>COPA Syndrome Foundation</td>
<td>3128</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>1405</td>
</tr>
<tr>
<td>CRC Press, Taylor &amp; Francis Group</td>
<td>912</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>Dynans</td>
<td>3424</td>
</tr>
<tr>
<td>Eastern Pulmonary Conference</td>
<td>4127</td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
<td>4426</td>
</tr>
<tr>
<td>Egyptian Pediatric Pulmonology Society</td>
<td>3541</td>
</tr>
<tr>
<td>Elsevier</td>
<td>3312, 3412</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>ERBE USA</td>
<td>2507</td>
</tr>
<tr>
<td>ERT</td>
<td>3636</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>FDA Center for Tobacco Products</td>
<td>3523</td>
</tr>
<tr>
<td>FibroGen, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Fisher &amp; Paykel Healthcare Inc.</td>
<td>2112</td>
</tr>
<tr>
<td>FLUIDDA NV</td>
<td>4429</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
<td>2921</td>
</tr>
<tr>
<td>FUJIFILM Medical Systems U.S.A., Inc.</td>
<td>4322</td>
</tr>
<tr>
<td>Fujifilm SonoSite</td>
<td>4320</td>
</tr>
<tr>
<td>Futuremed</td>
<td>3015</td>
</tr>
<tr>
<td>Galapagos NV</td>
<td>1</td>
</tr>
<tr>
<td>GCE Healthcare</td>
<td>2203</td>
</tr>
<tr>
<td>Genentech, A Member of the Roche Group</td>
<td>2106</td>
</tr>
<tr>
<td>Genentech/Novartis</td>
<td>2512</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>4344</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>3715</td>
</tr>
<tr>
<td>Great Lakes Dental Technologies</td>
<td>2201</td>
</tr>
<tr>
<td>Grifols USA, LLC</td>
<td>1908</td>
</tr>
<tr>
<td>Hans Rudolph, Inc.</td>
<td>1812</td>
</tr>
<tr>
<td>HCmed Innovations</td>
<td>3017</td>
</tr>
<tr>
<td>Healthup</td>
<td>AioCare</td>
</tr>
<tr>
<td>Hermansky-Pudlak Syndrome Network, Inc.</td>
<td>2915</td>
</tr>
<tr>
<td>Hexoskin</td>
<td>1408</td>
</tr>
<tr>
<td>Hill-Rom</td>
<td>2504</td>
</tr>
<tr>
<td>Hugger Medical Instrument Co. Ltd.</td>
<td>1403</td>
</tr>
<tr>
<td>IDbyDNA, Inc.</td>
<td>4419</td>
</tr>
<tr>
<td>Imbio, LLC</td>
<td>4319</td>
</tr>
<tr>
<td>Infinity Massage Chairs</td>
<td>2312</td>
</tr>
<tr>
<td>Insmed Incorporated</td>
<td>3722</td>
</tr>
<tr>
<td>Inspire Medical Systems, Inc.</td>
<td>3519</td>
</tr>
<tr>
<td>The Intensivist Company</td>
<td>3426</td>
</tr>
<tr>
<td>International Biophysics</td>
<td>3515</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>International Society for Aerosols in Medicine</td>
<td>3437</td>
</tr>
<tr>
<td>International Union Against Tuberculosis and Lung Disease</td>
<td>3441</td>
</tr>
<tr>
<td>INTUITIVE</td>
<td>1100</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Itamar Medical</td>
<td>2607</td>
</tr>
<tr>
<td>JAMA Network</td>
<td>4633</td>
</tr>
<tr>
<td>Japanese Respiratory Society</td>
<td>3538</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>1108</td>
</tr>
<tr>
<td>Kaiser Permanente</td>
<td>1409</td>
</tr>
<tr>
<td>Konica Minolta Healthcare Americas, Inc.</td>
<td>4636</td>
</tr>
<tr>
<td>The LAM Foundation/ Lymphangioliomyomatosis</td>
<td>2820</td>
</tr>
<tr>
<td>Level Ex</td>
<td>900</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>LUNGevity Foundation</td>
<td>2923</td>
</tr>
<tr>
<td>Lymol Medical Corporation</td>
<td>3326</td>
</tr>
<tr>
<td>Mallinckrodt Pharmaceuticals</td>
<td>4122</td>
</tr>
<tr>
<td>Marshfield Clinic Health System</td>
<td>4226</td>
</tr>
<tr>
<td>Masimo</td>
<td>4141</td>
</tr>
<tr>
<td>Maxor Specialty</td>
<td>4128</td>
</tr>
<tr>
<td>Mayne Pharma</td>
<td>4435</td>
</tr>
<tr>
<td>MedEd On The Go</td>
<td>4225</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>Medtronic</td>
<td>2500</td>
</tr>
<tr>
<td>Merit Medical Endotek</td>
<td>2200</td>
</tr>
<tr>
<td>Methapharm, Inc.</td>
<td>1008</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>3115</td>
</tr>
<tr>
<td>MIR – Medical International Research</td>
<td>4427</td>
</tr>
<tr>
<td>Monaghan Medical Corporation</td>
<td>4938</td>
</tr>
<tr>
<td>Morgan Scientific Inc.</td>
<td>1508</td>
</tr>
<tr>
<td>Mount Sinai Health System</td>
<td>812</td>
</tr>
<tr>
<td>Mylan Inc.</td>
<td>3733, 4333</td>
</tr>
<tr>
<td>National Board for Respiratory Care, Inc.</td>
<td>4329</td>
</tr>
<tr>
<td>National Board of Echocardiography, Inc.</td>
<td>2313</td>
</tr>
<tr>
<td>National Death Index</td>
<td>1603</td>
</tr>
<tr>
<td>National Disease Research Interchange</td>
<td>4229</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
</tbody>
</table>

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
National Institute of Environmental Health Science (NIEHS) 4534
National Jewish Health 813
ndd Medical Technologies Inc. 3626
NeilMed Pharmaceuticals 2508
NeuWave / Johnson & Johnson 612
Northwest Seminars 4536
Novabisis 1209
Novartis Pharmaceuticals 1500
Novartis Pharmaceuticals Corporation 1300
nSpire Health 2608
NTM Info & Research, Inc. 2815
Olympus America Inc. 3500
Oncimmune USA LLC 909
Owlstone Medical Ltd. 3520

P-R
Pan African Thoracic Society (PATS) 3435
patientMpower 3638
PCD Foundation 2920
Pediatric Search Partners 1308
Penn State Health 4228
PerkinElmer 1208
The PERT Consortium 3016
PF Warriors 3023
Philips Respironics 3318
Polarion, Inc. 2717
PracticeLink 4125
Praedicare 1012
Propeller Health 3522
Provider Solutions + Development 2101

Public Health Foundation of India 3440
Pulmonary Fibrosis Foundation 3126
Pulmonary Hypertension Association 4434
Pulmonary Wellness Online 712
PulmOne USA Inc. 4130
Pulmox Corp. 1505
RB 4706
Reata Pharmaceuticals 8
Regeneron Pharmaceuticals / Sanofi Genzyme 3111, 4515
ResMed 3726
Rocket Medical PLC 3526

S-U
Santhera Pharmaceuticals 9
Savara Inc. 708
SCIREQ - an emka TECHNOLOGIES company 3619
Scleroderma Foundation 2917
SEOIL PACIFIC CORP. 2303
Society of Critical Care Medicine (SCCM) 1503
SomnoMed, Inc. 3321
SoutheastHEALTH 2202
Spire Health 2403
St. Joseph Hospital & Medical Center 4126
STEMCELL Technologies, Inc. 4241
Sunovion Pharmaceuticals Inc. 3901
Taiwan Society of Pulmonary and Critical Care Medicine 3537

V-Z
Vathin Medical Co. Ltd. 4436
Ventec Life Systems 4521
Veracyte, Inc. 4838
Veran Medical Technologies 2300
Vertex Pharmaceuticals, Inc. 3729
Vitalograph, Inc. 1708
Vyaire Medical 4315
Wolters Kluwer 1309
3000s

3015 Futuremed
3016 The PERT Consortium
3017 HCmed Innovations
3020 UreSil LLC
3021 Alpha-1 Foundation
3022 Thirona
3023 PF Warriors
3111 Regeneron Pharmaceuticals/Sanofi Genzyme
3115 MGC Diagnostics
3118 Breathe Technologies, Inc.
3126 Pulmonary Fibrosis Foundation
3128 COPA Syndrome Foundation
3129 American Board of Internal Medicine
3130 American Thoracic Society
3218 Broncus Medical, Inc.
3226 UPMC
3229 American College of Chest Physicians (CHEST)
3311 Biodex, Inc.
3312 Elsevier
3315 Bayer
3318 Philips Respironics
3321 SomnoMed, Inc.
3323 Contec Medical Systems Co., Ltd.
3324 BRAEBON Snoring & Sleep Apnea
3326 Lymol Medical Corporation
3411 BMS/Pfizer
3412 Elsevier
3422 Bruker BioSpin
3423 Christus Health
3424 Dynaris
3426 The Intensivist Company
3429 Biogen
3433 Canadian Thoracic Society
3434 Brazilian Thoracic Society
3435 Pan African Thoracic Society (PATS)
3436 Turkish Thoracic Society
3437 International Society for Aerosols in Medicine
3438 Asociacion Latinoamericana de Torax - ALAT
3440 Public Health Foundation of India
3441 International Union Against Tuberculosis and Lung Disease
3443 Thoracic Society of Australia and New Zealand
3444 Irish Thoracic Society
3445 European Respiratory Society
3500 Olympus America Inc.
3504 COOK MEDICAL
3507 Allergan USA, Inc.
3511 United Therapeutics
3515 International Biophysics
3519 Inspire Medical Systems, Inc.
3520 Owlsone Medical Ltd.
3522 Propeller Health
3523 FDA Center for Tobacco Products
3524 Alliance Tech Medical, Inc.
3526 Rocket Medical PLC
3533 Boston Medical Products / Novatech
3536 Asociacion Argentina de Medicina Respiratoria
3537 Taiwan Society of Pulmonary and Critical Care Medicine
3538 Japanese Respiratory Society
3540 Asian Pacific Society of Respirology
3541 Egyptian Pediatric Pulmonology Society
3543 4Dx
3619 SCIREQ - an emka TECHNOLOGIES company
3622 BTG
3624 EMMS
3626 ndd Medical Technologies Inc.
3630 ERT
3636 patientMpower
3640 3D Systems Simbionix
3715 GlaxoSmithKline
3722 Insmed Incorporated
3726 ResMed
3729 Veritor Pharmaceuticals, Inc.
3733 Mylan Inc.
3901 Sunovion Pharmaceuticals Inc.
3908 Actelion Pharmaceuticals US Inc.

4000s

4122 Mallinckrodt Pharmaceuticals
4125 PracticeLink
4126 St. Joseph Hospital & Medical Center
4127 Eastern Pulmonary Conference
4128 Maxor Specialty
4129 Healthup | AioCare
4130 PulmOne USA Inc.
4133 THORASYS Thoracic Medical Systems Inc.
4134 Masimo
4225 MedEd On The Go
4226 Marshfield Clinic Health System
4227 Asthma and Allergoy Foundation of America
4228 Penn State Health
4229 National Disease Research Interchange
4230 Association of Pulmonary Advanced Practice Providers
4231 B. Braun Interventional Systems, Inc.
4233 MedQIA
4241 STEMCELL Technologies, Inc.
4308 Astrazeneca
4315 Vyaira Medical
4319 Imbio, LLC
4320 Fujifilm SonoSite
4322 FUJIFILM Medical Systems U.S.A., Inc.
4325 Cohero Health
4326 Centers for Disease Control and Prevention
4327 U.S. EPA's National Air and Energy Research Program
4329 National Board for Respiratory Care, Inc.
4333 Mylan Inc.
4344 Gilead Sciences, Inc.
4419 IDbyDNA, Inc.
4420 AMBU
4425 TSI Healthcare
4426 ECO MEDICS – ECO PHYSICS
4427 MIR – Medical International Research
4429 FLUIDDA NV
4433 Clement Clarke International
4434 Pulmonary Hypertension Association
4435 Mayne Pharma
4436 Vathin Medical Co. Ltd.
4438 Boehringer Ingelheim Pharmaceuticals, Inc.
4515 Regeneron Pharmaceuticals/Sanofi Genzyme
4521 Ventlec Life Systems
4524 Biofire Diagnostics, LLC
4533 CMI Health Inc.
4534 National Institute of Environmental Health Science (NIEHS)
4536 Northwest Seminars
4633 JAMA Network
4634 Body Vision Medical
4635 US Acute Care Solutions
4636 Konica Minolta Healthcare Americas, Inc.
4706 RB
4738 National Heart, Lung, and Blood Institute
4838 Veracyte, Inc.
4938 Monaghan Medical Corporation
4940 AyuVis Research
### Exhibitors by Product Category

#### Airway Measurement
- Bellerophon Therapeutics 2
- BleepSleep 2314
- Cincinnati Children's Hospital 1406
- Clement Clarke International 4433
- Cohero Health 4325
- COOK MEDICAL 3504
- Coreline Soft Co., Ltd. 1405
- ECO MEDICS – ECO PHYSICS 4426
- EMMS 3624
- ERT 3636
- GlaxoSmithKline 3715
- Hans Rudolph, Inc. 1812
- Hill-Rom 2504
- Lymol Medical Corporation 3326
- MedQIA 4233
- Methapharm, Inc. 1008
- Monaghan Medical Corporation 4938
- Morgan Scientific Inc. 1508
- PulmOne USA Inc. 4130
- SEOL PACIFIC CORP. 2303
- THORASYS Thoracic Medical Systems Inc. 4133
- Vathin Medical Co. Ltd. 4436
- Vitalograph, Inc. 1708

#### Allergy, Immunology, and Inflammation
- Alliance Tech Medical, Inc. 3524
- AyuVis Research 4940
- Bellerophon Therapeutics 2
- Boston Scientific Corporation 2412
- Circassia Pharmaceuticals, Inc. 1912
- Cohero Health 4325
- ECO MEDICS – ECO PHYSICS 4426
- EMMS 3624
- Foundation for Sarcoïdosis Research 2921
- GlaxoSmithKline 3715
- Mayne Pharma 4435
- MedQIA 4233
- Monaghan Medical Corporation 4938
- Morgan Scientific Inc. 1508
- National Institute of Environmental Health Science (NIEHS) 4534
- National Jewish Health 813
- Olympus America Inc. 3500
- Owlsone Medical Ltd. 3520
- PerkinElmer 1208
- Philips Respironics 3318
- PulmOne USA Inc. 4130
- SCIREQ - an emka TECHNOLOGIES company 3619
- STEMCELL Technologies, Inc. 4241

#### Animal Physiology
- Data Sciences International (DSI) 2715
- EMMS 3624
- PerkinElmer 1208
- SCIREQ - an emka TECHNOLOGIES company 3619
- STEMCELL Technologies, Inc. 4241

#### BioAssay Products
- Associates of Cape Cod, Inc. 2102
- IDbyDNA, Inc. 4419
- Novabiosis 1209
- Praedicare 1012

#### Biomedical Informatics
- Hexoskin 1408
- IDbyDNA, Inc. 4419

#### Biotech
- Associates of Cape Cod, Inc. 2102
- Bellerophon Therapeutics 2
- Biodexis, Inc. 3311
- FibroGen, Inc. 10
- Galapagos NV 1
- GlaxoSmithKline 3715
- Grifols USA, LLC 1908
- IDbyDNA, Inc. 4419
- Insmed Incorporated 3722
- Maxor Specialty 4128
- MedQIA 4233
- Owlsone Medical Ltd. 3520
- Praedicare 1012
- Reata Pharmaceuticals 8
- Spire Health 2403
- STEMCELL Technologies, Inc. 4241
- Takeda 305
- United Therapeutics 3511

#### Bronchoprovocation Testing
- Methapharm, Inc. 1008
- MGC Diagnostics 3115
- Vitalograph, Inc. 1708

#### Bronchoscopy
- AMBU 4420
- Aurs Health 613
- Boston Medical Products / Novatech 3533
- Boston Scientific Corporation 2412
- Cincinnati Children's Hospital 1406
- FUJIFILM Medical Systems U.S.A., Inc. 4322
- Huger Medical Instrument Co. Ltd. 1403
- Lymol Medical Corporation 3326
- Medtronic 2500
- Merit Medical Endotek 2200
- Olympus America Inc. 3500
- Temple Lung Center 1407
- Vathin Medical Co. Ltd. 4436

#### Business/Practice Management Tools
- Medtronic 2500
- nSpire Health 2608

#### CPAP/Bi-Level and Nasal High Flow
- Aerogen 2716
- Bellerophon Therapeutics 2
- BleepSleep 2314
- Cincinnati Children's Hospital 1406
- Fisher & Paykel Healthcare 2112
- Hans Rudolph, Inc. 1812
- Philips Respironics 3318
- ResMed 3726
- Ventec Life Systems 4521

#### Critical Care
- Aerogen 2716
- Allergan USA, Inc. 3507
- American College of Chest Physicians (CHEST) 3229
- ARDS Foundation 2823
- Associates of Cape Cod, Inc. 2102
- Bellerophon Therapeutics 2
- Boston Medical Products / Novatech 3533
- Cincinnati Children's Hospital 1406
- COOK MEDICAL 3504
- Fisher & Paykel Healthcare 2112
- Fujifilm SonoSite 4320
- Hans Rudolph, Inc. 1812
- Hill-Rom 2504
- IDbyDNA, Inc. 4419
- Konica Minolta Healthcare Americas, Inc. 4636
- Mayne Pharma 4435
- National Board of Echocardiography, Inc. 2313
- National Jewish Health 813
- Philips Respironics 3318
- Society of Critical Care Medicine (SCCM) 1503
- Spire Health 2403
- STEMCELL Technologies, Inc. 4241
- Takeda 305
- United Therapeutics 3511
- Vathin Medical Co. Ltd. 4436
### Exhibitors by Product Category, cont.

<table>
<thead>
<tr>
<th>Company</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>UreSil LLC</td>
<td>3020</td>
</tr>
<tr>
<td>US Acute Care Solutions</td>
<td>4635</td>
</tr>
<tr>
<td>Ventec Life Systems</td>
<td>4521</td>
</tr>
<tr>
<td><strong>Data Acquisition</strong></td>
<td></td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>Hans Rudolph, Inc.</td>
<td>1812</td>
</tr>
<tr>
<td>Healthup</td>
<td>4129</td>
</tr>
<tr>
<td>Hexoskin</td>
<td>1408</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES company</td>
<td>3619</td>
</tr>
<tr>
<td><strong>Diagnosis or Treatment of Lung Disease—Equipment or Device</strong></td>
<td></td>
</tr>
<tr>
<td>Auris Health</td>
<td>613</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>Body Vision Medical</td>
<td>4634</td>
</tr>
<tr>
<td>Boston Medical Products / Novatech</td>
<td>3533</td>
</tr>
<tr>
<td>Boston Scientific Corporation</td>
<td>2412</td>
</tr>
<tr>
<td>BTG</td>
<td>3622</td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital</td>
<td>1406</td>
</tr>
<tr>
<td>Contec Medical Systems Co., Ltd.</td>
<td>3323</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>1405</td>
</tr>
<tr>
<td>DynaRx</td>
<td>3424</td>
</tr>
<tr>
<td>Futuremed</td>
<td>3015</td>
</tr>
<tr>
<td>Healthup</td>
<td>4129</td>
</tr>
<tr>
<td>Hill-Rom</td>
<td>2504</td>
</tr>
<tr>
<td>IDbyDNA, Inc.</td>
<td>4419</td>
</tr>
<tr>
<td>Konica Minolta Healthcare Americas, Inc.</td>
<td>4636</td>
</tr>
<tr>
<td>Lyomol Medical Corporation</td>
<td>3326</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>Medtronic</td>
<td>2500</td>
</tr>
<tr>
<td>Monaghan Medical Corporation</td>
<td>4938</td>
</tr>
<tr>
<td>Morgan Scientific Inc.</td>
<td>1508</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>nSpire Health</td>
<td>2608</td>
</tr>
<tr>
<td>Olympus America Inc.</td>
<td>3500</td>
</tr>
<tr>
<td>Onctimmune USA LLC</td>
<td>909</td>
</tr>
<tr>
<td>Owlstone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Rocket Medical PLC</td>
<td>3526</td>
</tr>
<tr>
<td>Spire Health</td>
<td>2403</td>
</tr>
<tr>
<td>Thirona</td>
<td>3022</td>
</tr>
<tr>
<td>Vathin Medical Co. Ltd.</td>
<td>4436</td>
</tr>
<tr>
<td>Ventec Life Systems</td>
<td>4521</td>
</tr>
<tr>
<td>Veracyte, Inc.</td>
<td>4838</td>
</tr>
<tr>
<td><strong>Diagnostic Systems</strong></td>
<td></td>
</tr>
<tr>
<td>BRAEBON Snoring &amp; Sleep Apnea</td>
<td>3324</td>
</tr>
<tr>
<td>Clement Clarke International</td>
<td>4433</td>
</tr>
<tr>
<td>Contec Medical Systems Co., Ltd.</td>
<td>3323</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>1405</td>
</tr>
<tr>
<td>Fujifilm Sonosite</td>
<td>4320</td>
</tr>
<tr>
<td>Healthup</td>
<td>4129</td>
</tr>
<tr>
<td>Huger Medical Instrument Co. Ltd.</td>
<td>1403</td>
</tr>
<tr>
<td>IDbyDNA, Inc.</td>
<td>4419</td>
</tr>
<tr>
<td>Konica Minolta Healthcare Americas, Inc.</td>
<td>4636</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>3115</td>
</tr>
<tr>
<td>MIR – Medical International Research</td>
<td>4427</td>
</tr>
<tr>
<td>nSpire Health</td>
<td>2608</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Vitalograph, Inc.</td>
<td>1708</td>
</tr>
<tr>
<td>Vyair Medical</td>
<td>4315</td>
</tr>
<tr>
<td><strong>Diagnostic Testing</strong></td>
<td></td>
</tr>
<tr>
<td>Associates of Cape Cod, Inc.</td>
<td>2102</td>
</tr>
<tr>
<td>BD</td>
<td>1712</td>
</tr>
<tr>
<td>Bioptecx, Inc.</td>
<td>3311</td>
</tr>
<tr>
<td>Biofire Diagnostics, LLC</td>
<td>4524</td>
</tr>
<tr>
<td>Boston Scientific Corporation</td>
<td>2412</td>
</tr>
<tr>
<td>BRAEBON Snoring &amp; Sleep Apnea</td>
<td>3324</td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital</td>
<td>1406</td>
</tr>
<tr>
<td>Circassia Pharmaceuticals, Inc.</td>
<td>1912</td>
</tr>
<tr>
<td>Contec Medical Systems Co., Ltd.</td>
<td>3323</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>1405</td>
</tr>
<tr>
<td>Fujifilm Sonosite</td>
<td>4320</td>
</tr>
<tr>
<td>Healthup</td>
<td>4129</td>
</tr>
<tr>
<td>IDbyDNA, Inc.</td>
<td>4419</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>Methapharm, Inc.</td>
<td>1008</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>3115</td>
</tr>
<tr>
<td>MIR – Medical International Research</td>
<td>4427</td>
</tr>
<tr>
<td>Morgan Scientific Inc.</td>
<td>1508</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>nSpire Health</td>
<td>2608</td>
</tr>
<tr>
<td>Oncimmune USA LLC</td>
<td>909</td>
</tr>
<tr>
<td>Owlstone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Veracyte, Inc.</td>
<td>4838</td>
</tr>
<tr>
<td><strong>ECMO</strong></td>
<td></td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td><strong>Educational Organization</strong></td>
<td></td>
</tr>
<tr>
<td>3D Systems Symbionix</td>
<td>3640</td>
</tr>
<tr>
<td>Allergy &amp; Asthma Network</td>
<td>2916</td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>American Thoracic Society</td>
<td>2726, 3130</td>
</tr>
<tr>
<td>Asthma and Allergy Foundation of America</td>
<td>4227</td>
</tr>
<tr>
<td>Children’s Interstitial &amp; Diffuse Lung Disease Foundation (chiLD)</td>
<td>2816</td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital</td>
<td>1406</td>
</tr>
<tr>
<td>Eastern Pulmonary Conference</td>
<td>4127</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
<td>2921</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>International Society for Aerosols in Medicine</td>
<td>3437</td>
</tr>
<tr>
<td>The LAM Foundation/ Lymphangioleiomyomatosis</td>
<td>2820</td>
</tr>
<tr>
<td>MedEd On The Go</td>
<td>4225</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td><strong>Electronic Medical Record/ Electronic Health Record</strong></td>
<td></td>
</tr>
<tr>
<td>HCmed Innovations</td>
<td>3017</td>
</tr>
<tr>
<td>TSI Healthcare</td>
<td>4425</td>
</tr>
<tr>
<td><strong>E-Medicine</strong></td>
<td></td>
</tr>
<tr>
<td>Owlstone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>patientMpower</td>
<td>3638</td>
</tr>
<tr>
<td><strong>Endoscopic Devices</strong></td>
<td></td>
</tr>
<tr>
<td>3D Systems Symbionix</td>
<td>3640</td>
</tr>
<tr>
<td>Auris Health</td>
<td>613</td>
</tr>
<tr>
<td>Boston Scientific Corporation</td>
<td>2412</td>
</tr>
<tr>
<td>FUJIFILM Medical Systems U.S.A., Inc.</td>
<td>4322</td>
</tr>
<tr>
<td>Huger Medical Instrument Co. Ltd.</td>
<td>1403</td>
</tr>
<tr>
<td><strong>Environmental, Occupational, and Population Health</strong></td>
<td></td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
<td>4426</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
<td>2921</td>
</tr>
<tr>
<td>National Institute of Environmental Health Science (NIEHS)</td>
<td>4534</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>Owlstone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>U.S. EPA’s National Air and Energy Research Program</td>
<td>4327</td>
</tr>
<tr>
<td><strong>Exhaled Nitric Oxide Analyzer</strong></td>
<td></td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
<td>4426</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td><strong>Genomic Testing</strong></td>
<td></td>
</tr>
<tr>
<td>Biodesix, Inc.</td>
<td>3311</td>
</tr>
<tr>
<td>IDbyDNA, Inc.</td>
<td>4419</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>National Institute of Environmental Health Science (NIEHS)</td>
<td>4534</td>
</tr>
<tr>
<td>Veracyte, Inc.</td>
<td>4838</td>
</tr>
<tr>
<td><strong>Home Infusion</strong></td>
<td></td>
</tr>
<tr>
<td>Maxor Specialty</td>
<td>4128</td>
</tr>
<tr>
<td><strong>Humidifiers</strong></td>
<td></td>
</tr>
<tr>
<td>SEOIL PACIFIC CORP.</td>
<td>2303</td>
</tr>
<tr>
<td><strong>Insurance</strong></td>
<td></td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>3715</td>
</tr>
</tbody>
</table>
## Lung Volume Measurement
- Cincinnati Children’s Hospital 1406
- Clement Clarke International 4433
- Cohero Health 4325
- Contec Medical Systems Co., Ltd. 3323
- Coreline Soft Co., Ltd. 1405
- Data Sciences International (DSI) 2715
- EMMS 3624
- ERT 3636
- Futuemed 3015
- Hans Rudolph, Inc. 1812
- Healthup | AioCare 4129
- Hexoskin 1408
- Konica Minolta Healthcare
  - Americas, Inc. 4636
- MedQIA 4233
- MGC Diagnostics 3115
- MIR – Medical International Research 4427
- Morgan Scientific Inc. 1508
- nSpire Health 2608
- patientMPower 3638
- PulmOne USA Inc. 4130
- SCIREQ - an emka TECHNOLOGIES company 3619
- SEOIL PACIFIC CORP. 2303
- Vitalograph, Inc. 1708
- Vyaire Medical 4315

## Lung Volume Reduction
- PulmOne USA Inc. 4130
- Temple Lung Center 1407

## Medical Device
- Aerogen 2716
- AMBU 4420
- Auris Health 613
- B. Braun Interventional Systems, Inc. 4231
- BD 1712
- Bellerophon Therapeutics 2
- Boston Medical Products / Novatech 3533
- Boston Scientific Corporation 2412
- Breathe Technologies, Inc. 3118
- BTG 3622
- Circassia Pharmaceuticals, Inc. 1912
- Clement Clarke International 4433
- Contec Medical Systems Co., Ltd. 3323
- COOK MEDICAL 3504
- Data Sciences International (DSI) 2715
- Dynaris 3424
- ERT 3636
- ERT 3636
- Fisher & Paykel Healthcare 2112
- FUJIFILM Medical Systems U.S.A., Inc. 4322
- Fujifilm SonoSite 4320
- Futuremed 3015
- GCE Healthcare 2203
- GlaxoSmithKline 3715
- Hans Rudolph, Inc. 1812
- HCmed Innovations 3017
- Healthup | AioCare 4129
- Hexoskin 1408
- Hill-Rom 2504
- Huger MedicalInstrument Co. Ltd. 1403
- Inspire Medical Systems, Inc. 3519
- International Biophysics 3515
- Lyml Medical Corporation 3326
- MedQIA 4233
- Medtronic 2500
- Merit Medical Endotek 2200
- MIR – Medical International Research 4427
- Monaghan Medical Corporation 4938
- Morgan Scientific Inc. 1508
- NeillMed Pharmaceuticals 2508
- NeuWave / Johnson & Johnson 612
- Olympus America Inc. 3500
- Owstone Medical Ltd. 3520
- patientMPower 3638
- Philips Respironics 3318
- Propeller Health 3522
- PulmOne USA Inc. 4130
- Pulmonx Corp. 1505
- ResMed 3726
- Rocket Medical PLC 3526
- SEOIL PACIFIC CORP. 2303
- Spire Health 2403
- UreSil LLC 3020
- Vathin Medical Co. Ltd. 4436
- Ventec Life Systems 4521
- Veran Medical Technologies 2300
- Vitalograph, Inc. 1708
- Vyaire Medical 4315

## Oral Appliances
- BRAEBON Snoring & Sleep Apnea 3324
- Great Lakes Dental Technologies 2201

## Oximetry
- BRAEBON Snoring & Sleep Apnea 3324
- Contec Medical Systems Co., Ltd. 3323
- Hans Rudolph, Inc. 1812
- Hexoskin 1408
- MIR – Medical International Research 4427
- patientMPower 3638
- Vitalograph, Inc. 1708

## Patient Education
- Alliance Tech Medical, Inc. 3524
- American Association for Respiratory Care 2100
- American College of Chest Physicians (CHEST) 3229
- American Thoracic Society 2726, 3130
- ARDS Foundation 2823
- Asthma and Allergy Foundation of America 4227
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Fisher & Paykel Healthcare 2112
- Foundation for Sarcoidosis Research 2921
- Fujifilm SonoSite 4320
- Grifols USA, LLC 1908
- Hill-Rom 2504
- The LAM Foundation/
  - Lymphangioleiomyomatosis 2820
- Monaghan Medical Corporation 4938
- National Institute of Environmental Health Science (NIEHS) 4534
- NTM Info & Research, Inc. 2815
- patientMPower 3638
- PF Warriors 3023
- Pulmonary Hypertension Association 4434
- Pulmonary Wellness Online 712
- Scleroderma Foundation 2917
- Society of Critical Care Medicine (SCCM) 1503
- Tuberculosis Alliance 2821

## Pediatric Products/Services
- Aerogen 2716
- Cincinnati Children’s Hospital 1406
- Cohero Health 4325
- Contec Medical Systems Co., Ltd. 3323
- ECO MEDICS – ECO PHYSICS 4426
- Fisher & Paykel Healthcare 2112
- GlaxoSmithKline 3715
- Hexoskin 1408
- Hill-Rom 2504
- MedQIA 4233
- Monaghan Medical Corporation 4938
- Morgan Scientific Inc. 1508
- NeillMed Pharmaceuticals 2508
- RB 4706
- SEOIL PACIFIC CORP. 2303
- Thirona 3022

## Pharmaceuticals
- Actelion Pharmaceuticals US Inc. 3908
- Allergan USA, Inc. 3507
- AyuVis Research 4940
- Bayer 3315
- Bellerophon Therapeutics 2
- BMS/Pfizer 3411
- Boston Medical Products / Novatech 3533
- Circassia Pharmaceuticals, Inc. 1912
- Foundation for Sarcoidosis Research 2921
- Genentech, A Member of the Roche Group 2106
- Genentech/Novartis 2512
- GlaxoSmithKline 3715
- Grifols USA, LLC 1908
- InMed Incorporated 3722
Exhibitors by Product Category, cont.

International Institute for the Advancement of Medicine 1000
Jazz Pharmaceuticals, Inc. 1108
Mallinckrodt Pharmaceuticals 4122
Maxor Specialty 4128
Mayne Pharma 4435
MedQIA 4233
Mylan Inc. 3733, 4333
NeiMed Pharmaceuticals 2508
Novartis Pharmaceuticals Corporation 1300
Novartis Pharmaceuticals 1500
Novartis Pharmaceuticals Corporation 1300
Praedicare 1012
RB 4706
Reata Pharmaceuticals 8
Santhera Pharmaceuticals 9
Sunevion Pharmaceuticals Inc. 3901
Takeda 305
TEVA Pharmaceuticals 1412
United Therapeutics 3511
Vertex Pharmaceuticals, Inc. 3619

Publications–Scientific, Medical or Health Education
American Thoracic Society 2726, 3130
CRC Press, Taylor & Francis Group 912
Elsevier 3312, 3412
FDA Center for Tobacco Products 3523
JAMA Network 4633
MedQIA 4233
Monaghan Medical Corporation 4938
Oncimmune USA LLC 909
PracticeLink 4125
Pulmonary Fibrosis Foundation 3126
Pulmonary Hypertension Association 4434
Wolters Kluwer 1309

Pulmonary Function Testing–Animal
Data Sciences International (DSI) 2715
ECO MEDICS – ECO PHYSICS 4426
EMMS 3624
Hans Rudolph, Inc. 1812
Owlstone Medical Ltd. 3520
SCIREQ - an emka TECHNOLOGIES company 3619

Pulmonary Function Testing–Human
Cincinnati Children’s Hospital 1406
ECO MEDICS – ECO PHYSICS 4426
ERT 3636
Futuremed 3015
Hans Rudolph, Inc. 1812
Healthup | AioCare 4129
Hexoskin 1408
MedQIA 4233
Methapharm, Inc. 1008
MGC Diagnostics 3115
MIR – Medical International Research 4427
Monaghan Medical Corporation 4938
Morgan Scientific Inc. 1508

National Board of Echocardiography, Inc. 2313
National Jewish Health 813
nSpire Health 2608
patientMpower 3638
PulmOne USA Inc. 4130
THORASYS Thoracic Medical Systems Inc. 4133
Vitalograph, Inc. 1708
Vyaire Medical 4315

Recruiter (clinical trials)
FibroGen, Inc. 10
PF Warriors 3023
Reata Pharmaceuticals 8

Recruiter (employment)
Christus Health 3423
Kaiser Permanente 1409
Marshfield Clinic Health System 4226
Pediatric Search Partners 1308
Penn State Health 4228
PracticeLink 4125
Provider Solutions + Development 2101
SoutheastHEALTH 2202

Research–Equipment, Products or Services
Data Sciences International (DSI) 2715
ECO MEDICS – ECO PHYSICS 4426
EMMS 3624
ERT 3636
GlaxoSmithKline 3715
Hans Rudolph, Inc. 1812
Hexoskin 1408
International Institute for the Advancement of Medicine 1000
Konica Minolta Healthcare Americas, Inc. 4636
Lymol Medical Corporation 3326
MedQIA 4233
Monaghan Medical Corporation 4938
Novabiosis 1209
nSpire Health 2608
Owlstone Medical Ltd. 3520
patientMpower 3638
PerkinElmer 1208
PulmOne USA Inc. 4130
Reata Pharmaceuticals 8
SCIREQ - an emka TECHNOLOGIES company 3619
Spire Health 2403
STEMCELL Technologies, Inc. 4241

Respiratory Structure and Function
Aerogen 2716
AMBU 4420
American College of Chest Physicians (CHEST) 3229
Bellerophon Therapeutics 2
Cincinnati Children’s Hospital 1406
Clement Clarke International 4433
Coreline Soft Co., Ltd. 1405
ECO MEDICS – ECO PHYSICS 4426
GlaxoSmithKline 3715
MedQIA 4233
Monaghan Medical Corporation 4938
National Institute of Environmental Health Science (NIEHS) 4534
National Jewish Health 813
Oncimmune USA LLC 909
patientMpower 3638
PerkinElmer 1208
Pulmonary Hypertension Association 4434
PulmOne USA Inc. 4130
Reata Pharmaceuticals 8
Santhera Pharmaceuticals 9
SCIREQ - an emka TECHNOLOGIES company 3619
Spire Health 2403
STEMCELL Technologies, Inc. 4241

Research in Pulmonary Science or Medicine
Alliance Tech Medical, Inc. 3524
Alpha-1 Foundation 3021
Bellerophon Therapeutics 2
Children’s Intestinal & Diffuse Lung Disease Foundation (chILD) 2816
Cincinnati Children’s Hospital 1406
Coreline Soft Co., Ltd. 1405
Data Sciences International (DSI) 2715
ECO MEDICS – ECO PHYSICS 4426
EMMS 3624
FibroGen, Inc. 10
Foundation for Sarcoidosis Research 2921
Galapagos NV 1
GlaxoSmithKline 3715
Grifols USA, LLC 1908
Hans Rudolph, Inc. 1812
Hexoskin 1408
International Institute for the Advancement of Medicine 1000
International Society for Aerosols in Medicine 3437
Konica Minolta Healthcare Americas, Inc. 4636
MedQIA 4233
Monaghan Medical Corporation 4938
National Heart, Lung, and Blood Institute 4738
National Institute of Environmental Health Science (NIEHS) 4534
National Jewish Health 813
Oncimmune USA LLC 909
patientMpower 3638
PerkinElmer 1208
Pulmonary Hypertension Association 4434
PulmOne USA Inc. 4130
Reata Pharmaceuticals 8
Santhera Pharmaceuticals 9
SCIREQ - an emka TECHNOLOGIES company 3619
Spire Health 2403
STEMCELL Technologies, Inc. 4241
Temple Lung Center 1407
Tuberous Sclerosis Alliance 2821

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
<table>
<thead>
<tr>
<th><strong>Sleep Medicine and Supporting Products</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Alliance Tech Medical, Inc.</td>
</tr>
<tr>
<td>American College of Chest Physicians</td>
</tr>
<tr>
<td>(CHEST)</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
</tr>
<tr>
<td>BleepSleep</td>
</tr>
<tr>
<td>BRAINTON Snoring &amp; Sleep Apnea</td>
</tr>
<tr>
<td>Cincinnati Children's Hospital</td>
</tr>
<tr>
<td>Dynaris</td>
</tr>
<tr>
<td>Great Lakes Dental Technologies</td>
</tr>
<tr>
<td>Hans Rudolph, Inc.</td>
</tr>
<tr>
<td>Inspire Medical Systems, Inc.</td>
</tr>
<tr>
<td>National Jewish Health</td>
</tr>
<tr>
<td>Philips Respironics</td>
</tr>
<tr>
<td>ResMed</td>
</tr>
<tr>
<td>Spire Health</td>
</tr>
<tr>
<td>Vyaire Medical</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sleep Testing Equipment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BLEEP Sleep</td>
</tr>
<tr>
<td>BRAINTON Snoring &amp; Sleep Apnea</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
</tr>
<tr>
<td>Great Lakes Dental Technologies</td>
</tr>
<tr>
<td>Hans Rudolph, Inc.</td>
</tr>
<tr>
<td>Hexoskin</td>
</tr>
<tr>
<td>MIR – Medical International Research</td>
</tr>
<tr>
<td>Philips Respironics</td>
</tr>
<tr>
<td>ResMed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Software</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>3D Systems Simbionix</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
</tr>
<tr>
<td>EMMS</td>
</tr>
<tr>
<td>Hans Rudolph, Inc.</td>
</tr>
<tr>
<td>Healthup</td>
</tr>
<tr>
<td>IDbyDNA, Inc.</td>
</tr>
<tr>
<td>MedIQI</td>
</tr>
<tr>
<td>Medtronic</td>
</tr>
<tr>
<td>Morgan Scientific Inc.</td>
</tr>
<tr>
<td>nSpire Health</td>
</tr>
<tr>
<td>patientMpower</td>
</tr>
<tr>
<td>Philips Respironics</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES</td>
</tr>
<tr>
<td>company</td>
</tr>
<tr>
<td>Spire Health</td>
</tr>
<tr>
<td>Thirona</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Spirometry</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Alliance Tech Medical, Inc.</td>
</tr>
<tr>
<td>Cohero Health</td>
</tr>
<tr>
<td>Contec Medical Systems Co., Ltd.</td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
</tr>
<tr>
<td>EMMS</td>
</tr>
<tr>
<td>ERT</td>
</tr>
<tr>
<td>Futuremed</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Hans Rudolph, Inc.</td>
</tr>
<tr>
<td>Healthup</td>
</tr>
<tr>
<td>Hexoskin</td>
</tr>
<tr>
<td>MedIQI</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
</tr>
<tr>
<td>MIR – Medical International Research</td>
</tr>
<tr>
<td>Morgan Scientific Inc.</td>
</tr>
<tr>
<td>nSpire Health</td>
</tr>
<tr>
<td>patientMpower</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
</tr>
<tr>
<td>Spire Health</td>
</tr>
<tr>
<td>Vitalograph, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Stent Technology</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Scientific Corporation</td>
</tr>
<tr>
<td>Lymol Medical Corporation</td>
</tr>
<tr>
<td>Merit Medical Endotek</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Surgery and Transplantation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bellerophon Therapeutics</td>
</tr>
<tr>
<td>Boston Medical Products / Novatech</td>
</tr>
<tr>
<td>Cincinnati Children's Hospital</td>
</tr>
<tr>
<td>International Institute for the</td>
</tr>
<tr>
<td>Advancement of Medicine</td>
</tr>
<tr>
<td>Lymol Medical Corporation</td>
</tr>
<tr>
<td>Mayne Pharma</td>
</tr>
<tr>
<td>St. Joseph Hospital &amp; Medical Center</td>
</tr>
<tr>
<td>Temple Lung Center</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Telehealth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BRAINTON Snoring &amp; Sleep Apnea</td>
</tr>
<tr>
<td>Cincinnati Children's Hospital</td>
</tr>
<tr>
<td>Cohero Health</td>
</tr>
<tr>
<td>Healthup</td>
</tr>
<tr>
<td>Hexoskin</td>
</tr>
<tr>
<td>patientMpower</td>
</tr>
<tr>
<td>Pulmonary Wellness Online</td>
</tr>
<tr>
<td>ResMed</td>
</tr>
<tr>
<td>Spire Health</td>
</tr>
<tr>
<td>Temple Lung Center</td>
</tr>
<tr>
<td>Vitalograph, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Thoracic Oncology</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Auris Health</td>
</tr>
<tr>
<td>Biodesix, Inc.</td>
</tr>
<tr>
<td>Boston Medical Products / Novatech</td>
</tr>
<tr>
<td>MedIQI</td>
</tr>
<tr>
<td>Medtronic</td>
</tr>
<tr>
<td>National Jewish Health</td>
</tr>
<tr>
<td>NeuWave / Johnson &amp; Johnson</td>
</tr>
<tr>
<td>Oncimmune USA LLC</td>
</tr>
<tr>
<td>Owlsone Medical Ltd.</td>
</tr>
<tr>
<td>Praedicare</td>
</tr>
<tr>
<td>Rocket Medical PLC</td>
</tr>
<tr>
<td>Temple Lung Center</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tracheostomy Equipment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monaghan Medical Corporation</td>
</tr>
<tr>
<td>SEOIL PACIFIC CORP.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ultrasound</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>3D Systems Simbionix</td>
</tr>
<tr>
<td>Boston Scientific Corporation</td>
</tr>
<tr>
<td>FUSIFILM Medical Systems U.S.A., Inc.</td>
</tr>
<tr>
<td>Fujifilm SonoSite</td>
</tr>
<tr>
<td>MedIQI</td>
</tr>
<tr>
<td>Temple Lung Center</td>
</tr>
<tr>
<td>UreSil LLC</td>
</tr>
<tr>
<td>US Acute Care Solutions</td>
</tr>
<tr>
<td><strong>Ultrasonic Bronchoscope</strong></td>
</tr>
<tr>
<td>Boston Scientific Corporation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ventilators</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerogen</td>
</tr>
<tr>
<td>Breathe Technologies, Inc.</td>
</tr>
<tr>
<td>EMMS</td>
</tr>
<tr>
<td>Philips Respironics</td>
</tr>
<tr>
<td>ResMed</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES</td>
</tr>
<tr>
<td>company</td>
</tr>
<tr>
<td>Ventec Life Systems</td>
</tr>
<tr>
<td>Vyaire Medical</td>
</tr>
</tbody>
</table>
### Exhibitors by Disease State

#### Alpha-1 Antitrypsin
- **Alpha-1 Foundation** 3021
- **Breathe Technologies, Inc.** 3118
- **Canadian Thoracic Society** 3433
- **European Respiratory Society** 3445
- **Grifols USA, LLC** 1908
- **International Institute for the Advancement of Medicine** 1000
- **Irish Thoracic Society** 3444
- **Lung Transplant Foundation** 2817
- **Maxor Specialty** 4128
- **National Heart, Lung, and Blood Institute** 4738
- **National Jewish Health** 813
- **PerkinElmer** 1208
- **Provider Solutions + Development** 2101
- **Takeda** 305
- **Temple Lung Center** 1407
- **UPMC** 3226

#### ARDS
- **American Association for Respiratory Care** 2100
- **ARDS Foundation** 2823
- **AyuVis Research** 4940
- **Biofire Diagnostics, LLC** 4524
- **Data Sciences International (DSI)** 2715
- **International Institute for the Advancement of Medicine** 1000
- **Irish Thoracic Society** 3444
- **JAMA Network** 4633
- **MGC Diagnostics** 3115
- **Northwest Seminars** 4536
- **Provider Solutions + Development** 2101
- **SCIREQ - an emka TECHNOLOGIES company** 3619
- **Temple Lung Center** 1407

#### Asthma
- **4Dx** 3543
- **Allergy & Asthma Network** 2916
- **American Association for Respiratory Care** 2100
- **American College of Chest Physicians (CHEST)** 3229
- **Asthma and Allergy Foundation of America** 4227
- **AstraZeneca** 4308
- **Boehringer Ingelheim Pharmaceuticals, Inc.** 2800, 2811, 4438
- **Bruker BioSpin** 3422
- **Canadian Thoracic Society** 3433
- **Christus Health** 3423
- **Cincinnati Children’s Hospital** 1406
- **Clement Clarke International** 4433
- **CMI Health Inc.** 4533
- **Cohero Health** 4325
- **Contec Medical Systems Co., Ltd.** 3323
- **Dynarisi** 3424
- **Eastern Pulmonary Conference** 4127
- **ECO MEDICS – ECO PHYSICS** 4426
- **EMMS** 3624
- **ERT** 3636
- **European Respiratory Society** 3445
- **FLUIDDA NV** 4429
- **Futuremed** 3155
- **Genentech/Novartis** 2512
- **GlaxoSmithKline** 3715
- **Healthup | AioCare** 4129
- **Hexoskin** 1408
- **Hill-Rom** 2504
- **Imbio, LLC** 4319
- **Irish Thoracic Society** 3444
- **MedQIA** 4233
- **Methapharm, Inc.** 1008
- **MGC Diagnostics** 3115
- **MIR – Medical International Research** 4427
- **Monaghan Medical Corporation** 4938
- **Morgan Scientific Inc.** 1508
- **Mount Sinai Health System** 812
- **National Heart, Lung, and Blood Institute** 4738
- **nnd Medical Technologies Inc.** 3626
- **Novartis Pharmaceuticals Corporation** 1300
- **nSpire Health** 2608
- **Owlstone Medical Ltd.** 3520
- **PerkinElmer** 1208
- **Philips Respiromics** 3318
- **Propeller Health** 3522
- **Provider Solutions + Development** 2101
- **Public Health Foundation of India** 3440
- **Pulmonary Wellness Online** 712
- **PulmOne USA Inc.** 4130
- **RB** 4706
- **Regeneron Pharmaceuticals/Sanoﬁ Genzyme** 3111, 4515
- **SCIREQ - an emka TECHNOLOGIES company** 3619
- **Spire Health** 2403
- **STEMCELL Technologies, Inc.** 4241
- **Temple Lung Center** 1407
- **THORASYS Thoracic Medical Systems Inc.** 4133
- **U.S. EPA’s National Air and Energy Research Program** 4327
- **UPMC** 3226
- **US Acute Care Solutions** 4635
- **Vitalograph, Inc.** 1708
- **Vyaire Medical** 4315

#### Asthma, COPD, and Other Airway Diseases
- **Aerogen** 2716
- **Alliance Tech Medical, Inc.** 3524
- **Alung Technologies** 5
- **AstraZeneca** 4308
- **Bosch Healthcare Solutions GmbH** 1303
- **Boston Scientific Corporation** 2412
- **Cohero Health** 4325
- **Data Sciences International (DSI)** 2715
- **ERT** 3636
- **FLUIDDA NV** 4429
- **GCE Healthcare** 2203
- **HCmed Innovations** 3017
- **Healthup | AioCare** 4129
- **MedQIA** 4233
- **National Heart, Lung, and Blood Institute** 4738
- **National Jewish Health** 813
- **Polarlean, Inc.** 2717

#### Bronchiectasis
- **Aerogen** 2716
- **American Association for Respiratory Care** 2100
- **Bruker BioSpin** 3422
- **Canadian Thoracic Society** 3433
- **Christus Health** 3423
- **Data Sciences International (DSI)** 2715
- **EMMS** 3624
- **European Respiratory Society** 3445
- **HCmed Innovations** 3017
- **Hill-Rom** 2504
- **International Biophysics** 3515
- **Irish Thoracic Society** 3444
- **Lung Transplant Foundation** 2817
- **Maxor Specialty** 4128
- **Monaghan Medical Corporation** 4938
- **Mount Sinai Health System** 812
- **National Heart, Lung, and Blood Institute** 4738
- **nSpire Health** 2608
- **Optimis Network, Inc.** 2824
- **PerkinElmer** 1208
- **Philips Respiromics** 3318
- **Provider Solutions + Development** 2101
- **Public Health Foundation of India** 3440
- **Pulmonary Wellness Online** 712
- **Temple Lung Center** 1407
- **THORASYS Thoracic Medical Systems Inc.** 4133
- **U.S. EPA’s National Air and Energy Research Program** 4327
- **NTM Info & Research, Inc.** 2815
- **Olympus America Inc.** 3500
- **Owlnstone Medical Ltd.** 3520
- **PerkinElmer** 1208
- **Philips Respiromics** 3318
- **Provider Solutions + Development** 2101
- **Public Health Foundation of India** 3440
- **Pulmonary Wellness Online** 712
- **Temple Lung Center** 1407
- **THORASYS Thoracic Medical Systems Inc.** 4133
- **UPMC** 3226
- **Vathin Medical Co. Ltd.** 4436

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
### Exhibitors by Disease State, cont.

<table>
<thead>
<tr>
<th>Disease State</th>
<th>Exhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer</strong></td>
<td></td>
</tr>
<tr>
<td>ERT</td>
<td>3636</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td><strong>Chronic Thromboembolic Pulmonary Hypertension</strong></td>
<td>3543</td>
</tr>
<tr>
<td>4Dx</td>
<td></td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>Canadian Thoracic Society</td>
<td>3433</td>
</tr>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>INTUTIVE</td>
<td>1100</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>MedEd On The Go</td>
<td>4225</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>UPMC</td>
<td>3226</td>
</tr>
<tr>
<td>Ventec Life Systems</td>
<td>4521</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>1309</td>
</tr>
<tr>
<td><strong>COPD</strong></td>
<td></td>
</tr>
<tr>
<td>3D Systems Simbionix</td>
<td>3640</td>
</tr>
<tr>
<td>4Dx</td>
<td>3543</td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td>2800, 2811, 4438</td>
</tr>
<tr>
<td>Breathe Technologies, Inc.</td>
<td>3118</td>
</tr>
<tr>
<td>Broncus Medical, Inc.</td>
<td>3218</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>3422</td>
</tr>
<tr>
<td>Canadian Thoracic Society</td>
<td>3433</td>
</tr>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>Circassia Pharmaceuticals, Inc.</td>
<td>1912</td>
</tr>
<tr>
<td>Clement Clarke International</td>
<td>4433</td>
</tr>
<tr>
<td>CMI Health Inc.</td>
<td>4533</td>
</tr>
<tr>
<td>Cohero Health</td>
<td>4325</td>
</tr>
<tr>
<td>Contec Medical Systems Co., Ltd.</td>
<td>3323</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>1405</td>
</tr>
<tr>
<td>Dynaris</td>
<td>3424</td>
</tr>
<tr>
<td>Eastern Pulmonary Conference</td>
<td>4127</td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
<td>4426</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>ERT</td>
<td>3636</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>FLUIDDA NV</td>
<td>4429</td>
</tr>
<tr>
<td>Futuremed</td>
<td>3015</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>3715</td>
</tr>
<tr>
<td>Grifols USA, LLC</td>
<td>1908</td>
</tr>
<tr>
<td>Healthup</td>
<td>AioCare</td>
</tr>
<tr>
<td>Hexoskin</td>
<td>1408</td>
</tr>
<tr>
<td>Hill-Rom</td>
<td>2504</td>
</tr>
<tr>
<td>International Biophysics</td>
<td>3515</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>3115</td>
</tr>
<tr>
<td>Monaghan Medical Corporation</td>
<td>4938</td>
</tr>
<tr>
<td>Morgan Scientific Inc.</td>
<td>1508</td>
</tr>
<tr>
<td>Mount Sinai Health System</td>
<td>812</td>
</tr>
<tr>
<td>Mylan Inc.</td>
<td>3733, 4333</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>nSpire Health</td>
<td>2608</td>
</tr>
<tr>
<td>Olympus America Inc.</td>
<td>3500</td>
</tr>
<tr>
<td>Owlsion Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>Philips Respironics</td>
<td>3318</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Pulmonx Corp.</td>
<td>1505</td>
</tr>
<tr>
<td>ResMed</td>
<td>3726</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES company</td>
<td>3619</td>
</tr>
<tr>
<td>Spire Health</td>
<td>2403</td>
</tr>
<tr>
<td>STEMCELL Technologies, Inc.</td>
<td>4241</td>
</tr>
<tr>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>3901</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>Thirona</td>
<td>3022</td>
</tr>
<tr>
<td>THORASYS Thoracic Medical Systems Inc.</td>
<td>4133</td>
</tr>
<tr>
<td>U.S. EPA’s National Air and Energy Research Program</td>
<td>4327</td>
</tr>
<tr>
<td>UPMC</td>
<td>3226</td>
</tr>
<tr>
<td>US Acute Care Solutions</td>
<td>4635</td>
</tr>
<tr>
<td><strong>Critical Illness</strong></td>
<td></td>
</tr>
<tr>
<td>Biofire Diagnostics, LLC</td>
<td>4524</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>Masimo</td>
<td>4141</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>Northwest Seminars</td>
<td>4536</td>
</tr>
<tr>
<td><strong>Cystic Fibrosis</strong></td>
<td></td>
</tr>
<tr>
<td>4Dx</td>
<td>3543</td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>Breathe Technologies, Inc.</td>
<td>3118</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>3422</td>
</tr>
<tr>
<td>Cincinnati Children’s Hospital</td>
<td>1406</td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
<td>4426</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>Hexoskin</td>
<td>1408</td>
</tr>
<tr>
<td>International Biophysics</td>
<td>3515</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>Maxor Specialty</td>
<td>4128</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>3115</td>
</tr>
<tr>
<td>Monaghan Medical Corporation</td>
<td>4938</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>nSpire Health</td>
<td>2608</td>
</tr>
<tr>
<td>Owlsone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>Philips Respironics</td>
<td>3318</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>Santhera Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES company</td>
<td>3619</td>
</tr>
<tr>
<td>STEMCELL Technologies, Inc.</td>
<td>4241</td>
</tr>
<tr>
<td>THORASYS Thoracic Medical Systems Inc.</td>
<td>4133</td>
</tr>
<tr>
<td>UPMC</td>
<td>3226</td>
</tr>
<tr>
<td>Ventec Life Systems</td>
<td>4521</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals, Inc.</td>
<td>3729</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>1309</td>
</tr>
<tr>
<td><strong>Environmental and Occupational Lung Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>Foundation for Sarcoïdosis Research</td>
<td>2921</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>THORASYS Thoracic Medical Systems Inc.</td>
<td>4133</td>
</tr>
<tr>
<td><strong>Environmental, Exposure-Related, and Occupational Lung</strong></td>
<td></td>
</tr>
<tr>
<td>4Dx</td>
<td>3543</td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>3115</td>
</tr>
<tr>
<td>National Institute of Environmental Health Science (NIEHS)</td>
<td>4534</td>
</tr>
<tr>
<td>Olympus America Inc.</td>
<td>3500</td>
</tr>
<tr>
<td>Owlsone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>patientMpower</td>
<td>3638</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>Pulmonary Wellness Online</td>
<td>712</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>THORASYS Thoracic Medical Systems Inc.</td>
<td>4133</td>
</tr>
</tbody>
</table>
## Exhibitors by Disease State, cont.

<table>
<thead>
<tr>
<th>Fungal Lung Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associates of Cape Cod, Inc.</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
</tr>
<tr>
<td>EMMS</td>
</tr>
<tr>
<td>European Respiratory Society</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
</tr>
<tr>
<td>Mayne Pharma</td>
</tr>
<tr>
<td>Olympus America Inc.</td>
</tr>
<tr>
<td>PerkinElmer</td>
</tr>
<tr>
<td>Praedicare</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
</tr>
<tr>
<td>Temple Lung Center</td>
</tr>
<tr>
<td>THORASYS Thoracic Medical Systems Inc.</td>
</tr>
<tr>
<td>U.S. EPA’s National Air and Energy Research Program</td>
</tr>
</tbody>
</table>

### HIV / AIDS

| European Respiratory Society | 3445 |

<table>
<thead>
<tr>
<th>Idiopathic Pulmonary Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4Dx</td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Breathe Technologies, Inc.</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
</tr>
<tr>
<td>Canadian Thoracic Society</td>
</tr>
<tr>
<td>Christus Health</td>
</tr>
<tr>
<td>COPA Syndrome Foundation</td>
</tr>
<tr>
<td>Dynari</td>
</tr>
<tr>
<td>Eastern Pulmonary Conference</td>
</tr>
<tr>
<td>EMMS</td>
</tr>
<tr>
<td>European Respiratory Society</td>
</tr>
<tr>
<td>FibroGen, Inc.</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
</tr>
<tr>
<td>Galapagos NV</td>
</tr>
<tr>
<td>Genentech, A Member of the Roche Group</td>
</tr>
<tr>
<td>Hermansky-Pudlak Syndrome Network, Inc.</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
</tr>
<tr>
<td>Maxor Specialty</td>
</tr>
<tr>
<td>MedQIA</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
</tr>
<tr>
<td>National Jewish Health</td>
</tr>
<tr>
<td>nSpire Health</td>
</tr>
<tr>
<td>Owlsone Medical Ltd.</td>
</tr>
<tr>
<td>patientMpower</td>
</tr>
<tr>
<td>PerkinElmer</td>
</tr>
<tr>
<td>PF Warriors</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
</tr>
<tr>
<td>Pulmonary Fibrosis Foundation</td>
</tr>
<tr>
<td>Pulmonary Wellness Online</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES company</td>
</tr>
<tr>
<td>Temple Lung Center</td>
</tr>
<tr>
<td>THORASYS Thoracic Medical Systems Inc.</td>
</tr>
<tr>
<td>UPMC</td>
</tr>
<tr>
<td>Veracyte, Inc.</td>
</tr>
<tr>
<td>Vitalograph, Inc.</td>
</tr>
</tbody>
</table>

### Infection

| Biofire Diagnostics, LLC | 4524 |
| Boston Scientific Corporation | 2412 |
| Data Sciences International (DSI) | 2715 |
| HCmed Innovations | 3017 |
| MedQIA | 4233 |
| National Jewish Health | 813 |
| THORASYS Thoracic Medical Systems Inc. | 4133 |

### Interstitial Lung Disease

| COPA Syndrome Foundation | 3128 |
| Data Sciences International (DSI) | 2715 |
| Foundation for Sarcoidosis Research | 2921 |
| MedQIA | 4233 |
| National Jewish Health | 813 |
| PF Warriors | 3023 |
| Rocket Medical PLC | 3526 |
| THORASYS Thoracic Medical Systems Inc. | 4133 |

### Lung Cancers

| 3D Systems Simbionix | 3640 |
| 4Dx | 3543 |
| American Association for Respiratory Care | 2100 |
| American College of Chest Physicians (CHEST) | 3229 |
| Aura Health | 613 |
| Biodiesx, Inc. | 3311 |
| Body Vision Medical | 4634 |
| Boston Medical Products / Novatech | 3533 |
| Boston Scientific Corporation | 2412 |
| Broncus Medical, Inc. | 3218 |
| Bruker BioSpin | 3422 |
| Christus Health | 3423 |
| COOK MEDICAL | 3504 |
| Data Sciences International (DSI) | 2715 |
| EMMS | 3624 |
| ERT | 3636 |
| European Respiratory Society | 3445 |
| HCmed Innovations | 3017 |
| Hexoskin | 1408 |
| Irish Thoracic Society | 3444 |
| LUNGevity Foundation | 2923 |
| Lymol Medical Corporation | 3326 |
| Medtronic | 2500 |
| Merit Medical Endotek | 2200 |
| National Disease Research Interchange | 4229 |
| Olympus America Inc. | 3500 |
| Oncimmune USA LLC | 909 |
| Owlsone Medical Ltd. | 3520 |
| PerkinElmer | 1208 |
| Praedicare | 1012 |
| Provider Solutions + Development | 2101 |
| Pulmonary Wellness Online | 712 |
| SCIREQ - an emka TECHNOLOGIES company | 3619 |
| Temple Lung Center | 1407 |
| THORASYS Thoracic Medical Systems Inc. | 4133 |
| U.S. EPA’s National Air and Energy Research Program | 4327 |
| Vitalograph, Inc. | 4838 |
| Veracyte, Inc. | 4838 |
| Veran Medical Technologies | 2300 |
| Wolters Kluwer | 1309 |

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Lymphangioleiomyomatosis
European Respiratory Society 3445
Irish Thoracic Society 3444
The LAM Foundation/ Lymphangioleiomyomatosis 2820
Lung Transplant Foundation 2817
National Heart, Lung, and Blood Institute 4738
National Jewish Health 813
PerkinElmer 1208
Provider Solutions + Development 2101
Temple Lung Center 1407
Tuberous Sclerosis Alliance 2821

Mesothelioma
Irish Thoracic Society 3444
Owlsstone Medical Ltd. 3520
PerkinElmer 1208
Praedicare 1012
Provider Solutions + Development 2101
Temple Lung Center 1407
U.S. EPA’s National Air and Energy Research Program 4327

Myasthenia Gravis
European Respiratory Society 3445
Irish Thoracic Society 3444
National Jewish Health 813
PerkinElmer 1208
Provider Solutions + Development 2101
Temple Lung Center 1407

Narcolepsy
Irish Thoracic Society 3444
National Heart, Lung, and Blood Institute 4738
Provider Solutions + Development 2101
Temple Lung Center 1407

Nontuberculous Mycobacterial Infection
Bruker BioSpin 3422
Canadian Thoracic Society 3433
Chris’us Health 3423
European Respiratory Society 3445
HCmed Innovations 3017
Insmed Incorporated 3722
Irish Thoracic Society 3444
Lung Transplant Foundation 2817
Maxor Specialty 4128
National Jewish Health 813
NTM Info & Research, Inc. 2815
Oxilstone Medical Inc. 3500
Owlsstone Medical Ltd. 3520
PerkinElmer 1208
Praedicare 1012
Provider Solutions + Development 2101
Pulmonary Wellness Online 712
Temple Lung Center 1407
U.S. EPA’s National Air and Energy Research Program 4327

Obstructive Sleep Apnea
American Association for Respiratory Care 2100
American College of Chest Physicians (CHEST) 3229
BleepSleep 2314
BRAEBON Snoring & Sleep Apnea 3324
Canadian Thoracic Society 3433
Christus Health 3423
Cincinnati Children’s Hospital 1406
CMI Health Inc. 4533
Data Sciences International (DSI) 2715
Dynaris 3424
EMMS 3624
European Respiratory Society 3445
Foundation for Sarcoïdosis Research 2921
Great Lakes Dental Technologies 2201
Hans Rudolph, Inc. 1812
Hexoskin 1408
Inspire Medical Systems, Inc. 3519
Irish Thoracic Society 3444
Itamar Medical 2607
Jazz Pharmaceuticals, Inc. 1108
National Heart, Lung, and Blood Institute 4738
Philips Respironics 3318
Provider Solutions + Development 2101
ResMed 3726
SCIREQ - an emka TECHNOLOGIES company 3619
SomnoMed, Inc. 3321
Spire Health 2403
Temple Lung Center 1407
THORASYS Thoracic Medical Systems Inc. 4133
Vyaire Medical 4315
Wolters Kluwer 1309

Parasomnias
Irish Thoracic Society 3444
National Heart, Lung, and Blood Institute 4738
Provider Solutions + Development 2101
Temple Lung Center 1407

Pedicatrics/ Developmental Disorders
MedQIA 4233
THORASYS Thoracic Medical Systems Inc. 4133

Pleural Disease
Data Sciences International (DSI) 2715
ERT 3636
MedQIA 4233
Rocket Medical PLC 3526
UreSil LLC 3020

Pleural Effusion
American Association for Respiratory Care 2100
B. Braun Interventional Systems, Inc. 4231
BD 1712
Boston Medical Products / Novatech 3533
Christus Health 3423
COOK MEDICAL 3504
European Respiratory Society 3445
International Institute for the Advancement of Medicine 1000
Irish Thoracic Society 3444
Olympus America Inc. 3500
PerkinElmer 1208
Provider Solutions + Development 2101
Rocket Medical PLC 3526
Temple Lung Center 1407
UreSil LLC 3020

Pneumonia
Allergan USA, Inc. 3507
American Association for Respiratory Care 2100
AyuVis Research 4940
Biofire Diagnostics, LLC 4524
Bruker BioSpin 3422
Canadian Thoracic Society 3433
Cincinnati Children’s Hospital 1406
Data Sciences International (DSI) 2715
EMMS 3624
European Respiratory Society 3445
HCmed Innovations 3017
Hill-Rom 2504
IDbyDNA, Inc. 4419
International Institute for the Advancement of Medicine 1000
Irish Thoracic Society 3444
Olympus America Inc. 3500
PerkinElmer 1208
Praedicare 1012
Provider Solutions + Development 2101
Temple Lung Center 1407
UreSil LLC 3020

Plume infections
American Association for Respiratory Care 2100
American College of Chest Physicians (CHEST) 3229
Christus Health 3423
COOK MEDICAL 3504
European Respiratory Society 3445
International Institute for the Advancement of Medicine 1000
Irish Thoracic Society 3444
Olympus America Inc. 3500
PerkinElmer 1208
Provider Solutions + Development 2101
Rocket Medical PLC 3526
Temple Lung Center 1407
UreSil LLC 3020

U.S. EPA’s National Air and Energy Research Program 4327

conference.thoracic.org • 49
### Pulmonary Embolism / Deep Vein Thrombosis

<table>
<thead>
<tr>
<th>Company/Institute</th>
<th>Exhibitor Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>4Dx</td>
<td>3543</td>
</tr>
<tr>
<td>Acceleron Pharma</td>
<td>808</td>
</tr>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>B. Braun Interventional Systems, Inc.</td>
<td>4231</td>
</tr>
<tr>
<td>Bayer</td>
<td>3315</td>
</tr>
<tr>
<td>BMS/Pfizer</td>
<td>3411</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>3422</td>
</tr>
<tr>
<td>BTG</td>
<td>3622</td>
</tr>
<tr>
<td>Canadian Thoracic Society</td>
<td>3433</td>
</tr>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>INTUITIVE</td>
<td>1100</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Konica Minolta Healthcare</td>
<td>4636</td>
</tr>
<tr>
<td>Merit Medical Endotek</td>
<td>2200</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>nedd Medical Technologies Inc.</td>
<td>3626</td>
</tr>
<tr>
<td>Owlsone Medical Ltd.</td>
<td>3520</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>The PERT Consortium</td>
<td>3016</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>PulmOne USA Inc.</td>
<td>4130</td>
</tr>
<tr>
<td>Reata Pharmaceuticals</td>
<td>8</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES company</td>
<td>3619</td>
</tr>
<tr>
<td>Scleroderma Foundation</td>
<td>2917</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>United Therapeutics</td>
<td>3511</td>
</tr>
<tr>
<td>UPMC</td>
<td>3226</td>
</tr>
<tr>
<td>US Acute Care Solutions</td>
<td>4635</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>1309</td>
</tr>
</tbody>
</table>

### Pulmonary Vascular Disease

<table>
<thead>
<tr>
<th>Company/Institute</th>
<th>Exhibitor Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleron Pharma</td>
<td>808</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>ERT</td>
<td>3636</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
</tbody>
</table>

### Rare Lung Diseases

<table>
<thead>
<tr>
<th>Company/Institute</th>
<th>Exhibitor Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleron Pharma</td>
<td>808</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>Cincinnati Children's Hospital</td>
<td>1406</td>
</tr>
<tr>
<td>COPA Syndrome Foundation</td>
<td>3128</td>
</tr>
<tr>
<td>ECO MEDICS – ECO PHYSICS</td>
<td>4426</td>
</tr>
<tr>
<td>EMMS</td>
<td>3624</td>
</tr>
<tr>
<td>ERT</td>
<td>3636</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
<td>2921</td>
</tr>
<tr>
<td>Grifols USA, LLC</td>
<td>1908</td>
</tr>
<tr>
<td>Hermansky-Pudlak Syndrome</td>
<td>2915</td>
</tr>
<tr>
<td>Hexoskin</td>
<td>1408</td>
</tr>
<tr>
<td>Insmed Incorporated</td>
<td>3722</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>Maxor Specialty</td>
<td>4128</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>National Disease Research Interchange</td>
<td>4229</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>NTM Info &amp; Research, Inc.</td>
<td>2815</td>
</tr>
<tr>
<td>patientMpower</td>
<td>3638</td>
</tr>
<tr>
<td>PCD Foundation</td>
<td>2920</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>PF Warriors</td>
<td>3023</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>Pulmonary Fibrosis Foundation</td>
<td>3126</td>
</tr>
<tr>
<td>Savara Inc.</td>
<td>708</td>
</tr>
<tr>
<td>SCIREQ - an emka TECHNOLOGIES company</td>
<td>3619</td>
</tr>
</tbody>
</table>

### Sarcoidosis

<table>
<thead>
<tr>
<th>Company/Institute</th>
<th>Exhibitor Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>Bellerophon Therapeutics</td>
<td>2</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>Foundation for Sarcoidosis Research</td>
<td>2921</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Lung Transplant Foundation</td>
<td>2817</td>
</tr>
<tr>
<td>Mallindckrodt Pharmaceuticals</td>
<td>4122</td>
</tr>
<tr>
<td>MedQIA</td>
<td>4233</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>4738</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>813</td>
</tr>
<tr>
<td>Olympus America Inc.</td>
<td>3500</td>
</tr>
<tr>
<td>patientMpower</td>
<td>3638</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>UPMC</td>
<td>3226</td>
</tr>
</tbody>
</table>

### Sepsis

<table>
<thead>
<tr>
<th>Company/Institute</th>
<th>Exhibitor Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Association for Respiratory Care</td>
<td>2100</td>
</tr>
<tr>
<td>American College of Chest Physicians (CHEST)</td>
<td>3229</td>
</tr>
<tr>
<td>AyuVis Research</td>
<td>4940</td>
</tr>
<tr>
<td>Biofire Diagnostics, LLC</td>
<td>4524</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>3422</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>European Respiratory Society</td>
<td>3445</td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>National Disease Research Interchange</td>
<td>4229</td>
</tr>
<tr>
<td>Olympus America Inc.</td>
<td>3500</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>1208</td>
</tr>
<tr>
<td>Praedicare</td>
<td>1012</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>US Acute Care Solutions</td>
<td>4635</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>1309</td>
</tr>
</tbody>
</table>

### Shock

<table>
<thead>
<tr>
<th>Company/Institute</th>
<th>Exhibitor Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christus Health</td>
<td>3423</td>
</tr>
<tr>
<td>COOK MEDICAL</td>
<td>3504</td>
</tr>
<tr>
<td>Data Sciences International (DSI)</td>
<td>2715</td>
</tr>
<tr>
<td>Irish Thoracic Society</td>
<td>3444</td>
</tr>
<tr>
<td>Northwest Seminars</td>
<td>4536</td>
</tr>
<tr>
<td>Provider Solutions + Development</td>
<td>2101</td>
</tr>
<tr>
<td>Temple Lung Center</td>
<td>1407</td>
</tr>
<tr>
<td>US Acute Care Solutions</td>
<td>4635</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>1309</td>
</tr>
</tbody>
</table>

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
### Exhibitors by Disease State, cont.

#### Sleep Problems
- BleepSleep 2314
- ERT 3636
- Foundation for Sarcoidosis Research 2921
- Infinity Massage Chairs 2312
- National Jewish Health 813

#### Surgery and Transplantation
- Masimo 4141

#### Transplantation
- Bruker BioSpin 3422
- Cincinnati Children’s Hospital 1406
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Hexoskin 1408
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817
- Lympol Medical Corporation 3326
- Maxor Specialty 4128
- National Disease Research Interchange 4229
- patientMpower 3638
- Provider Solutions + Development 2101
- St. Joseph Hospital & Medical Center 4126
- Temple Lung Center 1407
- UPMC 3226
- Wolters Kluwer 1309

#### Other

##### Congenital, Genetic, and Developmental Lung Diseases
- 4Dx 3543
- American Association for Respiratory Care 2100
- AyuVis Research 4940
- Biogen 3429
- Bruker BioSpin 3422
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Cincinnati Children’s Hospital 1406
- COPA Syndrome Foundation 3128
- ECO MEDICS – ECO PHYSICS 4426
- EMMS 3624
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Hexoskin 1408
- International Biophysics 3515
- International Institute for the Advancement of Medicine 1000
- Irish Thoracic Society 3444
- Itamar Medical 2607
- Lympol Medical Corporation 3326
- MedQIA 4233
- MGC Diagnostics 3115
- Monaghan Medical Corporation 4938
- nSpire Health 2608
- Olympus America Inc. 3500
- Owlsone Medical Ltd. 3520
- PerkinElmer 1208
- Praedicare 1012
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- THORASYS Thoracic Medical Systems Inc. 4133
- U.S. EPA’s National Air and Energy Research Program 4327
- UPMC 3226

##### Non-specific Interstitial Pneumonitis
- 4Dx 3543
- American College of Chest Physicians (CHEST) 3229
- Biogen 3429
- Bruker BioSpin 3422
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Cincinnati Children’s Hospital 1406
- COPA Syndrome Foundation 3128
- Dynans 2403
- EMMS 3624
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817

##### Infectious Lung Diseases
- Aerogen 2716
- Bruker BioSpin 3422
- Christus Health 3423
- EMMS 3624
- European Respiratory Society 3445
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817
- National Jewish Health 813
- Olympus America Inc. 3500
- Owlstone Medical Ltd. 3520
- PerkinElmer 1208
- Praedicare 1012
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- THORASYS Thoracic Medical Systems Inc. 4133
- U.S. EPA’s National Air and Energy Research Program 4327
- UPMC 3226

##### Diseases of the Pleura and Chest Wall
- American Association for Respiratory Care 2100
- COOK MEDICAL 3504
- European Respiratory Society 3445
- International Institute for the Advancement of Medicine 1000
- Irish Thoracic Society 3444
- Merit Medical Endotek 2200
- National Heart, Lung, and Blood Institute 4738
- Olympus America Inc. 3500
- PerkinElmer 1208
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- U.S. EPA’s National Air and Energy Research Program 4327
- UreSil LLC 3020

##### Nonspecific Interstitial Pneumonitis
- 4Dx 3543
- American College of Chest Physicians (CHEST) 3229
- Bellerophon Therapeutics 2
- Bruker BioSpin 3422
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Cincinnati Children’s Hospital 1406
- COPA Syndrome Foundation 3128
- Dynans 2403
- EMMS 3624
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817

##### Sleep Problems
- BleepSleep 2314
- ERT 3636
- Foundation for Sarcoidosis Research 2921
- Infinity Massage Chairs 2312
- National Jewish Health 813

##### Surgery and Transplantation
- Masimo 4141

##### Transplantation
- Bruker BioSpin 3422
- Cincinnati Children’s Hospital 1406
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Hexoskin 1408
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817
- Lympol Medical Corporation 3326
- Maxor Specialty 4128
- National Disease Research Interchange 4229
- patientMpower 3638
- Provider Solutions + Development 2101
- St. Joseph Hospital & Medical Center 4126
- Temple Lung Center 1407
- UPMC 3226
- Wolters Kluwer 1309

##### Other

##### Congenital, Genetic, and Developmental Lung Diseases
- 4Dx 3543
- American Association for Respiratory Care 2100
- AyuVis Research 4940
- Biogen 3429
- Bruker BioSpin 3422
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Cincinnati Children’s Hospital 1406
- COPA Syndrome Foundation 3128
- ECO MEDICS – ECO PHYSICS 4426
- EMMS 3624
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Hexoskin 1408
- International Biophysics 3515
- International Institute for the Advancement of Medicine 1000
- Irish Thoracic Society 3444
- Itamar Medical 2607
- Lympol Medical Corporation 3326
- MedQIA 4233
- MGC Diagnostics 3115
- Monaghan Medical Corporation 4938
- nSpire Health 2608
- Olympus America Inc. 3500
- Owlsone Medical Ltd. 3520
- PerkinElmer 1208
- Praedicare 1012
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- THORASYS Thoracic Medical Systems Inc. 4133
- U.S. EPA’s National Air and Energy Research Program 4327
- UPMC 3226

##### Non-specific Interstitial Pneumonitis
- 4Dx 3543
- American College of Chest Physicians (CHEST) 3229
- Biogen 3429
- Bruker BioSpin 3422
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Cincinnati Children’s Hospital 1406
- COPA Syndrome Foundation 3128
- Dynans 2403
- EMMS 3624
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817
- National Jewish Health 813
- Olympus America Inc. 3500
- Owlstone Medical Ltd. 3520
- PerkinElmer 1208
- Praedicare 1012
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- THORASYS Thoracic Medical Systems Inc. 4133
- U.S. EPA’s National Air and Energy Research Program 4327
- UPMC 3226

##### Infectious Lung Diseases
- Aerogen 2716
- Bruker BioSpin 3422
- Christus Health 3423
- EMMS 3624
- European Respiratory Society 3445
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817
- National Jewish Health 813
- Olympus America Inc. 3500
- Owlstone Medical Ltd. 3520
- PerkinElmer 1208
- Praedicare 1012
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- THORASYS Thoracic Medical Systems Inc. 4133
- U.S. EPA’s National Air and Energy Research Program 4327
- UPMC 3226

##### Diseases of the Pleura and Chest Wall
- American Association for Respiratory Care 2100
- COOK MEDICAL 3504
- European Respiratory Society 3445
- International Institute for the Advancement of Medicine 1000
- Irish Thoracic Society 3444
- Merit Medical Endotek 2200
- National Heart, Lung, and Blood Institute 4738
- Olympus America Inc. 3500
- PerkinElmer 1208
- Provider Solutions + Development 2101
- Temple Lung Center 1407
- U.S. EPA’s National Air and Energy Research Program 4327
- UreSil LLC 3020

##### Nonspecific Interstitial Pneumonitis
- 4Dx 3543
- American College of Chest Physicians (CHEST) 3229
- Biogen 3429
- Bruker BioSpin 3422
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
- Cincinnati Children’s Hospital 1406
- COPA Syndrome Foundation 3128
- Dynans 2403
- EMMS 3624
- European Respiratory Society 3445
- Hermansky-Pudlak Syndrome Network, Inc. 2915
- Irish Thoracic Society 3444
- Lung Transplant Foundation 2817
Exhibitors by Disease State, cont.

**Pulmonary Vascular Diseases**
- 4Dx
- Actelion Pharmaceuticals US Inc.
- American Association for Respiratory Care
- American College of Chest Physicians (CHEST)
- Canadian Thoracic Society
- Christus Health
- COOK MEDICAL
- European Respiratory Society
- International Institute for the Advancement of Medicine
- INTUITIVE
- Irish Thoracic Society
- Lung Transplant Foundation
- National Disease Research Interchange
- National Heart, Lung, and Blood Institute
- ndd Medical Technologies Inc.
- PerkinElmer
- Provider Solutions + Development
- PulmOne USA Inc.
- Scleroderma Foundation
- SEOL PACIFIC CORP.
- Temple Lung Center
- UPMC
- Ventec Life Systems
- Wolters Kluwer

**Respiratory Failure, Injury**
- 3D Systems Simbionix
- American Association for Respiratory Care
- American College of Chest Physicians (CHEST)
- Breathe Technologies, Inc.
- COOK MEDICAL
- Data Sciences International (DSI)
- Fisher & Paykel Healthcare
- Hexoskin
- Irish Thoracic Society
- JAMA Network
- Maxor Specialty
- MGC Diagnostics
- National Disease Research Interchange
- National Jewish Health
- Northwest Seminars
- Olympus America Inc.
- Provider Solutions + Development
- Rocket Medical PLC
- Temple Lung Center
- THORASYS Thoracic Medical Systems Inc.
- US Acute Care Solutions
- Ventec Life Systems
- Wolters Kluwer

**Sleep-Related and Neuromuscular Breathing Disorders**
- American Association for Respiratory Care
- American College of Chest Physicians (CHEST)
- Christus Health
- Cincinnati Children’s Hospital
- CMI Health Inc.
- Coherent Healthcare
- Dynar
- Eastern Pulmonary Conference
- ECO MEDICS – ECO PHYSICS
- EMMS
- ERT
- European Respiratory Society
- Fisher & Paykel Healthcare
- FUJIDA NV
- Hans Rudolph, Inc.
- Healthish 
- Hexoskin
- International Institute for the Advancement of Medicine

**Rare Lung Diseases**
- Bellerophon Therapeutics
- Breathe Technologies, Inc.
- Children’s Interstitial & Diffuse Lung Disease Foundation (chILD)
- Cincinnati Children’s Hospital
- COPA Syndrome Foundation
- ECO MEDICS – ECO PHYSICS
- EMMS
- European Respiratory Society
- Foundation for Sarcoidosis Research
- Hermansky-Pudlak Syndrome Network, Inc.
- Hexoskin
- Inamed Incorporated
- Irish Thoracic Society
- Lung Transplant Foundation

**Systemic Diseases Affecting the Respiratory System**
- 3D Systems Simbionix
- 4Dx
- American Association for Respiratory Care
- American College of Chest Physicians (CHEST)
- Bellerophon Therapeutics
- Bruker BioSpin
- Christus Health
- Cincinnati Children’s Hospital
- Clement Clarke International
- CMI Health Inc.
- Coherent Healthcare
- Dynar
- Eastern Pulmonary Conference
- ECO MEDICS – ECO PHYSICS
- EMMS
- ERT
- European Respiratory Society
- Fisher & Paykel Healthcare
- FUJIDA NV
- Hans Rudolph, Inc.
- Healthish 
- Hexoskin
- International Institute for the Advancement of Medicine

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Clinical Trials Awareness Exhibitors

**ALung Technologies**  
2500 Jane St., Suite 1  
Pittsburgh, PA 15203  
p 412-238-7260  
w alung.com

**Altavant Sciences**  
324 Blackwell St., Suite 1104, Bay 11  
Durham, NC 27701

**Bellerophon Therapeutics**  
184 Liberty Corner Road, Suite 302  
Warren, NJ 07059  
p 908-574-4770  
w bellerophon.com

Bellerophon Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies that address significant unmet medical need in the treatment of cardiopulmonary diseases. Bellerophon's pipeline programs are researching three potential indications with INOpulse, a delivery system for inhaled nitric oxide (NO) for Pulmonary Hypertension in Interstitial Lung Disease (PH-ILD), Pulmonary Hypertension in Sarcoidosis (PH-Sarc) and Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD).

**FibroGen, Inc.**  
409 Illinois St.  
San Francisco, CA 94158  
p 415-978-1200  
w fibrogen.com

FibroGen is a leading biopharmaceutical company focused on development and commercialization of therapeutic agents for serious unmet medical needs. Pamrevlumab, an investigational anti-fibrotic therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), is advancing toward Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF). In previous phase 2 IPF clinical trials, Pamrevlumab was found to be well tolerated, and changes in fibrosis were correlated with changes in pulmonary function.

**Galapagos NV**  
Generaal de Wittelaan L11 A3  
Mechelen 2800  
Belgium  
p 32-15342900  
w glpg.com

Galapagos is a clinical-stage biotechnology company, specializing in the discovery and development of small molecule medicines with novel modes of action. We are committed to being a valued scientific partner in the race to combat idiopathic pulmonary fibrosis (IPF). Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development, and commercialization of innovative medicines that will improve people's lives.

**Santhera Pharmaceuticals**  
25 Corporate Drive, Suite 250  
Burlington, MA 01803  
p 781-365-0301  
e office@santhera.com  
w santhera.com

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. Its portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular, and pulmonary diseases. Our current clinical studies include idebenone to treat respiratory dysfunction in boys with DMD and POL6014 , an inhibitor human neutrophil elastase (hNE) in Phase I/II clinical development for treatment of cystic fibrosis.

**Reata Pharmaceuticals**  
2801 Gateway Drive, Suite 150  
Irving, TX 75063  
p 972-865-2219  
w reatapharma.com

Reata is a clinical-stage biopharmaceutical company located in Irving, Texas, focused on developing drugs that modulate the activity of important regulatory proteins, called transcription factors, to address serious or life-threatening diseases. One of our lead product candidates, bardoxolone methyl, is in Phase 3 clinical development for the treatment of pulmonary arterial hypertension associated with connective tissue disease.

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Global Community Exhibitors

Asian Pacific Society of Respirology

2F, UK’s Bldg., 2-29-3, Hongo, Bunkyo-Ku
Tokyo 113-0033
Japan
p 81-356843370
w apresp.org

Asociacion Argentina de Medicina Respiratoria

FD Roosevelt 2445 4B
Buenos Aires 1428
Argentina
p 54-1147862257
w aamr.org.ar

Asociacion Latinoamericana de Torax — ALAT

Libertad 2849
Montevideo 11200
Uruguay
p 598-57313893881
w alatorax.org

Brazilian Thoracic Society

SCS Quadra 01 Bloco K Salas 203/204 Ed. Denasa
Brasilia, DF 70398-900
Brazil
p 55-6132451030
w sbpt.org.br

Canadian Thoracic Society

30 Concourse Gate #27
Ottawa, Ontario K2E 7V7
Canada
p 613-235-6650
w cts-sct.ca

The Canadian Thoracic Society (CTS) is Canada’s national interprofessional specialty society for respirology, bringing together more than 1,000 members representing specialists, physicians, researchers, and health care professionals from a variety of disciplines working in respiratory health. The CTS promotes lung health by enhancing the ability of health care professionals through leadership, collaboration, research, learning, and advocacy, and providing the best respiratory practices in Canada. For more information, visit cts-sct.ca.

Egyptian Pediatric Pulmonology Society

142 El Shahed Galal St., Apt. 61, Sixth Floor Alexandria
Egypt
p 20-34286556
w egyptiancpp.org

European Respiratory Society

Avenue Sainte Luce 4
Lausanne, Vaud CH-1003
Switzerland
p 41-212130143
w ersnet.org
ERS is an international organization that brings together physicians, health care professionals, scientists, and other experts working in respiratory medicine. We are one of the leading medical organizations in the respiratory field, with a growing membership representing more than 160 countries. Our mission is to promote lung health in order to alleviate suffering from disease, and drive standards for respiratory medicine globally. Science, education, and advocacy are at the core of everything we do.

International Society for Aerosols in Medicine

1525 Seneca Lane
San Mateo, CA 94402
p 650-341-7277
w isam.org
The International Society for Aerosols in Medicine (ISAM) was founded in 1970. The objectives of ISAM are to stimulate and further the interdisciplinary cooperation and exchange of information in all aspects of aerosol research in medicine, including health effects of inhaled aerosols and pulmonary drug delivery. ISAM sponsors international conferences, publications, study groups, and special research projects. ISAM is a non-profit organization.

International Union Against Tuberculosis and Lung Disease

61 Broadway, Suite 1720
New York, NY 10006
p 212-500-5736
w theunion.org

Irish Thoracic Society

Credim Centre Leopardstown Road
Co Dublin
D18FF64
Ireland
p 353-15677201
w irishthoracicsociety.com
The Irish Thoracic Society is the national organization representing respiratory health care professionals on the island of Ireland. The society is dedicated to leading and advancing the care of people with respiratory illness through its work in advocacy, education, and research.

Japanese Respiratory Society

Nichinai Kaikan, Seventh Floor, 3-28-8 Hongo
Bunkyo-ku, Tokyo 1130033
Japan
p 81-358053553
w jrs.or.jp

Pan African Thoracic Society (PATS)

719 Umbilo Road
Durban 4001
South Africa
p 27-0312604811
w panafricanthoracic.org

Public Health Foundation of India

Plot #47, Sector 44
Gurgaon, Haryana 122002
India
p 91-1244781400
w phfi.org
Public Health Foundation of India (PHFI) is a public private partnership. PHFI was started as a response to redress the limited institutional capacity in India by strengthening training, research, and policy development in the area of public health. The training wing of PHFI implements various capacity building initiatives that aim to upgrade the knowledge, skills, and core competencies of physicians in chronic disease management. Established in 2010.

Taiwan Society of Pulmonary and Critical Care Medicine

No. 123, Dapi Road, NiaoSong Dist.
Kaohsiung 83301
Taiwan R.O.C.
p 886-77359117
w tsppcm.org.tw

Thoracic Society of Australia and New Zealand

Level 4, 5 Hunter St.
Sydney, NSW 2000
Australia
p 61-292226200
w thoracic.org.au

Turkish Thoracic Society

Turan Gunes Bulvari Koynulu Sitesi
No 175/19 ORAN
Ankara
Turkey
p 90-3124904050

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
About the Exhibitors

3D Systems Simbionix 3640
5381 S. Alkire Circle
Littleton, CO 80127
p 303-273-5344
w simbionix.com
3D Systems is a world-leading provider of innovative training and education solutions for medical professionals and the health care industry. 3D Systems combines innovative R&D, cutting-edge technology, and strong clinical relationships to promote adoption of best medical practices to advance clinical performance and to optimize procedural outcomes. The company’s comprehensive education solutions include top-of-the-line medical simulators and a simulation management system and patient-specific simulation.

4Dx 3543
30721 Russell Ranch Road, Suite 140
Westlake Village, CA 91362
w 4dx.com
4Dx Limited is a medical technology company established to commercialize four-dimensional lung imaging technology. 4DxV. 4DxV provides a state-of-the-art, non-invasive way of understanding regional lung motion and airflow in real time within the breathing lungs. This enables highly detailed maps of patterns of lung motion and pulmonary function, with functional deficits detected through local differences in movement. The end result: improving millions of lives through earlier disease detection and more accurate monitoring of chronic respiratory conditions.

3DX Systems Simbionix
w simbionix.com

Actelion Pharmaceuticals
US Inc. 3908
5000 Shoreline Court, Suite 200
South San Francisco, CA 94080
p 650-624-6900
e tmcmahe2@its.jnj.com
w actelion.com
Actelion, a leader in pulmonary arterial hypertension, became part of the Janssen Pharmaceutical Companies of Johnson & Johnson following its acquisition in June 2017. Actelion’s medicines have helped to expand and strengthen Janssen’s portfolio. Janssen has added pulmonary hypertension as a therapeutic area of focus to maintain the leadership position Actelion has built in this rare disease area.

Aerogen 2716
410 N. Michigan Ave., Suite 920
Chicago, IL 60611-4203
p 312-718-9547
w aerogen.com
Pioneering aerosol drug delivery. Aerogen's patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of patients of all ages. Aerogen's innovative products, such as the Aerogen® Solo and Aerogen® Ultra, significantly improve aerosol drug delivery resulting in a faster patient response, ultimately increasing throughput in the hospital.

Allergan USA, Inc. 3507
5 Giraldia Farms
Madison, NJ 07940
p 862-261-7920
w allergan.com
Allergan plc (NYSE: AGN) is a bold, global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceuticals, devices, and biologic products for patients around the world. For more information, visit Allergan.com.

Aerogen

Allergy & Asthma Network 2916
8229 Boone Blvd., Suite 260
Vienna, VA 22182
p 703-641-9595
w allergyasthmanetwork.org

American Association for Respiratory Care 2100
9425 N. MacArthur Blvd., Suite 100
Irving, TX 75063-4706
p 972-243-2272
e info@aarc.org
w aarc.org
The American Association for Respiratory Care (AARC) is the leading national and international professional association for respiratory care. The AARC encourages and promotes professional excellence, advances the science and practice of respiratory care, and serves as an advocate for patients and their families, the public, the profession, and the respiratory therapist.

American Board of Internal Medicine 3129
510 Walnut St., Suite 1700
Philadelphia, PA 19106
p 215-282-3838
w abim.org
Certification by ABIM has meant that internists have demonstrated that they have the clinical judgment, skills, and attitudes essential for the delivery of excellent patient care. ABIM is not a membership society, but a physician-led nonprofit, independent evaluation organization with accountability to the profession of medicine and the public.

Aerogen

Amercien Tech Medical, Inc. 3524
4053 Acton Highway
Granbury, TX 76049
p 817-326-6357
w alliancetechmedical.com
Alliance Tech Medical (ATM) features the G-16 In-Check Dial, inspiratory training, and measurement device. Incorporating by its design, improving patient education, understanding performance and safety, while using Mdii and FMdi inhalers. ATM also provides other economical tools to assist the clinician achieve more successful patient outcomes for the COPD, allergy and asthma patient. Visit us in Booth 3524.

Alpha-1 Foundation 3021
3300 Ponce de Leon Blvd.
Coral Gables, FL 33134
p 305-567-9888
w alpha1.org
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.

AMBU 4420
6230 Old Dobbins Lane
Columbia, MD 21045
p 443-875-6520
w ambu.com

American Association for Respiratory Care

Aerogen

Allergan USA, Inc.

About the Exhibitors

Actelion

Aerogen

Allergan USA, Inc.

About the Exhibitors

Actelion

Aerogen

Allergan USA, Inc.

About the Exhibitors

Actelion

Aerogen

Allergan USA, Inc.

About the Exhibitors

Actelion

Aerogen

Allergan USA, Inc.

About the Exhibitors

Actelion

Aerogen

Allergan USA, Inc.

About the Exhibitors

Actelion

Aerogen

Allergan USA, Inc.
American College of Chest Physicians (CHEST) 3229
2595 Patriot Blvd.
Glenview, IL 60026
p 224-521-9800
w chestnet.org
CHEST is a global leader in advancing best patient outcomes through innovative education, clinical research, and team-based care. We champion the prevention, diagnosis, and treatment of chest diseases through education, communication, and research. We are an essential connection to clinical knowledge and resources for the global chest community that provides patient care in pulmonary, critical care, and sleep medicine. Visit our booth to learn how you can join the global leaders in chest medicine.

American Thoracic Society 2726, 3130
25 Broadway, 18th Floor
New York, NY 10004
p 212-315-8600
w thoracic.org
With a mission of improving respiratory health worldwide, the American Thoracic Society offers educational opportunities to medical professionals through high-impact journals, International Conference sessions, online programs, and clinical guidelines and statements. Many of these offer ABIM and ABP MOC, CME, and nursing contact hours. We provide research grant support, advocacy programs, and patient education, ATS activities advance research, education, global health, patient health, and clinical services. Visit Booth 3130 to review job postings.

ARDS Foundation 2823
3330 Dundee Road, Suite C4
Northbrook, IL 60062
p 312-749-7047
w ardsglobal.org
ARDS Foundation is a nonprofit organization dedicated toward providing information, education, public awareness, and facilitating medical research. We work with the ARDS community, including patients, families, and medical professionals. The ARDS Foundation also engages in medical research to further the objectives of those within the ARDS Community.

Astrazeneca 4308
1800 Concord Pike
Wilmington, DE 19850
p 800-236-9933
w astrazeneca-us.com
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas—oncology, cardiovascular and metabolic diseases and respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience, and infection. AstraZeneca operates in more than 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Auris Health 613
150 Shoreline Drive
Redwood City, CA 94065
p 650-610-0750
w aurishealth.com
Auris is committed to tackling some of the biggest problems in health care. Lung cancer is the first disease in our sights. With the Monarch™ Platform, Auris” offers physicians revolutionary robotic endoscopic technology. It is designed to enable physicians to diagnose, and eventually, treat hard-to-reach lung nodules with greater precision than ever before. Auris envisions additional uses for the technology across future endoscopic clinical indications.

Ayuvis Research 4940
1120 S. Freeway, #123E
Fort Worth, TX 76014
p 817-845-0304
w ayuvis.com
AyuVis is a preclinical stage pharmaceutical company with a novel small molecule for treating lung diseases such as bronchopulmonary dysplasia (BPD), pseudomonas aeruginosa pneumonia, and cystic fibrosis as well as infectious diseases such as complicated Intra-Abdominal Infection (cIAI) and skin infections. The proprietary compounds use a unique three-pronged approach of immunomodulation, anti-inflammatory, and antimicrobial action to deliver the therapy. Pre-clinical testing has demonstrated effective results for intravenous, intranasal, and intraperitoneal administration of the drug.

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
B. Braun Interventional Systems, Inc.
824 12th Ave.
Bethlehem, PA 18018
p 610-997-4349
w bisusa.org
B. Braun Interventional Systems offers state-of-the-art interventional devices designed and developed to provide innovative ways to add safety, efficiency, precision, and convenience to interventional procedures. Our products have been developed in collaboration with, and in response to, the specific needs of physicians, technicians, and nurses in the areas of radiology, adult and pediatric cardiology, vascular and thoracic surgery, ultrasound, and specialty procedures. Stop by Booth 4231 for a product demonstration.

Biodex, Inc.
2970 Wilderness Place, Suite 100
Boulder, CO 80301
p 303-417-0500
w biodesix.com
Biodex, Inc. is a fully integrated multi-omic company with clinically validated blood-based diagnostics for non-small cell lung cancer. Biodexis Lung Reflex testing integrates the GeneStrat and VeriStrat tests to inform mutational status, treatment decisions, and facilitate patient-physician conversations about prognosis and care preferences.

Biofire Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108
p 801-736-6354
w biofiredx.com
The BioFire® FilmArray® System uses syndromic testing to identify infectious diseases with several FDA-cleared and CE-marked assay-specific reagent panels. Each panel combines a broad grouping of probable pathogenic causes into a single, rapid test and simultaneously tests for a comprehensive set of targets in about an hour.

Biogen
133 Boston Post Road
Weston, MA 02493
w biogen.com

BleepSleep
11312 U.S. 15-501 N., Suite 107-206
Chapel Hill, NC 27517
p 919-971-4933
w bleepsleep.com
Now available for purchase, “The Most Innovative PAP Interface on the Planet.” The Bleep DreamPort Sleep Solution is the world’s first PAP interface with no headgear, no leaks, weighs less than 1 ounce, and one size fits all users. Our promise is: 1. No lines from headgear. 2. No leaks. 3. No pain. “Help us make the mask a thing of the past.”

Bodyscan
11312 U.S. 15-501 N., Suite 107-206
Chapel Hill, NC 27517
p 919-971-4933
w bodyscan.com
Now available for purchase, “The Most Innovative PAP Interface on the Planet.” The Bodyscan DreamPort Sleep Solution is the world’s first PAP interface with no headgear, no leaks, weighs less than 1 ounce, and one size fits all users. Our promise is: 1. No lines from headgear. 2. No leaks. 3. No pain. “Help us make the mask a thing of the past.”

Bristol-Myers Squibb
235 E. 42nd St.
New York, NY 10017
p 212-733-2323
w eliquis.com
Pfizer and Bristol-Myers Squibb are partners in a worldwide collaboration. This global alliance combines both Bristol-Myers Squibb’s and Pfizer’s longstanding strengths in drug development and commercialization.

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877
p 203-798-9988
w us.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. With headquarters in Ingelheim, Germany, the company has remained family-owned and today creates value through innovation for three business areas, including human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. For more information, visit boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.

Bosch Healthcare Solutions GmbH
Postfach 1127, Suite 200
Waiblingen 71301
Germany
p 49-1605395390
Boston Medical Products / Novatech 3533
70 Chestnut St.
Shrewsbury, MA 01545
p 508-898-9300
e jduquette@bosmed.com
w bosmed.com
Boston Medical Products is proud to be the exclusive distributor of the DUMON™ stent, the original patented design, used successfully worldwide to treat tracheal and bronchial obstructions and stenoses, and STERITALC®, intended for treatment of malignant pleural effusions and recurrent spontaneous pneumothorax.

Broncus Medical, Inc. 3218
125 Nicholson Lane
San Jose, CA 95134
p 650-428-1600
w broncus.com
Broncus Medical, the leader in virtual bronchoscopic navigation, has developed Archimedes™ total lung access platform, including Bronchoscopic Trans-Parenchymal Nodule Access (BTPNA). Now Broncus has combined Bronchoscopic Thermal Vapor Ablation (BTVLA) to treat emphysematous segments. Broncus Medical is proud to introduce next-generation pulmonary technology for access, diagnosis to treatment.

Bruker BioSpin 3422
15 Fortune Drive
Billerica, MA 01821
p 978-667-9580
w bruker.com/products/predclinical-imaging.html

BTG 3622
11911 N. Creek Parkway S.
Bothell, WA 98011
p 425-415-3100
w btgplc.com
BTG is a global health care company focused on interventional medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer and vascular conditions. Our vascular products are used in the treatment of varicose veins, pulmonary embolism, deep vein thrombosis, and peripheral arterial occlusions. To learn more about BTG, visit btgplc.com.

CDC National Center for Environmental Health 902
1600 Clifton Road
Atlanta, GA 30329
p 770-488-0589

Centers for Disease Control and Prevention 4326
1600 Clifton Road NE
Atlanta, GA 30329
p 404-639-8988
w cdc.gov/tb
Division of Tuberculosis Elimination

Children’s Interstitial & Diffuse Lung Disease Foundation (chILD) 2816
9937 Montclaire Drive
Mason, OH 45040
p 513-478-4962
w child-foundation.org
Children’s Interstitial Lung Disease (chILD) is a group of rare pediatric lung diseases. There are more than 30 disorders included under the chILD umbrella. The mission of the chILD Foundation is to fund vital research to fight for the promise of more breaths. Such research offers children and their families hope, better treatments, and, ultimately, a cure. chILD disorders are true “orphan” diseases, with less than 10,000 estimated cases in the U.S.

Christus Health 3423
1001 ESE Loop 323, Suite 260
Tyler, TX 75701
p 903-606-3043
w christushealth.org
Physician Recruitment: Christus Trinity Clinic and Christus Physician Group are multispecialty medical groups with more than 850 physicians and advanced practice providers. Our clinicians represent more than 60 specialties in over 140 clinic locations across four states: Arkansas, Louisiana, New Mexico, and Texas. Christus Trinity Clinic and Christus Physician Group are physician-led and governed medical groups and are a part of the Christus Health family.

Cincinnati Children’s Hospital 1406
3333 Burnet Ave.
Cincinnati, OH 45229
p 513-803-6880
w cincinnatichildren.org
Cincinnati Children’s is one of the most distinguished medical centers in the United States, recognized nationally and internationally for excellence in patient care, training, education, and research. Our pediatric subspecialists collaborate in multidisciplinary programs to diagnose and treat the most complex conditions and rare diseases, pioneering clinical procedures and treatments used worldwide. We’re ranked No. 2 overall for Best Children’s Hospitals in 2018-19, and No. 3 for Pulmonology & Lung Surgery by U.S. News & World Report.

BRAEBON Snoring & Sleep Apnea 3324
100 Schneider Road, Suite 1
Kanata, ON K2K1Y2
Canada
p 613-831-6690
w braebon.com

Breathe Technologies, Inc. 3118
15091 Bake Parkway
Irvine, CA 92618
p 949-988-7700
w breathetechnologies.com
Breathe Technologies is the manufacturer of the Life2000® Ventilation System for COPD and other pulmonary-compromised patients diagnosed with chronic respiratory failure. It is a modular ventilation system consisting of the 1-pound Life2000 ventilator and the Life2000 compressor, and provides ventilatory support for patients requiring mechanical ventilation, while allowing them to increase their physical activity level. The Life2000 System is classified by the FDA as a life support ventilator under the CBK code.

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Circassia Pharmaceuticals, Inc. 1912
5151 McCrimmon Parkway, Suite 260
Morrisville, NC 27560
p 866-275-6469
w circassia.com
Circassia is a specialty pharmaceutical business focused on respiratory disease. It sells its NIOX® asthma management products in the U.S., U.K., China, and Germany, and elsewhere through partners. In the U.S., Circassia also has COPD products Tudorza® and Duakrir® and late-stage ventilator-compatible nitric oxide product, AirNOvent.

Clement Clarke International 4433
Cartel Business Estate Edinburgh Way Harlow, Essex CM20 2TT
England
p 44-1279414969
e resp@clement-clarke.com
w clement-clarke.com
Respiratory specialists Clement Clarke International has a series of innovations to showcase at the ATS International Conference. These include training tools aimed at improving pMDI technique including Trainhaler, a placebo-like pMDI simulator for patient coaching together with Flo-Tone, a flow and coordination tool. If you are involved in inhaler technique training, come and check out our range of tools.

CMI Health Inc. 4533
5975 Shiloh Road
Alpharetta, GA 30005
p 888-985-1125
w cmih.com
CMI Health is dedicated to providing innovation in patient monitoring. We have developed, manufactured, and marketed oximeters, vital sign monitors and patient monitors since 2000. CMI Health having provided proven technology to hospitals, physicians, and other health professionals now delivers a viable solution for those focusing on telemedicine. Our mission is to provide higher-quality and cost-effective monitoring devices for those receiving care at home, in the community, or in a care facility.

Cohero Health 4325
335 Madison Ave., Fourth Floor
New York, NY 10017
p 833-426-4376
e contact@coherohealth.com
w coherohealth.com
Cohero Health is a digital health and wellness company transforming respiratory disease management for asthma and COPD using innovative tools and technologies to improve respiratory care, reduce avoidable costs, and optimize medication utilization. The company’s connected devices and mobile applications actively engage and empower respiratory patients by measuring lung function and tracking adherence. For more information, visit coherohealth.com.

Contec Medical Systems Co., Ltd. 3323
112 Qinhuang W. Road
E&T Development Zone
Qinhuangdao, Hebei 066004
China
p 86-3358508888
w contecmed.com
Contec has always been committed to the research, development, production, and sales of medical examination and diagnosis equipment. The product range covers more than 20 categories, including pulse oximeter, blood pressure monitor, ECG, EEG, ultrasound, monitoring, and imaging. With 142 national patents and 85 software copyrights.

Cook Medical 3504
P.O. Box 489, 750 Daniels Way
Bloomington, IN 47402
p 812-339-2235
w cookmedical.com
Since 1963, Cook Medical has worked with physicians to develop minimal invasive technologies. Today, we offer medical devices, biologic materials, and cellular therapies to deliver better patient outcomes more efficiently. We remain family-owned so we can focus on what we care about most: our patients, our employees, and our communities. Find out more at cookmedical.com, and for the latest news, follow us on Twitter, Facebook, and LinkedIn.

COPA Syndrome Foundation 3128
1860 FM 359, #146
Richmond, TX 77406
p 713-550-2620
w corelinsesoft.com
Coreline Soft Company Ltd. is an AI-based imaging software company located in Korea. Coreline Soft provides a quantitative COPD analysis solution that offers AI-powered lung/lobe segmentation, airway measurement, and INSPI/EXP lung registration for air trapping and other various quantification. All quantification is performed automatically without any single click, which might be the first development in the world.

CRC Press, Taylor & Francis Group 912
6000 Broken Sound Parkway NW
Suite 300
Boca Raton, FL 33487
p 561-994-0555
w crcpress.com
CRC Press is a premier global publisher of science, technology, and medical resources. We offer unique, trusted content by expert authors, spreading knowledge and promoting discovery worldwide. We aim to broaden thinking and advance understanding in the sciences, providing researchers, academics, professionals, and students with the tools they need to share ideas and realize their potential. CRC Press is a member of Taylor & Francis Group, an Informa business.

Data Sciences International (DSI) 2715
119 14th St. NW, Suite 100
St. Paul, MN 55112
p 651-481-7400
w datasci.com
DSI offers preclinical physiological monitoring solutions for acute or chronic studies. The FinePointe Platform for respiratory and inhalation is powerful and easy-to-use for collecting, analyzing, and reporting life science data. Products include whole body plethysmograph, resistance and compliance, non-invasive airway mechanics, telemetry, stackable inhalation tower, and more. With DSI being cited in over 11,000 peer-reviewed publications, DSI provides unsurpassed quality and service, with 47 global sales and support staff here to help.

Dynaris 3424
743 Spirit 40 Park Drive, Suite 108
Chesterfield, MO 63005
p 636-778-1926
e info@dynaris.com
w dynaris.com
Patients predominately breathe through a dominant naris with over 80 percent studied exhibiting alternating unilateral nasal resistance. This can dramatically impact oxygen therapy and cost. Dynaris is developing efficient and effective products addressing this concern. We sense and deliver oxygen instantaneously, each breath, to the most patent naris. This means patients can get their required dosage without wasting oxygen to the occluded side. Dynaris powered technologies is also addressing the population of mouth breathers during sleep.
deliver better care. empowering them to make better decisions and science, health, and technology professionals, solutions that enhance the performance of Elsevier is a world-leading provider of information. elsevierhealth.com

Philadelphia, PA 19103
1600 JFK Blvd., Suite 1800
Philadelphia, PA 19103
e sales@emms.email
w emms.global
Inhalation and respiratory measurement equipment for preclinical applications. Three decades of experience designing, manufacturing, and supporting high-quality equipment and software. Inhalation towers, whole body plethysmography, resistance, and compliance, double chamber, pulmonary function testing, forced oscillation technique, and more.

ECO MEDICS – ECO PHYSICS 4426
3915 Research Park Drive, Suite A-3
Ann Arbor, MI 48108
p 734-998-1600
e tom@ecophysics-us.com
w ecophysics-us.com/product-categories/
medical-research-products/
Experts in nasal and exhaled breath NO (nitric oxide) measurements with a protocol that complies with the ATS Guidelines. Also easy to use LCI (Lung Clearance Index) determinations using the Nitrogen Multiple Breath Washout (N2 MBW) technique. Our analyzers are sold for research purposes only in the U.S. and Canada, but they are approved as medical devices in most of Europe. Stop by for a chat.

ERT 3636
1818 Market St., Suite 1000
Philadelphia, PA 19103
p 215-972-0420
w ert.com
ERT is a global clinical trial data solution and analytics company. With more than 1,000 respiratory trials supported, we offer proven respiratory solutions for centralized spirometry and PFT. ERT is proud to announce the launch of our respiratory device SpiroSphere, the industry’s first and only spirometer designed specifically for use in global clinical trials.

FDA Center for Tobacco Products 3523
10903 New Hampshire Ave., Building 71, Room G335
Silver Spring, MD 20993
p 877-287-1373
w fda.gov/Tobacco

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
concentrators in the U.S. market, the Zen-O® and Healthcare has introduced two portable oxygen with more than 30 years of experience. GCE medical devices and medical gas systems manufacturing and distribution of high purity GCE Healthcare is a global leader in us.gcegroup.com weuscustsvc@gcegroup.com p 817-268-9220 Keller, TX 76262 1508 Windsor Forest Trail GCE Healthcare 2203

G

GCE Healthcare 2203

1508 Windsor Forest Trail
Keller, TX 76262
p 817-268-9220
e uscustsvc@gcegroup.com
w us.gcegroup.com

GCE Healthcare is a global leader in manufacturing and distribution of high purity medical devices and medical gas systems with more than 30 years of experience. GCE Healthcare has introduced two portable oxygen concentrators in the U.S. market, the Zen-O® and Zen-O lite®. In addition, GCE Healthcare features Clarity Connected Care, a remote monitoring system that allows home oxygen providers and patients to monitor their devices on any platform anywhere in the world.
Hans Rudolph, Inc.  
8325 Cole Parkway  
Shawnee, KS 66227-3128  
p 913-422-7788, 800-456-6695  
w rudolphkc.com

Hans Rudolph, Inc. is a leading designer and manufacturer of respiratory valves and other respiratory products in the world today. Its innovative research and development is helping bring the field of respiratory health care into the 21st century.

HCmed Innovations  
Rm. B, 10F., No.319, Sec.2, Dubhua S. Road  
Taipei City, Taipei 10669  
Taiwan R.O.C.

HCmed works with leading pharma companies around the world to design, develop, and manufacture highly effective drug device combinations for respiratory disease control. We are the all-round solution provider for creating future of inhalation therapy. Based on leading-edge medical expertise, combined with the strength of Taiwan’s world-class manufacturing industry, the team of HCmed has developed 21st-century nebulizers since 2006 and the first own-brand device 2015. We now work with pharma companies on cost-efficient drug device combinations.

Hexoskin  
5800, rue Saint-Denis, Suite 402A  
Montreal, Quebec H2S 3L5  
Canada

Since 2006, Hexoskin provides innovative health sensors, remote monitoring solutions, and data science services with machine learning and AI. Hexoskin proposes a non-invasive remote monitoring solution to continuously track the patients’ cardiac, respiratory, and activity data with body sensors embedded in comfortable smart garments. The Hexoskin Connected Health Platform allows home monitoring and reduces the frequency of travel for patients and study volunteers. Hexoskin’s clients include government agencies, hospitals, biopharmaceutical companies, health researchers, and professionals.

Hill-Rom  
1069 State Road, Route 46 E.  
Batesville, IN 47006-9167  
p 812-931-2455  
w hillrom.com

Hill-Rom is a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across all care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency, and respiratory health.

Hugan Medical Instrument Co. Ltd.  
Building 26, 3825 Xinzhuang Highway,  
Songjiang  
Shanghai 201619  
China

We are a 17-year-old video flexible manufacturer for gastro, colono, broncho, and nasopharyngoscopy with TUV, CE registered.
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
<th>Address</th>
<th>Phone</th>
<th>Website</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensivist Company</td>
<td>3426</td>
<td>820 Evergreen Ave., Pittsburgh, PA 15229</td>
<td>412-680-6294</td>
<td><a href="http://www.intensivistjobs.com">www.intensivistjobs.com</a></td>
<td></td>
</tr>
<tr>
<td>International Biophysics</td>
<td>3515</td>
<td>2101 E. St. Elmo, Suite 275, Austin, TX 78744</td>
<td>512-326-3244</td>
<td><a href="http://www.biophysicscorp.com">www.biophysicscorp.com</a></td>
<td><a href="mailto:info@biophysicscorp.com">info@biophysicscorp.com</a></td>
</tr>
<tr>
<td>Insmed Incorporated</td>
<td>3722</td>
<td>10 Finderne Ave., Bldg. 10, Bridgewater, NJ 08807</td>
<td>908-977-9900</td>
<td><a href="http://www.insmed.com">www.insmed.com</a></td>
<td></td>
</tr>
<tr>
<td>Intuitive</td>
<td>1100</td>
<td>1020 Kifer Road, Sunnyvale, CA 94086</td>
<td>408-523-2100</td>
<td><a href="http://www.intuitive.com">www.intuitive.com</a></td>
<td></td>
</tr>
<tr>
<td>Itamar Medical</td>
<td>2607</td>
<td>3290 Cumberland Club Drive, Suite 2, Atlanta, GA 30339</td>
<td>888-748-2627</td>
<td><a href="http://www.itamarmedical.com">www.itamarmedical.com</a></td>
<td></td>
</tr>
<tr>
<td>International Institute for the Advancement of Medicine</td>
<td>1000</td>
<td>125 May St. Edison, NJ 08837</td>
<td>800-486-4426</td>
<td><a href="http://www.iiam.org">www.iiam.org</a></td>
<td></td>
</tr>
<tr>
<td>JAMA Network</td>
<td>4633</td>
<td>330 N. Wabash Ave., Suite 39300, Chicago, IL 60611</td>
<td>312-644-5000</td>
<td><a href="http://www.jamanetwork.com">www.jamanetwork.com</a></td>
<td></td>
</tr>
<tr>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>1108</td>
<td>3170 Porter Drive, Suite 510, Palo Alto, CA 94304</td>
<td>650-496-3777</td>
<td><a href="http://www.jazzpharma.com">www.jazzpharma.com</a></td>
<td></td>
</tr>
<tr>
<td>Jazz Pharmaceuticals plc</td>
<td>1554</td>
<td>11 Penn Plaza, 23rd Floor, New York, NY 10001</td>
<td>212-771-2200</td>
<td><a href="http://www.jazzpharma.com">www.jazzpharma.com</a></td>
<td></td>
</tr>
<tr>
<td>Kaiser Permanente</td>
<td>1409</td>
<td>1800 Harrison St., Seventh Floor, Oakland, CA 94612</td>
<td>800-777-4912</td>
<td><a href="mailto:mdrecruitment.tpmg@kp.org">mdrecruitment.tpmg@kp.org</a></td>
<td><a href="mailto:info@kp.org">info@kp.org</a></td>
</tr>
<tr>
<td>Intuitive</td>
<td>1100</td>
<td>1020 Kifer Road, Sunnyvale, CA 94086</td>
<td>408-523-2100</td>
<td><a href="http://www.intuitive.com">www.intuitive.com</a></td>
<td></td>
</tr>
<tr>
<td>Itamar Medical</td>
<td>2607</td>
<td>3290 Cumberland Club Drive, Suite 2, Atlanta, GA 30339</td>
<td>888-748-2627</td>
<td><a href="http://www.itamarmedical.com">www.itamarmedical.com</a></td>
<td></td>
</tr>
<tr>
<td>LAM Foundation</td>
<td>2820</td>
<td>1099</td>
<td>1099</td>
<td>w <a href="http://www.iamm.org">www.iamm.org</a></td>
<td></td>
</tr>
<tr>
<td>LAM Foundation</td>
<td>2820</td>
<td>1099</td>
<td>1099</td>
<td>w <a href="http://www.iamm.org">www.iamm.org</a></td>
<td></td>
</tr>
<tr>
<td>The LAM Foundation/Lymphangioleiomyomatosis</td>
<td>2820</td>
<td>4520 Cooper Road, Suite 300, Cincinnati, OH 45242</td>
<td>513-777-6889</td>
<td><a href="mailto:info@thelamfoundation.org">info@thelamfoundation.org</a></td>
<td>w thelamfoundation.org</td>
</tr>
</tbody>
</table>

### Inspire Medical Systems, Inc. (3519)
Inspire Medical Systems, Inc. is the leading developer of implantable neurostimulation systems to treat obstructive sleep apnea (OSA). Using well-established technologies from cardiac pacing and neurostimulation, Inspire developed a proprietary upper airway stimulation (UAS) therapy designed to improve sleep and enrich the lives of people suffering from this challenging condition.

### Intensive Care Services, Inc. (3519)
Intensive Care Services, Inc. is a leader providing cutting-edge technologies and support aimed at providing real solutions to meet customers’ needs. Some innovative solutions include the KDR™ U-Arm DR System, the AeroDR® Wireless Flat Panel Detector, Exa™, and the SONIMAGE® HS1 and JS Ultrasound Systems.

### Jazz Pharmaceuticals, Inc. (1108)
Jazz Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options, so they can live their lives more fully and redefine what is possible. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines.

### JAMA Network (4633)
Building on a tradition of editorial excellence, JAMA Network brings JAMA together with 11 specialty journals to offer enhanced access to the research, reviews, and opinions shaping the future of medicine.

### Jazz Pharmaceuticals plc (1554)
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with rare conditions, such as nontuberculous mycobacterial (NTM) lung disease. Visit us at Booth 3722 to learn about new developments in NTM.

### Kaiser Permanente (1409)
Kaiser Permanente is recruiting for all specialties. With the Permanente Medical Group, Inc., you’ll find recognition, stability, opportunity, and independence. We can also afford you a high quality of life and a work schedule, allowing for time spent with family and friends. Contact 800-777-4912 or physiciancareers.kp.org.

### Konica Minolta Healthcare Americas, Inc. (4636)
Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and health care information technology. With over 75 years of relentless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and support aimed at providing real solutions to meet customers’ needs. Some innovative solutions include the KDR™ U-Arm DR System, the AeroDR® Wireless Flat Panel Detector, Exa™, and the SONIMAGE® HS1 and JS Ultrasound Systems.

### LAM Foundation/Lymphangioleiomyomatosis (2820)
The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical, and patient communities by offering information, resources, and a worldwide network of hope and support.
Level Ex 363 W. Erie St., #4E Chicago, IL 60654 p 781-724-4299 w level-ex.com Level Ex® creates industry-leading medical video games for physicians—featuring challenging cases that expose physicians to new techniques, medical devices, and drug therapies, while sharpening their skills and allowing them to earn CME credits. Their game Pulm Ex presents physicians with difficult patient case scenarios seen in general and interventional pulmonology—including obstructive and restrictive diseases, foreign bodies, endobronchial masses, and lung cancers—and allows physicians to perform interventional bronchoscopies on ultra-realistic simulations of the trachea and bronchi.

Lung Transplant Foundation 1249 Kildaire Farm Road, Suite 323 Cary, NC 27511 p 786-348-0210 w lungtransplantfoundation.org The Lung Transplant Foundation strives to improve the lives of lung transplant patients by raising awareness about organ donation, supporting research to improve long-term outcomes and providing mentoring services for lung transplant recipients and caregivers. We work tirelessly to bring the issues of post-transplant rejection to the forefront through networking and activism with government agencies, the medical community, pharmaceutical, and medical technology companies. We also are working to make more organs available for transplant.

LUNGevity Foundation 6917 Arlington Road, Suite 352 Bethesda, MD 20814 p 312-407-6100 e kbrown@lungevity.org w lungevity.org LUNGevity is the nation’s leading lung cancer-focused nonprofit. We are changing outcomes for people with lung cancer through research, education, and support.

Lymol Medical Corporation Four Plympton St. Woburn, MA 01801 p 781-935-0004 w lymolmedical.com Leading supplier and manufacturer of medical equipment used by experts in interventional pulmonology; rigid bronchoscopy, stent placement kits, silicone stents such as bronchial stents, tracheal stents and Y-stents, forceps, optical telescopes, and other.

Mallinckrodt Pharmaceuticals 1425 U.S. Route 206 Bedminster, NJ 07921 p 908-238-6600 w mallinckrodt.com Mallinckrodt is a global business that develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. The company’s autoimmune and rare diseases business includes H.P. Acthar® Gel (repository corticotropin injection), indicated for use in multiple specialities. Mallinckrodt’s other areas of focus include immunotherapy and neonatal respiratory critical care therapies, analgesics, and gastrointestinal products. To learn more about Acthar, visit Acthar.com.

Marshfield Clinic Health System 1000 N. Oak Ave. Marshfield, WI 54449 p 715-221-5775 e baka.heidi@marshfieldclinic.org w marshfieldclinic.org Marshfield Clinic Health System is committed to enriching the lives of others through accessible, affordable compassionate health care. Marshfield Clinic physicians and staff serve more than 325,000 unique patients each year through accessible, high-quality health care, research and education. With 700+ physicians in 86 medical specialties and subspecialties as well as over 9,000 employees in more than 60 locations in Wisconsin, Marshfield Clinic is nationally recognized for innovative practices and quality care.

Maxor Specialty 320 S. Polk, Suite 900 Amarillo, TX 79101 p 806-324-5400 e baikins@maxor.com w abetterspecialtypharmacy.com Maxor Specialty is a sub-speciality pharmacy that is focused on the delivery of pharmacy care to patients suffering from rare and orphan pulmonary diseases. Maxor Specialty partners with manufacturers, health care providers, advocacy groups, and patients to insure maximum adherence for complex biopharmaceutical therapies. Our teams are trained and experienced with more than 20 years on the delivery of care for patients suffering from complex pulmonary disorders. Please stop by and visit our care team members.

Mayne Pharma 3301 Benson Drive, Suite 401 Raleigh, NC 27609 p 984-242-1386 w maynepharma.com Mayne Pharma is an ASX-listed specialty pharmaceutical company with a 30-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been applied to a number of products that have been successfully marketed around the world, including super-bioavailable itraconazole used to treat fungal infections. Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia, and Greenville, North Carolina.

Maxor Specialty 320 S. Polk, Suite 900 Amarillo, TX 79101 p 806-324-5400 e baikins@maxor.com w abetterspecialtypharmacy.com Maxor Specialty is a sub-speciality pharmacy that is focused on the delivery of pharmacy care to patients suffering from rare and orphan pulmonary diseases. Maxor Specialty partners with manufacturers, health care providers, advocacy groups, and patients to insure maximum adherence for complex biopharmaceutical therapies. Our teams are trained and experienced with more than 20 years on the delivery of care for patients suffering from complex pulmonary disorders. Please stop by and visit our care team members.

MedEd On The Go 6707 113th Place SE Bellevue, WA 98006 p 267-395-0001 w mededonthego.com MedEd On The Go is a mobile-friendly platform that delivers comprehensive education in short video episodes. We offer a host of educational opportunities, including weekly online publications delivered by leading experts, free certified CE/CME programs, quiz challenges to test your knowledge and review in-depth explanations for incorrect answers, and downloadable assets for most programs.

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Merit Medical Endotek® integrates non-vascular stent technology with procedural kits for thoracentesis and bronchoscopy, inflation devices, dilation balloons, guide wires, and other accessories used throughout the medical community. Merit Endotek develops next-generation stent technology for use in the airway (AERO® and AEROMim®), to build value and quality in the creation of interventional and palliative treatment alternatives.

MedQIA is a global imaging CRO specializing in cutting-edge, innovative quantitative image analysis (QIA) for both clinical trials and radiology decision support (RDS) services. MedQIA provides clinical trial services related to image management and data analysis from project initiation to close-out. MedQIA provides these services using its imaging biomarker information system (IBIS) explorer and markup software medical device, which has been FDA 510(k) cleared for its intended use.

Methapharm focuses on respiratory diagnostics for the U.S. market. We currently offer Provocholine for methacholine challenge testing, and Aridol for mannitol challenge testing. These dose response tests can help to confirm or rule out a diagnosis of current asthma.

MGC Diagnostics® is a global medical technology company dedicated to providing cardiopulmonary health solutions. We develop, manufacture, and market non-invasive diagnostic systems for detecting, classifying, and managing cardiopulmonary disease. That singular focus guides our strategy and defines our commitment to customers, employees, and shareholders. With more than 35 years of experience in the industry and product placement in more than 45 countries, MGC Diagnostics brings unmatched insight for solving today’s challenges and anticipating tomorrow’s opportunities.

MIR – Medical International Research

Morgan Scientific has a legacy of three generations, providing top-line PFT diagnostic equipment/software. If you struggle with downtime and reliability of your equipment and are interested in going paperless and stop printing, scanning, and faxing, stop by and find out more. Learn why seven of the top 10 pediatric hospitals and No. 1 teaching hospital in the U.S. use our equipment and ComPAS software. Come get a personalized demo and meet our dragon.
Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Novartis Pharmaceuticals
One Health Plaza
East Hanover, NJ 07936
p 862-778-8300
w novartis.com
Novartis is a leading medicines company based in Basel, Switzerland, with a history going back more than 150 years. We use innovative science, digital technology, and new business models to address the evolving needs of patients and societies worldwide. Novartis products are sold in about 155 countries, and they reached nearly 1 billion people globally in 2017. About 126,000 people of more than 140 nationalities work at Novartis around the world.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936
p 862-778-8300
w novartis.com

Owlstone Medical Ltd.
1550 Madruga Ave., Suite 230
Coral Gables, FL 33146
p 305-667-6461
e ntminfotntminfo.org
w ntminfo.org
NTM Info & Research (NTMIR) is a 501(c)(3) nonprofit patient advocacy organization formed on behalf of patients with pulmonary nontuberculous mycobacterial (NTM) disease for the purpose of patient support, medical education, and research.

Olympus America Inc.
3500 Corporate Parkway
Center Valley, PA 18034-0610
p 484-896-5000
w medical.olympusamerica.com
Our medical business works with health care professionals to combine our innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance quality of life for patients. Visit medical.olympusamerica.com and truetolife.com.

Oncimmune USA LLC
8960 Commerce Drive, Building 6
De Soto, KS 66018
p 913-583-9000
e clientservices@oncimmune.com
w oncimmune.com
Oncimmune is a pioneer, a leader, and an expert in early cancer detection and improved cancer outcomes. Since 2002, Oncimmune has pioneered technologies that enable early cancer detection. The company’s proprietary technology platform, EarlyCDT®, is extensively validated for all types of lung cancer. Oncimmune is helping to lead the advancement of early cancer detection across a range of solid tumor types.

Penn State Health
1500 University Drive, University Park
Pennsylvania 16802
p 862-778-8300
e patientshealth@pennstatehealth.psu.edu
w pennstatehealth.org
Penn State Health is a multihospital health system serving patients and communities across central Pennsylvania. The system includes Penn State Health St. Joseph Medical Center, Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital, Penn State Cancer Institute, and Penn State Health Rehabilitation Hospital, as well as more than 1,300 physicians and direct care providers at 78 medical office locations. Consider a career with us today. Contact patientshealth@pennstatehealth.psu.edu

PatientMpower
3638
MATTER 222 Merchandise Mart Plaza,
Suite 1230
Chicago, IL 60654
p 617-207-6699
e info@patientmpower.com
w patientmpower.com
Empowering patients to improve their lung health outcomes while reducing the burden on health providers by moving care away from the clinical setting toward the patient’s home.

Pediatric Search Partners
1308
100 Congress Ave., Suite 2000
Austin, TX 78701
p 877-440-3832
w pediatricsearchpartners.com
Pediatric Search Partners is a boutique search firm solely focused on serving the pediatricians, pediatric subspecialists, and leaders dedicated to providing children’s health care. Since 2009, we’ve placed more than 500 physicians with leading children’s hospitals and health care organizations across the nation. Our passion is matching those who care for children with opportunities they truly care about. Because we believe children shouldn’t have to wait a minute longer for the kind of health care they deserve.

Penn State Health
4228
P.O. Box 855, 500 University Drive,
MC 15095
Hershey, PA 17033
p 717-531-6205
e pshdocs@pennstatehealth.psu.edu
w hmc.pennstatehealth.org
Penn State Health is a multihospital health system serving patients and communities across central Pennsylvania. The system includes Penn State Health St. Joseph Medical Center, Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital, Penn State Cancer Institute, and Penn State Health Rehabilitation Hospital, as well as more than 1,300 physicians and direct care providers at 78 medical office locations. Consider a career with us today. Contact pshdocs@pennstatehealth.psu.edu
PerkinElmer
940 Winter St.
Waltham, MA 02451-1457
p 781-663-6900
e perkinelmer.com
PerkinElmer is a global leader committed to innovating for a healthier world. Our passionate employees help customers solve critical issues impacting the diagnostics, discovery, and analytical solutions markets. Our innovative detection, imaging, informatics, and service capabilities, plus deep market expertise, enable better insights to improve lives and the world around us.

The PERT Consortium
P.O. Box 108
East Hanover, NJ 07936
p 609-479-5899
e w pertconsortium.org
The PERT Consortium is a nonprofit organization composed of leading academic and research institutions that work together to advance the cause of pulmonary embolism (PE). The PERT Consortium’s mission is to guide and influence PE care and research throughout the United States and the world, and to be the leading source of information and support for patients and their caregivers.

PF Warriors
3325 Landershire Lane
Plano, TX 75023
p 972-612-8425
e support@pfwarrior.com
e w pfwarrior.com
Our motto of Patients Helping Patients says it all. We are the world’s largest support group of ILD patients and families supporting each other through education, events, and inspiration. We host two meetings a month. One a physical meeting in Dallas, Texas, and the other an online or virtual meeting to better serve our more than 1,000 members worldwide.

Philips Respironics
1010 Murry Ridge Lane
Murraysville, PA 15668
p 724-387-5281
e w philips.com/respironics
Philips Respironics is a leading health technology company with a more than 125-year legacy in delivering meaningful innovation and more than 40 years of leadership in sleep apnea management, respiratory care solutions, and most recently, consumer sleep solutions designed to improve people’s lives by improving the quality of their sleep. Philips has a presence in more than 100 countries and 60 R&D and manufacturing sites across all continents. Offering localized support to our customers globally.

Polarean, Inc.
P.O. Box 14805
Durham, NC 27709-4805
p 919-206-7900
e w polarean.com
Physicians searching for their first or next practice rely on PracticeLink—the Career Advancement Resource for Physicians. PracticeLink helps physicians find the practice opportunities that best suit their personal and professional needs, and provides helpful career development and job search information. Find your next practice on PracticeLink.com.

PracticeLink
415 Second Ave.
Hinton, WV 25951
p 800-776-8383
e w practicelink.com
Physicians searching for their first or next practice rely on PracticeLink—the Career Advancement Resource for Physicians. PracticeLink helps physicians find the practice opportunities that best suit their personal and professional needs, and provides helpful career development and job search information. Find your next practice on PracticeLink.com.

Praedicare
14812 Venture Drive
Dallas, TX 75234
p 214-954-7671
e w praedicarelabs.com
Pharmacometric analysis and consulting for drug development. Praedicare accelerates drug development with lead compound selection, safety and efficacy determination, dose and regimen optimization, and clinical development consulting. We provide critical results for go/no-go decisions and clinically relevant data to focus animal studies and strengthen FDA packages. Praedicare’s hollow fiber system is qualified as a drug development tool by the U.S. FDA and the European Medicines Agency. Praedicare has experience in infectious diseases, oncology, and other indications.

Propeller Health
47 Maiden Lane
San Francisco, CA 94108
p 619-987-6620
e provider@propellerhealth.com
e w propellerhealth.com
Propeller is the leading digital health company in respiratory disease dedicated to helping people with asthma or COPD breathe easier. Propeller makes sensors that attach to inhalers and track medication use. Inhaler information is sent to the Propeller app where robust analytics and machine learning create personalized insight and support. The company has nine FDA clearances, 65+ commercial programs, and is validated in 18+ peer-reviewed clinical studies.

Provider Solutions + Development
1201 NE Lloyd Blvd., Suite 510
Portland, OR 97229
p 844-874-7742
e w psdrecruit.org
Founded within Providence St. Joseph Health, Provider Solutions + Development is a not-for-profit clinical career navigation organization. For more than 20 years, we’ve helped thousands of physicians and providers achieve their practice potential. Our growing network of health system partners offers innovative care models, diverse practice locations across the nation, and a shared culture of service.

Pulmonary Fibrosis Foundation
3126
230 E. Ohio St., Suite 500
Chicago, IL 60611
p 844-825-5733
e w pulmonaryfibrosis.org
The Pulmonary Fibrosis Foundation is the trusted resource for everyone affected by PF. Signature programs include free, comprehensive education materials; PFF Care Center Network & Patient Registry; PFF Patient Communication Center and Oxygen Information Line; and international support groups and online communities. Our medical advisory board and PFF Summit maintain ongoing dialogue with health care professionals and the patient community. Our peer-reviewed research program supports projects that improve understanding of PF leading to successful therapies.

Pulmonary Hypertension Association
4434
801 Roeder Road, Suite 1000
Silver Spring, MD 20910
p 301-565-3004
e e PHA@PHAssociation.org
e w PHAssociation.org
Pulmonary hypertension is an undiagnosed illness that affects people of all ages and backgrounds. PHA is the voice of the medical community, patients, and family members united against this illness. Visit PHA’s booth for complimentary information on PH such as PHA’s medical journal, Advances in Pulmonary Hypertension, and educational resources for you and your patients.

Data current as of March 20, 2019. While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions.
Pulmonary Wellness Online 712
10 E. 38th St., Floor 10
New York, NY 10016-0615
p 212-921-0214
e noah@pulmonarywellnessonline.com
w pulmonarywellnessonline.com
The Pulmonary Wellness & Rehabilitation Center, now in its 21st year of providing the highest quality and most expertly delivered patient experience in pulmonary wellness, presents its latest innovation, a 6-week Pulmonary Wellness Online Boot Camp. The program—a collaborative effort between the most accomplished wellness and rehabilitation professionals in the field—offers daily thoughts and motivation, exercise, and education programs designed to enhance the quality of life for respiratory patients.

PulmOne USA Inc. 4130
270 Madison Ave., Floor 9
New York, NY 10016-0606
p 844-785-6663
w pulm-one.com

Pulmonx Corp. 1505
700 Chesapeake Drive
Redwood City, CA 94063
p 650-364-0400
w mylungsmylife.com
Pulmonx helps improve the lives of patients suffering from emphysema with its minimally invasive, personalized treatment, and diagnostic tools. The company's commercial portfolio includes the Zephyr Endobronchial Valve (EBV), the most-studied device for endoscopic lung volume reduction; the Chartis System, an assessment tool that identifies collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based quantitative computed tomography (CT) analysis service. These tools enable physicians to successfully predict outcomes and provide optimal treatment for emphysema patients.

RB 4706
399 Interpace Parkway
 Parsippany, NJ 07054
w rb.com
RB, a global force in health, hygiene, and home products, will be exhibiting cough and cold over-the-counter products, including Mucinex, the No. 1 doctor-recommended cough and cold brand.

SANOFI GENZYME REGENERON 3111, 4515
777 Old Saw Mill River Road
 Tarrytown, NY 10591
p 914-847-7000
w regeneron.com, sanofigenzyme.com
Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including therapies for eye diseases, high LDL cholesterol, atopic dermatitis, rheumatoid arthritis, and a rare inflammatory condition. Sanofi, a global health care leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies using proprietary technologies.

ResMed 3726
9001 Spectrum Center Blvd.
 San Diego, CA 92123
p 800-424-0737
e reception@resmed.com
w resmed.com
At ResMed, we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.

Rocket Medical PLC 3526
50 Corporate Park Drive, Suite 890
Pembroke, MA 02359
p 781-749-6223
e bruce@rocketmedical.com
w usa.rocketmedical.com
Medical design and manufacturer specializing in pleural disease. World leader in thoracocentesis, chest tubes, and indwelling pleural catheters.

Savara Inc. 708
6836 Bee Cave Road, Building 3, Suite 200
Austin, TX 78746
p 512-961-1891
w savarapharma.com

SCIREQ—an emka TECHNOLOGIES company 3619
6600 St-Urbain, Suite 300
Montreal, Quebec H2S 3G8
Canada
p 514-286-1429
e info@scireq.com
w scireq.com
SCIREQ and emka TECHNOLOGIES offer integrated solutions for physiology, pharmacology, and toxicology research. We provide a complete range of innovative instruments and services for in vivo and in vitro research. Our biomedical instruments combine accuracy and reproducibility to provide unparalleled insight into preclinical research, as cited in over 1,300 scientific publications. Through our distribution network, our solutions are available globally.

Scleroderma Foundation 2917
300 Rosewood Drive, Suite 105
Danvers, MA 01923
p 800-722-4673
w scleroderma.org
The Scleroderma Foundation is the leading nonprofit supporter of scleroderma research in the U.S., budgeting $1 million annually. Since 1989, the foundation has funded over $26 million in grants. The foundation facilitates seminars, distributes literature, and conducts publicity campaigns. For patients, the foundation offers peer counseling, support programs, and physician referrals.
SoutheastHEALTH
1701 Lacey St.
Cape Girardeau, MO 63701
p 573-331-6374
w sehealth.org
At SoutheastHEALTH, the region's premier health care system in Southeast Missouri, our patients receive excellent care of the highest clinical quality, close to home. Within our network are more than 50 care locations in 13 communities, including hospitals, primary and specialty care clinics representing over 30 clinical specialties, and extending care for patients in a four-state area. Southeast Hospital in Cape Girardeau has been a trusted health care resource in the community for nearly 100 years.

Spire Health
2403
2030 Harrison St., Second Floor
San Francisco, CA 94110
p 800-501-CALM
e partners@spirehealth.com
w spirehealth.com
Spire Health is the market leader in continuous respiratory sensing and high-adherence, patient-friendly ambulatory monitoring. Our mission is to harness the power of algorithms and sensors to improve health outcomes by empowering patients and physicians with useful and actionable data. We currently work with partners across a range of health conditions, including chronic obstructive pulmonary disease (COPD), congestive heart failure, asthma, sleep disorders, and anxiety.

St. Joseph Hospital & Medical Center
4126
Norton Thoracic Institute, Lung Transplant Program, 500 W. Thomas Road, #300
Phoenix, AZ 85013
p 602-406-8000
w dignityhealth.org/stjosephs/services/lung-disease/programs

STEMCELL Technologies, Inc.
4241
1618 Station St.
Vancouver, BC V6A1B6
Canada
p 604-877-0713
e info@stemcell.com
w stemcell.com
At STEMCELL, science is our foundation. This is why we are collaborating with ATS to offer the STEMCELL Technologies Travel Scholarships to two outstanding scientists attending ATS 2019. Visit us at Booth 4241 to learn about PneumaCult™, the leading culture system that supports the long-term expansion and differentiation of human airway epithelial cells at the air-liquid interface. Find out more at stemcell.com/PneumaCult.

Takeda
300 Shire Way
Lexington, MA 02421
p 617-441-6930
w takeda.com
Takeda is a global, values-based, R&D-driven biopharmaceutical leader with headquarters in Japan, committed to bringing better health and a brighter future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience, and rare diseases. We also make targeted R&D investments in plasma-derived therapies and vaccines. takeda.com

Temple Lung Center
1407
3401 N. Broad St.
Philadelphia, PA 19140
p 800 Temple Med
w lung.templehealth.org
Located in Philadelphia, Pennsylvania, the Temple Lung Center is the nation’s first entirely multidisciplinary hub for thoracic medicine and surgery. Bringing together basic science and clinical faculty, collaboration among specialties reinforces Temple’s leadership in lung transplantation, thoracic surgery, acute and chronic care of pulmonary diseases, clinical and scientific research, and medical education.
TEVA Pharmaceuticals 1412
41 Moores Road
Frazer, PA 19355
p 816-718-1624
w tevausa.com
Teva Pharmaceuticals is a global leader in generic medicines and biopharmaceuticals. Building on more than a century-old legacy, Teva delivers high-quality products to patients in nearly every therapeutic area, has an established presence in generics, specialty, OTC, and API, a fully integrated R&D function, strong operational base, and global infrastructure and scale.

Thirona 3022
Toernooiveld 300 (Mercator 2) 300
Nijmegen, Gelderland 6525EC
Netherlands
e info@thirona.eu
w thirona.eu
Thirona creates products that include the latest technologies but at the same time are intuitive for the user and aid medical specialists in their daily tasks. Thirona has developed three software products focusing on the analysis of thoracic CT scans (LungQ), chest X-rays (CAD4TB), and retinal images (RetCAD). Also, Thirona offers a certified image analysis service delivering accurate and repeatable measurements from medical images.

THORASYS Thoracic Medical Systems Inc. 4133
6560 Avenue de l’Esplanade, Suite 103
Montreal, Quebec H2V 4L5
Canada
p 514-384-8555
e info@thorasys.com
w thorasys.com
THORASYS Thoracic Medical Systems Inc. is a respiratory medical device company based in Montreal, Quebec, Canada, that applies cutting-edge research and technology to the development of products for respiratory diagnosis. THORASYS designs, manufactures, and commercializes pulmonary function test equipment for the diagnosis and monitoring of lung diseases such as asthma and COPD. Our tremoFlo™ C-100 airwave oscillometry system (AOS™) is a compact and portable medical device that provides an effortless assessment of lung function.

TSI Healthcare 4425
101 Europa Drive, Suite 200
Chapel Hill, NC 27517
p 800-354-4205
w tsihealthcare.com/pulmonary
TSI Healthcare is the No. 1 pulmonary and sleep medicine EHR, supporting hundreds of independent pulmonologists. Providers have the freedom to document how they want, whether it’s dictating, smart phrases, templates, or typing. Providers can also bring forward their previous note, along with ordering PSGs or home sleep apnea tests directly out of the system. Fewer clicks.

Tuberous Sclerosis Alliance 2821
801 Roeder Road, Suite 750
Silver Spring, MD 20910
p 301-562-9890
e info@tsalliance.org
w tsalliance.org
For 45 years, the Tuberous Sclerosis Alliance has been dedicated to finding a cure for tuberous sclerosis complex while improving the lives of those affected by providing support and information to anyone impacted by the disease, funding and driving research, and raising visibility of the disorder.

U.S. EPA’s National Air and Energy Research Program 4327
656 Quince Orchard Road, Suite 210
Durham, MD 20878
w epa.gov/air-research
The Air and Energy National Research Program at the U.S. EPA conducts state-of-the-art science to improve air quality and protect public health and the environment. The research objectives are to assess human and ecosystem impacts of air pollutants, develop and evaluate new approaches to prevent and reduce air pollution now and in the future, advance air measurement and modeling, and deliver the science needed to implement the nation’s air quality regulations and policies.

United States Navy Recruiting Command 1306
5722 Integrity Drive
Millington, TN 38054
p 800-872-6289

United Therapeutics 3511
55 TW Alexander Drive
Research Triangle Park, NC 27709
p 919-425-5551
w unither.com
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

UPMC 3226
200 Lothrop St.
Pittsburgh, PA 15213
p 412-864-6344
w upmc.com

UreSil LLC 3020
5418 W. Touhy Ave.
Skokie, IL 60077
p 800-538-7374
e sales@uresil.com
w uresil.com
UreSil is a medical device development, manufacturing, and distribution company that serves the needs of physicians who perform minimally invasive procedures. Through innovation and relationships, we provide high-quality devices that improve patient care and reduce overall treatment costs. Every product that UreSil markets must provide a clear benefit or improvement for the patient, the clinician, and the supply chain.

US Acute Care Solutions 4635
4535 Dressler Road NW
Canton, OH 44718
p 800-828-0898
w usacscare.com
US Acute Care Solutions was founded by like-minded groups that share an ironclad commitment to a physician-owned model and an unwavering emphasis on quality and support. We participate together as owners and work within a team dedicated to success without sacrificing our values. At USACS, we own our careers and love our lives.

conference.thoracic.org • 71
Veracyte, Inc. 4838
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
p 650-243-6300
e support@veracyte.com
w veracyte.com

Veracyte, a leading genomic diagnostics company, provides actionable tests that help improve confidence in lung disease diagnosis. Our portfolio of tests includes the Percepta Bronchial Genomic Classifier, a clinically proven complement to lung cancer diagnostic bronchoscopies, and the Envisia Genomic Classifier, helping physicians more confidently diagnose interstitial lung disease. For more information, visit veracyte.com/lung.

Vertebral Medical Technologies 2300
1908 Innerbelt Business Center Drive
St Louis, MO 63114
p 314-659-8500
e info@veranmedical.com
w veranmedical.com
Veran is a privately held medical device company with headquarters in St. Louis, Missouri. The company’s main focus is assisting physicians in the early diagnosis and treatment of lung cancer. Veran has developed and commercialized an FDA-cleared, next-generation electromagnetic navigation platform called the SPiN Thoracic Navigation System, which includes both endobronchial and transthoracic approaches.

Vyaire Medical 4315
26125 N. Riverwoods Blvd.
Mettawa, IL 60045
w vyaire.com
Maker of brands like AirLife™, Vital Signs™, Vyntus™, AVEA™, SuperNO2VA™, Vyaire Medical brings a laser focus to improving patient outcomes and increasing value for customers. Formed in October 2016, Vyaire serves health care customers around the world with innovative device and service solutions across the respiratory and anesthesia continua of care.

Vitalograph, Inc. 1708
13310 W, 99th St.
Lenexa, KS 66215
p 800-255-6626
w vitalograph.com

Vitalograph is a global pulmonary diagnostic device manufacturer and clinical trial professional services provider with a presence at the ATS conference for many years. Our extensive respiratory range includes world-class spirometers, asthma monitors, COPD screeners, peak flow meters, e-diaries, and inhaler trainers. Our latest version of Spirotrac V software offers advanced spirometry, SP02, ECG, and audiometry. Our handheld Micro spirometer provides F/V loops and pneumotachometer accuracy at an attractive price. Experience Vitalograph quality today!
DOWNLOAD THE ATS 2019 INTERNATIONAL CONFERENCE APP

Search for ATS 2019 in the App Store or Google Play or go to conference.app.thoracic.org

App supported by Gilead Sciences, Inc.
Applications Now Being Accepted

Gilead Sciences Research Scholars Program In Cystic Fibrosis

The program supports innovative scientific research that will advance knowledge in the field of cystic fibrosis, and provides support for 3 junior faculty researchers in Canada, Europe, or the United States for a 2-year period.

Each award will be funded up to USD130,000, to be paid in annual installments of up to USD65,000.

Awards are subject to separate terms and conditions.

SCIENTIFIC REVIEW COMMITTEE
Applications will be reviewed by a committee comprised of internationally recognized experts in basic and clinical research in the field of cystic fibrosis.

Application Deadline:
Friday, August 9, 2019, 11:59 PM Eastern Daylight Savings

For more information and to apply for an award, please visit:
http://researchscholars.gilead.com
Click on the CF program logo.

© 2019 Gilead Sciences, Inc. All rights reserved.
GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc.